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A B S T R A C T
Background
Inflammatory bowel disease (IBD) is an umbrella term used to describe a group of chronic, progressive inflammatory disorders of the
digestive tract. Crohn's disease and ulcerative colitis are the two main types. Fatigue is a common, debilitating and burdensome symptom
experienced by individuals with IBD. The subjective, complex nature of fatigue can oNen hamper its management. The eLicacy and safety
of pharmacological or non-pharmacological treatments for fatigue in IBD is not yet established through systematic review of studies.
Objectives
To assess the eLicacy and safety of pharmacological and non-pharmacological interventions for managing fatigue in IBD compared to no
treatment, placebo or active comparator.
Search methods
A systematic search of the databases Embase, MEDLINE, Cochrane Library, CINAHL, PsycINFO was undertaken from inception to July 2018.
A top-up search was run in October 2019. We also searched the Cochrane IBD Group Specialized Register, the Cochrane Central Register of
Controlled Trials, ongoing trials and research registers, conference abstracts and reference lists for potentially eligible studies.
Selection criteria
Randomised controlled trials of pharmacological and non-pharmacological interventions in children or adults with IBD, where fatigue was
assessed as a primary or secondary outcome using a generic or disease-specific fatigue measure, a subscale of a larger quality of life scale
or as a single-item measure, were included.
Data collection and analysis
Two authors independently screened search results and four authors extracted and assessed bias independently using the Cochrane 'Risk
of bias' tool. The primary outcome was fatigue and the secondary outcomes included quality of life, adverse events (AEs), serious AEs and
withdrawal due to AEs. Standard methodological procedures were used.
Main results
We included 14 studies (3741 participants): nine trials of pharmacological interventions and five trials of non-pharmacological
interventions. Thirty ongoing studies were identified, and five studies are awaiting classification. Data on fatigue were available from nine
trials (1344 participants). In only four trials was managing fatigue the primary intention of the intervention (electroacupuncture, physical
activity advice, cognitive behavioural therapy and solution-focused therapy).
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Electroacupuncture
Fatigue was measured with Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) (scores range from 0 to 52). The FACIT-
F score at week eight was 8.00 points higher (better) in participants receiving electroacupuncture compared with no treatment (mean
diLerence (MD) 8.00, 95% CI 6.45 to 9.55; 1 RCT; 27 participants; low-certainty evidence). Results at week 16 could not be calculated. FACIT-F
scores were also higher with electroacupuncture compared to sham electroacupuncture at week eight (MD 5.10, 95% CI 3.49 to 6.71; 1 RCT;
30 participants; low-certainty evidence) but not at week 16 (MD 2.60, 95% CI 0.74 to 4.46; 1 RCT; 30 participants; low-certainty evidence).
No adverse events were reported, except for one adverse event in the sham electroacupuncture group.
Cognitive behavioural therapy (CBT) and solution-focused therapy
Compared with a fatigue information leaflet, the eLects of CBT on fatigue are very uncertain (Inflammatory Bowel Disease-Fatigue (IBD-
F) section I: MD -2.16, 95% CI -6.13 to 1.81; IBD-F section II: MD -21.62, 95% CI -45.02 to 1.78; 1 RCT, 18 participants, very low-certainty
evidence). The eLicacy of solution-focused therapy on fatigue is also very uncertain, because standard summary data were not reported
(1 RCT, 98 participants).
Physical activity advice
One 2 x 2 factorial trial (45 participants) found physical activity advice may reduce fatigue but the evidence is very uncertain. At week 12,
compared to a control group receiving no physical activity advice plus omega 3 capsules, FACIT-F scores were higher (better) in the physical
activity advice plus omega 3 group (FACIT-F MD 6.40, 95% CI -1.80 to 14.60, very low-certainty evidence) and the physical activity advice plus
placebo group (FACIT-F MD 9.00, 95% CI 1.64 to 16.36, very low-certainty evidence). Adverse events were predominantly gastrointestinal
and similar across physical activity groups, although more adverse events were reported in the no physical activity advice plus omega 3
group.
Pharmacological interventions
Compared with placebo, adalimumab 40 mg, administered every other week ('eow') (only for those known to respond to adalimumab
induction therapy), may reduce fatigue in patients with moderately-to-severely active Crohn's disease, but the evidence is very uncertain
(FACIT-F MD 4.30, 95% CI 1.75 to 6.85; very low-certainty evidence). The adalimumab 40 mg eow group was less likely to experience serious
adverse events (OR 0.56, 95% CI 0.33 to 0.96; 521 participants; moderate-certainty evidence) and withdrawal due to adverse events (OR
0.48, 95%CI 0.26 to 0.87; 521 participants; moderate-certainty evidence).
Ferric maltol may result in a slight increase in fatigue, with better SF-36 vitality scores reported in the placebo group compared to the
treatment group following 12 weeks of treatment (MD -9.31, 95% CI -17.15 to -1.47; 118 participants; low-certainty evidence). There may
be little or no diLerence in adverse events (OR 0.55, 95% CI 0.26 to 1.18; 120 participants; low-certainty evidence)
Authors' conclusions
The eLects of interventions for the management of fatigue in IBD are uncertain. No firm conclusions regarding the eLicacy and safety of
interventions can be drawn. Further high-quality studies, with a larger number of participants, are required to assess the potential benefits
and harms of therapies. Future studies should assess interventions specifically designed for fatigue management, targeted at selected IBD
populations, and measure fatigue as the primary outcome.
P L A I N   L A N G U A G E   S U M M A R Y
Treatments for extreme tiredness and lack of energy (fatigue) in inflammatory bowel disease
Review question
What are the eLects of drug and non-drug treatments on fatigue in individuals with inflammatory bowel disease (IBD) compared to no
treatment, placebo (e.g. a sugar pill) or active comparator (e.g. a known eLective treatment)?
Background
IBD is a life-long illness that causes inflammation and ulceration in the gut. Crohn's disease and ulcerative colitis are the two main types
of IBD. People living with IBD oNen experience fatigue, which can be burdensome and negatively impact on their quality of life. DiLerent
treatments, such as medications and exercise, may improve fatigue. However, it is unclear what the eLects of such treatments on fatigue
in IBD are. This review presents the available evidence of the eLectiveness of treatments on fatigue in IBD.
Search date
Extensive searches were undertaken from inception up to July 2018. A top-up search was run in October 2019.
Study characteristics
Fourteen studies (3741 participants with IBD) met the inclusion criteria. Nine diLerent drug trials, four non-drug trials and one
multimodular trial were included in the review. Thirty ongoing studies were also identified and five studies are awaiting classification. In
only four trials was managing fatigue the aim of the intervention. In the remaining trials the interventions were aimed at managing other
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Cochrane Database of Systematic Reviews
symptoms, including fatigue. Data on fatigue were not available for the fourteen trials, therefore, the findings of this review are based on
1344 participants in nine trials. Most studies were small in size and had low or very low quality of evidence.
Key results and quality of evidence
The evidence suggests electroacupuncture may result in a large reduction in fatigue compared to control and sham electroacupuncture,
however, the overall certainty of the evidence is low due to sparse data. No adverse events were reported, except for one adverse event
in the sham acupuncture group.
We are very uncertain about the eLect of cognitive behavioural therapy and solution-focused therapy on fatigue, as the quality of the
evidence is very low.
One small study found that physical activity advice plus omega 3 and physical activity advice plus placebo may reduce fatigue compared to
no physical activity advice plus omega 3. Adverse events were similar across physical activity groups, although more adverse events were
reported in the no physical activity advice plus omega 3 group. Adverse events were mainly mild gastrointestinal events like diarrhoea
and bloating
Compared with placebo, the drug alimumab 40 mg, administered every other week, may reduce fatigue in patients with moderately-to-
severely active Crohn's disease, who are already known to respond to adalimumab treatment, but the evidence is very uncertain. People
taking adalimumab 40 mg weekly were less like to experience serious adverse events or withdraw from the trial due to adverse events,
compared to people taking placebo.
The evidence suggests ferric maltol results in a slight increase in fatigue in participants with Crohn's disease and ulcerative colitis, in
remission or with mild-to-moderate disease activity. Following 12 weeks of ferric maltol treatment, less fatigue was reported in the placebo
group compared to the treatment group, however, the quality of evidence is low.
Conclusion
The eLects of interventions for the management of fatigue on IBD are uncertain, with limited evidence available. No firm conclusions
regarding the benefits and harms (e.g. side eLects) can be drawn, Further high-quality studies, with a larger number of participants, are
needed to determine the potential eLect of treatments on fatigue in IBD. Future studies should assess fatigue as a primary outcome, be
specifically designed for fatigue management and targeted at specific IBD populations.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Electroacupuncture compared to no treatment for participants with quiescent IBD
Electroacupuncture compared to control for participants with quiescent IBD
Patient or population: participants with quiescent IBD








































FACIT-F scores ranged from 0 to 52, with higher scores indicating
less fatigue. The difference in fatigue levels at the week-16 fol-















IBDQ-9 scores ranged from 9 to 63, with higher scores indicating
better quality of life.
Adverse events
follow-up: 16 weeks




Safety evaluations occurred throughout the treatment period; no
events were reported in either group.
Serious adverse events
follow-up: 16 weeks




Safety evaluations occurred throughout the treatment period; no
events were reported in either group.
Withdrawal due to adverse
events
follow-up: 16 weeks




Safety evaluations occurred throughout the treatment period; no
events were reported in either group.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;





































































































































High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded two levels due to very serious imprecision as the number of participants was small and the confidence interval was wide.
2 Downgraded two levels due to very serious imprecision as the number of participants was small and an unvalidated outcome measure was used.
 
 
Summary of findings 2.   Electroacupuncture compared to sham electroacupuncture for participants with quiescent IBD
Electroacupuncture compared to sham electroacupuncture for participants with quiescent IBD
Patient or population: participants with quiescent IBD
Setting: outpatients from a single centre in Spain
Intervention: electroacupuncture
Comparison: sham electroacupuncture







































of life score was
58.6
MD 2.2 higher






IBDQ-9 scores ranged from 9 to 63, with higher scores
indicating better quality of life.
Adverse events
follow-up: 16 weeks















Safety evaluations occurred throughout the treatment
period; no events were reported in either group.
Withdrawal due to adverse
events
follow-up: 16 weeks







There was one withdrawal due to adverse events in





































































































































*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded two levels for very serious imprecision; small number of participants from a single study and the confidence interval was wide.
 
 
Summary of findings 3.   CBT with therapist support compared to fatigue information leaflet only for participants with IBD
CBT with therapist support compared to fatigue information leaflet only for participants with IBD
Patient or population: participants with IBD
Setting: outpatients from a single centre in the United Kingdom
Intervention: CBT with therapist support
Comparison: fatigue information leaflet only


































IBD-F Section I scores ranged from 0 to 20, with
higher scores indicating greater levels of fatigue.
Fatigue
assessed with: IBD-F Section II












IBD-F Section II scores ranged from 0 to 120, with






ty of life score was
95.7
MD 0.19 higher







UK-IBDQ scores ranged from 32 to 224, with high-





































































































































Adverse events - - - - This outcome was not measured.
Serious adverse events - - - - This outcome was not measured.
Withdrawal due to adverse events - - - - This outcome was not measured.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded two levels for very serious imprecision; small number of participants from a single study and the confidence interval was wide.
2 Downgraded one level due to risk of bias in blinding of participants and personnel and blinding in outcome assessment.
 
 
Summary of findings 4.   Physical activity advice plus omega 3 compared to no physical activity advice plus omega 3 for participants with quiescent
IBD
Physical activity advice plus omega 3 compared to no physical activity advice plus omega 3 for participants with quiescent IBD
Patient or population: participants with quiescent IBD
Setting: outpatients from a single centre in the United Kingdom
Intervention: physical activity advice plus omega 3
Comparison: no physical activity advice plus omega 3
Anticipated absolute effects* (95% CI)Outcomes
Risk with no physical
activity advice plus
omega 3
Risk with physical activity




























FACIT-F scores ranged from 0 to 52, with

















































































































































MFI scores ranged from 0 to 84, with higher
scores indicating greater fatigue.
Fatigue











IBD-F Section I scores ranged from 0 to 20,
with higher scores indicating greater levels
of fatigue.
Fatigue












IBD-F Section II scores ranged from 0 to 120,
with higher scores indicating greater impact
of fatigue.
Quality of life assessed with:
IBDQ
follow-up: 12 weeks
The mean QoL score
was 167







IBDQ scores ranged from 32 to 224, with
higher scores indicating better quality of
life.
Adverse events
assessed with: Medication di-
ary
follow-up: 12 weeks
There were five reported adverse events in the physi-
cal activity advice plus omega 3 group and 14 adverse
events in the control group, including epigastric pain,






Adverse events were recorded in the med-
ication diary and assessed by the researcher
during the 6 follow-up contact time points.
Serious adverse events - - - - This outcome was not reported.
Withdrawal due to adverse
events
- - - - This outcome was not reported.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded two levels due to very serious imprecision as the number of participants was small, confidence interval was wide and pre-protocol analyses used.







































































































































Summary of findings 5.   Physical activity advice plus placebo compared to no physical activity advice plus placebo for participants with quiescent
IBD
Physical activity advice plus placebo compared to no physical activity advice plus placebo for participants with quiescent IBD
Patient or population: participants with quiescent IBD
Setting: outpatients from a single centre in the United Kingdom
Intervention: physical activity advice plus placebo
Comparison: no physical activity advice plus placebo
Anticipated absolute effects* (95% CI)Outcomes
Risk with no physical
activity advice plus
placebo




















The mean fatigue was
38.4
MD 2.7 higher






FACIT-F scores ranged from 0 to 52,





The mean fatigue was
15.3
MD 2.6 lower






MFI scores ranged from 0 to 84, with
higher scores indicating greater fa-
tigue.
Fatigue
assessed with: IBD-F Section I
follow-up: 12 weeks
The mean fatigue was
8.5
MD 1.7 lower






IBD-F Section I scores ranged from 0
to 20, with higher scores indicating
greater levels of fatigue.
Fatigue
assessed with: IBD-F Section II
follow-up: 12 weeks
The mean fatigue was
27.9
MD 8.5 lower






IBD-F Section II scores ranged from 0
to 120, with higher scores indicating
greater impact of fatigue.
Adverse events: assessed with:
Medication diary
follow-up: 12 weeks
There were four reported adverse events in the physical
activity advice plus placebo group and five reported ad-
verse events in the no physical activity advice plus place-
bo group, including epigastric pain, diarrhoea, bloating,






Adverse events were recorded in the
medication diary and assessed by the
researcher during the 6 follow-up con-
tact time points.
Serious adverse events - not re-
ported
- - - - This outcome was not reported.
Withdrawal due to adverse
events - not reported






































































































































*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded two levels due to very serious imprecision as the number of participants was small, the confidence interval was wide and per protocol analyses used.
2 Downgraded one level due to high risk of bias for blinding of participants and personnel and blinding of outcome assessments.
 
 
Summary of findings 6.   Physical activity advice plus placebo compared to no physical activity advice plus omega 3 for participants with quiescent
IBD
Physical activity advice plus placebo compared to no physical activity advice plus omega 3 for participants with quiescent IBD
Patient or population: participants with quiescent IBD
Setting: outpatients from a single centre in the United Kingdom
Intervention: physical activity advice plus placebo
Comparison: no physical activity advice plus omega 3
Anticipated absolute effects* (95% CI)Outcomes
Risk with no physical ac-
tivity advice plus omega
3




















The mean fatigue score
was 32.1
MD 9 higher






FACIT-F scores ranged from 0 to 52,





The mean fatigue score
was 14.1
MD 1.4 lower






MFI scores ranged from 0 to 84, with
higher scores indicating greater fa-
tigue.
Fatigue
assessed with: IBDF Section 1
follow-up: 12 weeks
The mean fatigue score
was 9.6
MD 2.8 lower






IBD-F Section I scores ranged from 0
to 20, with higher scores indicating







































































































































assessed with: IBDF Section 2
follow-up: 12 weeks
The mean fatigue score
was 34.8
MD 15.4 lower






IBD-F Section II scores ranged from 0
to 120, with higher scores indicating




There were four reported adverse events in the physical ac-
tivity advice plus placebo group and fourteen reported ad-
verse events in the no physical activity advice plus omega
3 group, including epigastric pain, diarrhoea, bloating, nau-






Adverse events were recorded in the
medication diary and assessed by the
researcher during the 6 follow-up con-
tact time points.
Serious adverse events - not
reported
- - - - This outcome was not reported.
Withdrawal due to adverse
events - not reported
- - - - This outcome was not reported.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded two levels due to very serious imprecision as the number of participants was small, confidence interval was wide and per protocol analyses used.
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B A C K G R O U N D
Description of the condition
Inflammatory bowel disease (IBD) represents a group of chronic,
progressive, complex inflammatory disorders of the digestive tract,
and approximately five million people have a diagnosis of IBD
worldwide (Wilson 2012). Crohn's disease (CD) and ulcerative colitis
(UC) are the two most common forms of IBD. Both diseases
are characterised by periods of relapse and remission, and they
have overlapping and distinct pathological and clinical features
(Bernstein 2010). Individuals with CD or UC experience a wide range
of symptoms including diarrhoea, abdominal pain, fatigue, weight
loss and rectal bleeding (Cronin 2005).
Fatigue has been identified as one of the most burdensome
symptoms experienced by individuals with IBD (Farrell 2013; Farrell
2016). This symptom is particularly problematic during active
disease with prevalence rates as high as 86% reported (Van
Langenberg 2010). However, patients also continue to experience
fatigue during remission (41% to 48%) (Van Langenberg 2010).
These high rates of fatigue are comparable with rates experienced
by oncology patients (Stone 2008). Furthermore, a study by
Jelsness-Jørgensen 2011a found that chronic fatigue, defined
as substantial fatigue with duration of more than six months,
was significantly more common in patients with UC and CD
than healthy controls. In addition, patients with IBD experiencing
chronic fatigue have significantly higher levels of disease-related
worries and concerns (Jelsness-Jørgensen 2012). Reduced energy
level is a leading and consistent concern among individuals
with IBD (Casati 2000; Casellas 2001; De Rooy 2001; Drossman
1989; Jelsness-Jørgensen 2011b). In addition, IBD-related fatigue
negatively impacts on health-related quality of life and activities
of daily living (Czuber-Dochan 2013a; Czuber-Dochan 2013b;
GraL 2011; Jelsness-Jørgensen 2011c; Minderhoud 2003; Opheim
2014). Despite the high prevalence of chronic fatigue in IBD, this
subjective complaint remains largely ignored in the IBD literature,
particularly regarding the investigation of underlying mechanisms
and treatment strategies for fatigue.
Fatigue has been diLicult to delineate due to the subjective nature
of the symptom. In chronic diseases, fatigue has been defined
as a ‘persistent, overwhelming sense of tiredness, weakness or
exhaustion resulting in a decreased capacity for physical and
mental work’ (Dittner 2004; Lai 2003). Although some studies
have continued to measure fatigue in IBD from a unidimensional
perspective, for example, in terms of prevalence (Minderhoud
2003), or severity (Opheim 2014), it is now generally accepted
that fatigue is a multidimensional phenomenon, characterised
by diminished perceived physical energy, mental capacity and
psychological status (Van Langenberg 2010). These physical,
cognitive and aLective dimensions of fatigue form the components
of generic fatigue measures such as the Multidimensional
Fatigue Inventory. More recent studies have assessed fatigue
using multiple dimensions, such as severity/intensity, frequency,
duration, distress and impact (Bager 2012; Czuber-Dochan 2013a).
Furthermore, the characteristics of fatigue are captured to varying
degrees by the diverse range of symptom and quality of life
measures available, including both generic and disease-specific
indices (Czuber-Dochan 2014c; Hjollund 2007). It is known that
IBD-related fatigue is associated with a number of physical,
psychological and situational factors, with increased disease
activity, depression, anxiety and stress found to be consistently
associated with greater levels of fatigue (Czuber-Dochan 2013a).
As a result, the nonspecific, subjective, complex nature of
fatigue can oNen hamper the management of this burdensome
symptom. Although healthcare professionals perceive fatigue as
an important and problematic symptom in patients with IBD,
the management of fatigue remains poorly understood (Czuber-
Dochan 2014a). Healthcare professionals have identified the need
for more information and education to facilitate the management
of fatigue in clinical practice (Czuber-Dochan 2014b). However,
the eLectiveness of interventions for fatigue in IBD has not been
systematically reviewed.
Description of the intervention
Given the multidimensional nature of fatigue involving biological,
psychosocial, and behavioural processes (Opheim 2014),
pharmacological and non-pharmacological interventions either
alone or in combination may help to improve or alleviate
fatigue. Pharmacological interventions involve the administration
of drugs through any route. Non-pharmacological interventions
may include any type of physical, psychological, psychosocial,
behavioural or educational interventions. Interventions have been
developed to address the problem of IBD-related fatigue either
directly or indirectly. For example, this could be directly in terms
of an intervention specifically aimed at improving or alleviating
fatigue (Vogelaar 2014), or indirectly in terms of an intervention
aimed at the overall management of IBD which assesses fatigue
as a secondary outcome (Garcia-Vega 2004). However, there is
uncertainty regarding the eLectiveness of these interventions in
alleviating fatigue, particularly in the long term.
How the intervention might work
Interventions may address the physical, psychological or
situational factors contributing to fatigue. It is important that
these contributory factors are clearly understood in order to
target interventions eLectively. For example, where fatigue is
related to a physical problem such as anaemia, iron supplements
or intravenous iron therapy may be beneficial. Alternatively, if
the physical issue is inflammation due to a disease flare, a
pharmacological intervention such as biological therapy may be
valuable. If altered mood is a factor contributing to fatigue,
psychosocial behavioural interventions may be valuable. ONen
fatigue is influenced by a number of factors, therefore a
multicomponent intervention may be an eLective approach.
Why it is important to do this review
The incidence of IBD has been increasing over time (Molodecky
2012). Fatigue has been identified as the most burdensome
symptom experienced by individuals with IBD that impacts
negatively on all aspects of daily life (Farrell 2013; Farrell 2016;
Wilson 2012). Due to the increasing prevalence, debilitating
character and unknown aetiology, interventions for IBD-related
fatigue have received increased attention. Recently, in other
chronic conditions which are associated with fatigue, there
has been an increase in the number of Cochrane reviews
on interventions for fatigue. For example, for cancer-related
fatigue, there are reviews assessing the eLect of pharmaceutical
interventions (Minton 2010), blood transfusions (Preston 2012),
exercise (Cramp 2012), education (Bennett 2009), and psychosocial
interventions (Goedendorp 2009). However, unlike cancer and
other chronic conditions, such as multiple sclerosis (Heine 2015),
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peripheral neuropathy (White 2014) and rheumatoid arthritis
(Cramp 2013), no systematic review has been undertaken to assess
the eLects of interventions for fatigue in IBD. It is therefore
proposed to systematically review and synthesise existing evidence
on the eLects of interventions for the management of fatigue in
individuals with IBD.
O B J E C T I V E S
The aim of this review is to assess the eLicacy and safety
of pharmacological and non-pharmacological interventions on
fatigue in IBD compared to no treatment, placebo or active
comparator.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All types of randomised controlled trials (RCTs), including cluster
and cross-over trials, were considered for inclusion.
Types of participants
Children, adolescents and adults of all ages with a clinical diagnosis
of Crohn's disease, ulcerative colitis (with or without a total
colectomy), or any other form of IBD (e.g. indeterminate colitis or
IBD unclassified) were considered for inclusion. Participants were
included regardless of whether disease status was active or in
remission.
Types of interventions
Any pharmacological and non-pharmacological interventions
designed to help alleviate fatigue in individuals with IBD were
included. To be eligible for inclusion, an intervention must have a
focus on fatigue explicitly stated in its aims, content, or as a primary
or secondary outcome measure.
The following comparisons were considered:
• Pharmacological versus non-pharmacological;
• Pharmacological versus pharmacological (diLerent drugs or
same drugs with diLerent doses and time intervals);
• Pharmacological versus usual or standard care;
• Non-pharmacological versus usual or standard care;
• Non-pharmacological versus non-pharmacological (diLerent
non-pharmacological interventions or same non-
pharmacological intervention with diLerent formats); or
• Any of the above versus placebo.
Interventions may be delivered in any form, for example, but not
limited to face to face, telephone, the internet, or technology in the
case of non-pharmacological interventions. Interventions may be
delivered individually or be group-focused and occur in diLerent
settings such as a clinic or home environment.
Types of outcome measures
Primary outcomes
The primary outcome for this review was fatigue. Therefore,
eligible studies for inclusion must have fatigue or loss of energy
measured as a primary or secondary outcome. Measures of fatigue
are self-reported as it is a subjective phenomenon and these
instruments may be generic or disease-specific. Examples of
generic self-reported measures include but are not limited to: the
Fatigue Severity Scale (FSS) (Krupp 1989), Chalder Fatigue Scale
(CFQ) (Chalder 1993), Fatigue Impact Scale (FIS) (Fisk 1994; Fisk
2002), Visual Analogue Scale of Fatigue (VAS-F) (Lee 1991), Piper
Fatigue Scale (PFS) (Piper 1998), Functional Assessment of Chronic
Illness Therapy – Fatigue (FACIT-F) (Yellen 1997), Multidimensional
Fatigue Inventory (MFI) (Smets 1996), and the Multidimensional
Assessment of Fatigue (MAF) (Tack 1991). An example of a disease-
specific measure includes the Inflammatory Bowel Disease-Fatigue
scale (IBD-F) (Czuber-Dochan 2014c).
In addition, studies that reported data on fatigue, loss of energy,
vigour and vitality which was assessed as a single question or as a
subscale of a questionnaire (e.g. the vitality subscale of the Short
Form-36 (SF-36) or Inflammatory Bowel Disease Questionnaire
(IBDQ) ( Irvine 1999; Ware 1992) were included. Multidimensional
characteristics of fatigue symptoms may be measured. For
example, these characteristics may include intensity, severity,
frequency, duration, distress or dimensions including physical
fatigue, mental fatigue or general fatigue.
Secondary outcomes
Secondary outcomes included:
• Any measure of quality of life (e.g. validated generic or disease-
specific quality of life measures, such as the SF-36 or IBDQ); and
• Adverse events.
Adverse events included:
• The proportion of participants who experience any adverse
event (i.e. an unfavourable outcome occurring during, but not
necessarily caused by, the intervention);
• Serious adverse events (i.e. an adverse event that results
in death, requires hospitalisation or a life-threatening event,
resulting in a persistent or significant disability); and
• Withdrawal due to adverse events.
Search methods for identification of studies
Electronic searches
The databases Embase, MEDLINE, CINAHL, and PsycINFO were
searched from inception to July 2018 and these searches were
updated in October 2019. We also searched the Cochrane IBD
Group Specialized Register and the Cochrane Central Register
of Controlled trials (CENTRAL) for applicable RCTs. The search
strategies were modified for each database. Search limits included
humans and publication in English language only. The search
strategies used the relevant database filters or the recommended
Cochrane search string for the identification of RCTs (Lefebvre
2011). The search strategies for each database are reported in
Appendix 1, Appendix 2, Appendix 3, Appendix 4, and Appendix 5.
One author (DF) liaised with the Cochrane IBD Group Trials Search
Coordinator for the identification of potentially eligible studies.
Searching other resources
To identify other relevant published, unpublished and ongoing
trials we:
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• Examined the reference lists of included studies and review
articles for additional citations;
• Searched ongoing trials and research registers including
the Current Controlled Trials register (www.controlled-
trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the
WHO International Clinical Trials Registry Platform (ICTRP)
(www.who.int/ictrp/en/), using the search terms 'fatigue' and
'inflammatory bowel disease' or 'ulcerative colitis' or 'Crohn’s
disease';
• Contacted trial authors to identify further published and
unpublished trials and asked if they were willing to disclose their
unpublished data;
• Searched published abstracts from conference proceedings,
including the European Crohn’s and Colitis Organisation
Congress, Digestive Disease Week and Advances in
Inflammatory Bowel Diseases; and
• Searched relevant journals (Journal of Crohn's and
Colitis; Inflammatory Bowel Diseases; Gastroenterology;
Gastrointestinal Endoscopy).
Data collection and analysis
Selection of studies
Initially, two review authors (DF and MA) independently screened
and examined the eligibility of the titles and abstracts identified by
the search based on the predetermined inclusion criteria described
above. Full-text papers were retrieved for all studies appearing to
meet the inclusion criteria and were read independently by two
review authors (DF and MA). Trials with a heterogeneous sample
of disorders were included, only if relevant data from participants
with IBD could be extracted. All trial authors were contacted
regarding information that was unclear or missing in order to reach
a decision about inclusion. In case of disagreement about the
selection of a study, arbitration was sought from a third author with
content expertise (CN) and a decision made by consensus.
Data extraction and management
For each included study, two review authors independently
extracted and documented the relevant data using standardised
data extraction forms. The lead author (DF) extracted data for
all included studies (Appendix 6). Second independent extraction
of data from included studies was shared between three review
authors (WCD or LPJJ or MA). All trial authors were contacted
to provide additional (unpublished) relevant information. Any
disagreements regarding inclusion or exclusion were resolved
through discussion and by consultation with another author (CN)
as necessary.
Assessment of risk of bias in included studies
For each study, the reviewers who extracted the data
also independently assessed methodological quality using the
Cochrane 'Risk of bias' tool (Higgins 2011a). We assessed trials
for random sequence generation, allocation concealment, blinding
(participants, personnel and outcome assessors), incomplete
outcome data, outcome misclassification, selective outcome
reporting and other potential sources of bias. We then made a
judgement on each of these criteria relating to the risk of bias,
of 'low risk of bias', 'high risk of bias' or 'unclear risk of bias'.
Judgement justification was provided in the Characteristics of
included studies section of the review. When agreement was not
achieved by the two paired review authors (DF and WCD or LPJJ
or MA) through discussion, another review author (CN) provided
consensus assessment.
Measures of treatment e:ect
We used the Cochrane Collaboration’s Review Manager SoNware,
RevMan 5, for all analyses. Outcomes were recorded both at the
end of the intervention period and at the end of the follow-
up for the purpose of comparison between the intervention and
control groups. These were the only time points at which outcomes
were recorded in studies with multiple time points. We calculated
the mean diLerence (MD) and the corresponding 95% confidence
interval (CI) for continuous outcomes. We calculated the risk ratio
(RR) and 95% CI for dichotomous outcomes.
Unit of analysis issues
The level at which randomisation occurred was accounted for in
the data analysis. We planned that the unit of analysis would be
individuals for participants individually randomised to one of two
groups. Where groups of individuals were randomised together to
the same intervention (i.e. cluster-randomised trials), we planned
to contact the trial authors for further information if these group
data were not reported. Where individuals underwent more than
one intervention during the period of the study (i.e. cross-over
trial), we planned to only include the first part of the study (i.e.
before the cross-over) to avoid potential carry-over eLects. For
multi-arm pharmacological trials with a single placebo group and
two treatment dose groups, we planned to split the placebo group
in half to avoid a unit of analysis error (Higgins 2011b). We did
not find any available cluster-randomised or cross-over studies.
However, we did find study designs where multiple treatment
attempts were used, therefore, we selected the dose group that
reflected clinical practice as the comparison for all continuous
variables, as a mean and standard deviation for each placebo
comparator was not possible.
Dealing with missing data
Data were analysed on an intention-to-treat basis. Where data
were missing, we contacted the trial authors and requested the
missing data. The trial authors who replied to our additional
information request are detailed in the 'Acknowledgements'
section. If this information was unattainable, we planned to
undertake an available case analysis by analysing only the available
data (i.e. ignoring the missing data). If change scores were not
available and the mean change could be calculated, we planned
to impute standard deviations from baseline data using methods
recommended in Chapter 16 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011b). If the number
of patients randomised to each group and the number of dropouts
were known, we planned to calculate a worst case intention-to-
treat (ITT) analysis, where by all dropouts were assumed to be
treatment failures.
Assessment of heterogeneity
The studies were assessed for clinical homogeneity with regards
to participants, interventions and outcomes. We planned to assess
statistical heterogeneity in terms of the diLerence in the eLects
of interventions, by firstly visually inspecting the forest plots and
secondly using statistical tests of variation (Chi2 and I2 statistics).
We planned to investigate heterogeneity by visually inspecting the
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forest plots to identify outliers. If outliers were identified, we would
conduct sensitivity analysis to explore potential explanations for
the heterogeneity. For the Chi2 test, a P value of less than 0.1 would
be considered statistically significant. We planned to use the I2
statistic to quantify heterogeneity (I2 0% - 40%: low heterogeneity;
I2 30% – 60%: moderate heterogeneity; 50% - 90%: substantial
heterogeneity; 75 – 100%: considerable heterogeneity) (Higgins
2011b). However, the size of the I2 would be interpreted in light of
the size and direction of eLects, as well as the strength of evidence
for heterogeneity (e.g. P value from Chi2 test). If heterogeneity was
suspected, the possibility of utilising a random-eLects model of
meta-analysis would be considered as recommended in Chapter 9
of the Cochrane Handbook for Systematic Reviews of Interventions
(Deek 2011). We pooled statistically homogeneous studies (I2 <
50%) using a fixed-eLect model.
Assessment of reporting biases
All studies were assessed for reporting bias. We assessed selective
reporting by comparing outcomes that were prespecified in study
protocols to those reported in study manuscripts. If protocols were
not available for the included studies, we assessed reporting bias
by comparing the outcomes specified in the methods section of the
manuscript to those reported in the results section. If there were
more than 10 included studies in a pooled analysis, we planned
to investigate publication bias by constructing funnel plots (Sterne
2011).
Data synthesis
We combined data from individual studies when the interventions,
participant groups and outcomes were suLiciently similar,
which was determined by consensus. When pooling studies
was not possible, we narratively summarised the results of
individual studies. For continuous outcomes, we calculated the
pooled mean diLerence (MD) and corresponding 95% CI. For
continuous outcomes that utilised diLerence scales to measure
the same underlying construct, we planned to calculate the
standardised mean diLerence (SMD) and corresponding 95% CI. For
dichotomous outcomes, we planned to calculate the pooled risk
ratio (RR) and 95% CI.
Subgroup analysis and investigation of heterogeneity
If suLicient power and data were available, we planned to perform
subgroup analyses to investigate possible reasons for variations
in fatigue results across trials for the following subsets: disease
type (Crohn’s disease, ulcerative colitis); disease activity (active
disease, inactive disease), sex (male, female); age groups (child,
adolescents, adults, elderly (aged 65 years and old)), comorbidities,
and intervention type (pharmacological, non-pharmacological).
Sensitivity analysis
We planned to perform sensitivity analysis, where appropriate,
to explore the eLects of risk of bias on fatigue. For example,
studies identified as having high risk of bias would be excluded
from the pooled analysis to see if the eLect estimate changed in
a substantive way. However, due to insuLicient data, sensitivity
analysis was deemed not appropriate in this review.
Summary of findings and assessment of the certainty of the
evidence
We used the GRADE criteria (risk of bias, inconsistency, imprecision,
indirectness and publication bias) to assess the overall quality of
evidence for the prespecified primary and secondary outcomes
(Schünemann 2011a; Schünemann 2011b). Using this approach,
outcome data were rated high, moderate, low or very low certainty.
All decisions to downgrade the quality of the evidence were
explained using footnotes.
Using the GRADEpro soNware, a 'Summary of findings' table was
created for the following outcomes:
• Fatigue;
• Quality of life;
• Adverse events:
• Serious adverse events; and
• Withdrawal due to adverse events.
Comparisons where the primary intention of the intervention
was management of fatigue were prioritised for presentation
in summary of findings tables. Other comparisons, where the
management of fatigue was not the primary intention of the
intervention with fatigue being assessed as a secondary outcome,
were presented as additional tables.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
The electronic search identified a total of 3183 citations (Figure 1)
of which 3055 were excluded based on titles and abstracts alone.
The search of conference abstracts, relevant journals, reference
lists, ongoing trials and research registers, and contact with
trial authors yielded 18 further potentially eligible citations. The
full texts of 91 reports were examined in detail. A total of 34
citations were excluded, mostly as fatigue outcome data were
not assessed or reported (n = 24), not an RCT design (n = 7), or
data from IBD participants was not presented separately (n = 3).
A total of fourteen trials were identified as meeting the inclusion
criteria of this review (Artom 2018; Colombel 2007; Colombel
2017; Feagan 2013; García-Vega 2004; Gasche 2015; Hetzel
2013a; Horta 2017; McNelly 2016; RaNery 2013; Sandborn 2013;
Therkelsen 2016a; Therkelsen 2016b; Vogelaar 2014). Furthermore,
27 ongoing trials were identified as eligible and will be included
in future updates of this review (ACTN12617000586314P; EudraCT
Number: 2008-004277-17; EudraCT Number: 2011-002122-43;
EudraCT Number: 2012-005644-26; NCT02193750; NCT02208310;
NCT02517151; NCT02704624; NCT02707068; NCT02772965;
NCT02849717; NCT02861053; NCT02891226; NCT02963246;
NCT03104413; NCT03105102; NCT03105128; NCT03107793;
NCT03162575; NCT03266484; NCT03345823; NCT03345836;
NCT03345849; NCT03398135; NCT03398148; NCT03456752;
NCT03466411) (Characteristics of ongoing studies).
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Figure 1.   Study flow diagram
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Figure 1.   (Continued)
 
The electronic search was re-run in October 2019, which identified
an additional 337 citations (Figure 1). Five potentially relevant
studies (Ghosh 2019; Louis 2019; O' Connor 2019; Sands 2018;
Tew 2019) and three ongoing trials (ACTRN12619000150145;
ISRCTN11470370; NCT03574948) were identified. Additional
information is needed from the study authors and these studies
will be assessed for inclusion at the next update (Characteristics
of studies awaiting classification and Characteristics of ongoing
studies)
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Included studies
Fourteen trials published in peer-reviewed journals (28 citations)
were included in this review. Multiple records for ten of the
trials were identified: four trials were reported in conference
proceeding abstracts (and published in journals) (Artom 2018;
Horta 2017; Hetzel 2013a; RaNery 2013) and six trials were reported
in journal articles and conference proceeding abstracts (Colombel
2007; Colombel 2017; Feagan 2013; McNelly 2016; Sandborn 2013;
Vogelaar 2014). The primary reference for four trials did not
report fatigue (Colombel 2007; Colombel 2017; Feagan 2013;
Sandborn 2013), however secondary publications reported the
outcome (LoNus 2008; Panaccione 2018; Rubin 2009; Rubin 2018).
Therefore, for the purpose of this review, the trials were included
as eligible studies and the primary publication (Colombel 2007;
Colombel 2017; Feagan 2013; Sandborn 2013) was used as the study
identifier. In one trial (Colombel 2007), results for all randomised
participants were presented in a conference proceedings abstract
(Rubin 2009) and results from a subset of participants (participants
who responded [achieved clinically meaningful change in disease
activity by week 4] to open-label adalimumab induction therapy)
were presented in a full-text paper (LoNus 2008). For the purpose
of data synthesis, the results from all randomised participants
and randomised responders were presented separately in this
review, as the sample sizes and fatigue data diLered between the
datasets. Another secondary publication (Rubin 2018) presented
fatigue subcomponent data from both the GEMINI I and II trials
in a conference proceedings abstract, therefore, these two trials
were presented as eligible studies in this review (Feagan 2013;
Sandborn 2013). A total of five trials were reported in insuLicient
detail to allow for inclusion in the analysis (Colombel 2017; Feagan
2013; Hetzel 2013a; RaNery 2013; Sandborn 2013), however we are
currently awaiting additional information from one trial (Colombel
2017).
Type of studies
All studies used standard therapy as a comparator. In three studies,
a three-arm design was used, with two studies including two
intervention arms and a control group (Colombel 2007; García-Vega
2004) and one study including an intervention and sham arm and
a control group (Horta 2017). In one study, a four-arm design was
used (McNelly 2016).
Six studies were double-blinded (Colombel 2007; Feagan 2013;
Gasche 2015; Hetzel 2013a; RaNery 2013; Sandborn 2013), with the
remaining studies single-blinded (Horta 2017; Therkelsen 2016a;
Therkelsen 2016b) or unblinded (Artom 2018; Colombel 2017;
García-Vega 2004; McNelly 2016; Vogelaar 2014). Four studies used
open allocation (García-Vega 2004; Therkelsen 2016a; Therkelsen
2016b; Vogelaar 2014), three used an interactive voice response
system (Colombel 2007; Colombel 2017; Gasche 2015) and two
studies used sealed opaque envelopes (Artom 2018; Horta 2017).
One study used a combination of open allocation and sequentially
named drug containers of identical appearance (McNelly 2016).
Four studies (Feagan 2013; Hetzel 2013a; RaNery 2013; Sandborn
2013) did not present information on group allocation.
The follow-up time ranged from 21 days (Therkelsen 2016a;
Therkelsen 2016b) to 56 weeks (Colombel 2007). Only two studies
had a follow-up period longer than 12 months (Colombel 2007;
García-Vega 2004).
Populations
All studies were conducted on adults. Sample size ranged from
27 participants (RaNery 2013) to 1115 participants (Sandborn
2013). Most sample sizes were small (< 100 participants) (Artom
2018; García-Vega 2004; Horta 2017; McNelly 2016; RaNery
2013; Therkelsen 2016a; Therkelsen 2016b; Vogelaar 2014).
Settings varied from single (Artom 2018; García-Vega 2004; Horta
2017; McNelly 2016; Therkelsen 2016a; Therkelsen 2016b) to
multicentred studies (Colombel 2007; Colombel 2017; Feagan
2013; Gasche 2015; RaNery 2013; Sandborn 2013; Vogelaar 2014).
It is unclear if one study (Hetzel 2013a) was a single or
multicentred study. The multicentred studies ranged from two
centres (RaNery 2013) to 285 centres (Sandborn 2013). Most studies
recruited participants from hospital-based settings, specifically
inflammatory bowel disease clinics (Artom 2018; García-Vega
2004; Gasche 2015; Horta 2017; McNelly 2016; Therkelsen 2016a;
Therkelsen 2016b), with the specific location of recruitment
unclear for some studies, although it appeared to be hospital-
based (Colombel 2007; Colombel 2017; Feagan 2013; Hetzel 2013a;
RaNery 2013; Sandborn 2013; Vogelaar 2014). Most studies were
conducted in European countries (Artom 2018; García-Vega 2004;
Gasche 2015; Horta 2017 McNelly 2016; RaNery 2013; Therkelsen
2016a; Therkelsen 2016b; Vogelaar 2014), with four trials being
conducted worldwide (Colombel 2007; Colombel 2017; Feagan
2013; Sandborn 2013).
Some studies sampled those with a diagnosis of Crohn's disease
(Colombel 2007; Colombel 2017; García-Vega 2004; RaNery 2013;
Sandborn 2013; Therkelsen 2016b), with two studies focused
specifically on ulcerative colitis only (Feagan 2013; Therkelsen
2016a). The remaining studies recruited individuals with Crohn's
disease and ulcerative colitis (Gasche 2015; McNelly 2016) or
inflammatory bowel disease (Crohn's disease, ulcerative colitis
and unclassified) (Artom 2018; Hetzel 2013a; Horta 2017; Vogelaar
2014). In all studies, results were presented as an overall group
rather than by disease type.
Disease status or activity was defined as an inclusion criterion
in all studies, except one (Hetzel 2013a). Some studies recruited
participants in remission only (Artom 2018; García-Vega 2004;
Horta 2017; McNelly 2016; RaNery 2013; Vogelaar 2014). Other
studies recruited individuals with mixed disease activity, including
remission or mild- to-moderate disease (Gasche 2015), mild-
to-moderately active disease (Therkelsen 2016a; Therkelsen
2016b) and moderate-to-severely active disease (Colombel 2007;
Colombel 2017; Sandborn 2013). For Crohn's disease, the Crohn's
Disease Activity Index (CDAI) was most commonly used, with
remission defined as a CDAI score < 150 (RaNery 2013; Vogelaar
2014), mild-to-moderately active disease defined as a CDAI score
< 220 (Gasche 2015) and moderate-to-severely active disease
defined as a CDAI score 220 to 450 (Colombel 2007; Colombel
2017; Sandborn 2013). The Harvey Bradshaw Index (HBI) (García-
Vega 2004; McNelly 2016) and the short CDAI (Therkelsen 2016b)
were also used to characterise disease activity for Crohn's disease
populations. For ulcerative colitis, the Simple Clinical Colitis
Activity Index (SSCAI) (Gasche 2015; McNelly 2016), the Clinical
Activity Index (CAI) (Therkelsen 2016a; Vogelaar 2014) and the Mayo
score (Feagan 2013) were used. Although there was consistency
in defining disease activity in Crohn's disease, disparity existed in
the cut-oL points for the ulcerative colitis disease activity indices.
For example, remission was defined as SSCAI score < 4 (Gasche
2015) and also as a score < 3 (McNelly 2016). Remission was also
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defined in a study as CAI score < 10 (Vogelaar 2014), however, a CAI
score ≥ 3 indicated a mild-to-moderate active disease (Therkelsen
2016a). Some studies (Colombel 2017; McNelly 2016; Sandborn
2013; Vogelaar 2014) also used c-reactive protein (CRP) levels as a
measure of disease activity, however, the studies diLered in terms
of the cut-oL used to define remission [ranging from <5 mg/dL
(McNelly 2016) to < 10mg/dL (Vogelaar 2014)] and moderately-
to-severely active disease [ranging from > 2.87 mg/L (Sandborn
2013) to ≥ 5 mg/L (Colombel 2017). Endoscopy disease activity
scores (Colombel 2017; Feagan 2013; Sandborn 2013) and faecal
calprotectin (Colombel 2017) were also used to evaluate disease
activity of eligible participants.
Studies used diLerent inclusion criteria, such as a history of TNF-
antagonist treatment (Colombel 2007; Feagan 2013; Sandborn
2013) or drug treatments (sulfasalazine or 5ASA) (García-Vega
2004), iron deficiency anaemia (Gasche 2015; Hetzel 2013a) and
fatigue severity (Artom 2018; Horta 2017; McNelly 2016; Vogelaar
2014).
The loss to follow-up ranged from 0% (García-Vega 2004) to 34%
(Therkelsen 2016b), although most studies had less than 25% loss
to follow-up (Colombel 2007; Colombel 2017; Feagan 2013; Gasche
2015; Horta 2017; McNelly 2016; Sandborn 2013; Therkelsen 2016a;
Vogelaar 2014). Information regarding loss to follow-up was not
available for two studies (Hetzel 2013a; RaNery 2013).
Interventions
Most studies measured fatigue as a secondary outcome, with
only four trials specifically designed for managing fatigue
(Artom 2018; Horta 2017; McNelly 2016; Vogelaar 2014). Mostly
trials were pharmacological (Colombel 2007; Colombel 2017;
Feagan 2013; Gasche 2015; Hetzel 2013a; RaNery 2013; Sandborn
2013; Therkelsen 2016a; Therkelsen 2016b), with four studies
being non-pharmacological (Artom 2018; Horta 2017; García-
Vega 2004; Vogelaar 2014). One study used a multi-interventional
approach of both pharmacological and non-pharmacological
interventions (McNelly 2016). The pharmacological interventions
included adalimumab (Colombel 2007), vedolizumab (Feagan
2013; Sandborn 2013), iron therapies (Gasche 2015; Hetzel
2013a), and supplements, such as agaricus blazei murill-based
mushroom extract (Therkelsen 2016a; Therkelsen 2016b), omega
3 (McNelly 2016) and vitamin D3 (RaNery 2013). One trial used
a combination customised pharmacological therapy, including
prednisone, adalimumab and azathioprine (Colombel 2017). The
non-pharmacological interventions included cognitive behavioural
therapy with therapist support (Artom 2018), electroacupuncture
(Horta 2017), stress management (García-Vega 2004), solution-
focused therapy (Vogelaar 2014) and physical activity advice
(McNelly 2016).
Most of the pharmacological interventions were oral therapies
administered daily (Colombel 2017; McNelly 2016; RaNery 2013)
or twice daily (Gasche 2015; Therkelsen 2016a; Therkelsen 2016b),
although five studies involved intravenous (Feagan 2013; Hetzel
2013a; Sandborn 2013) or subcutaneous injection treatments
(Colombel 2007; Colombel 2017), administered either weekly
(Colombel 2007; Colombel 2017), every other week (Colombel
2007; Colombel 2017; Sandborn 2013), as two stat doses (three
to eight days apart) (Hetzel 2013a) or every four or eight weeks
(Feagan 2013; Sandborn 2013). The duration of administration of
regularly administered pharmacological interventions ranged from
21 days (Therkelsen 2016a; Therkelsen 2016b) to 58 weeks (Feagan
2013; Sandborn 2013). The duration of the pharmacological
interventions for three studies was 12 weeks (Gasche 2015; McNelly
2016; RaNery 2013).
The non-pharmacological interventions ranged from face-to-face
or telephone/Skype individuals sessions (Artom 2018; Horta 2017;
McNelly 2016; García-Vega 2004), group sessions (Vogelaar 2014) to
self-directed sessions using a written guide and audiotape (García-
Vega 2004). The intensity of the interventions varied from a one-
oL 15-minute consultation on physical activity (McNelly 2016) to
nine electroacupuncture sessions over an eight week period (Horta
2017). These non-pharmacological interventions were delivered in
the hospital (Horta 2017; McNelly 2016; Vogelaar 2014) or in the
participants' homes (Artom 2018; García-Vega 2004).
Outcomes
Fatigue
Fatigue was assessed in studies either using a generic or disease-
specific fatigue scale, as a subscale of a broader questionnaire
or as a single-item question. Predominantly, fatigue was assessed
using a single scale (Artom 2018; Colombel 2007; Colombel 2017;
Feagan 2013; Horta 2017; Gasche 2015; Hetzel 2013a; RaNery 2013;
Sandborn 2013), the remaining four studies used two (Therkelsen
2016a; Therkelsen 2016b; Vogelaar 2014) or three diLerent fatigue
scales (McNelly 2016). Fatigue was most commonly assessed using
the generic fatigue scale, the Functional Assessment of Chronic
Illness Therapy - Fatigue (FACIT-F) scale, in five studies (Colombel
2007; Colombel 2017; Horta 2017; Hetzel 2013a; McNelly 2016).
Other generic scales of fatigue, included the Multidimensional
Fatigue Inventory (MFI) (McNelly 2016; RaNery 2013), the Fatigue
Questionnaire (Therkelsen 2016a; Therkelsen 2016b), the Checklist
of Individual Strength (Vogelaar 2014) and the Fatigue Severity
Scale (Vogelaar 2014). Six studies presented fatigue data from
a single-item question (García-Vega 2004), or as a subscale or
subcomponent of quality of life questionnaires (Feagan 2013;
Gasche 2015; Sandborn 2013; Therkelsen 2016a; Therkelsen
2016b). Only two studies assessed fatigue using a disease-specific
fatigue measure, namely the IBD-Fatigue scale (IBD-F) (Artom 2018;
McNelly 2016). Summary data for fatigue were not available in five
studies (Colombel 2017; Feagan 2013; Hetzel 2013a; RaNery 2013;
Sandborn 2013), therefore, although eligible studies, the findings
could not be included in the analysis of this review.
Quality of life
The secondary outcome of this review, quality of life, was assessed
in twelve of the fourteen studies (Artom 2018; Colombel 2007;
Colombel 2017; Feagan 2013; Gasche 2015; Horta 2017; McNelly
2016; RaNery 2013; Sandborn 2013; Therkelsen 2016a; Therkelsen
2016b; Vogelaar 2014). Four studies measured the outcome using
both a generic and disease-specific quality of life questionnaire
(Colombel 2007; Colombel 2017; Gasche 2015; Vogelaar 2014).
Six studies (Artom 2018; Feagan 2013; Horta 2017; McNelly 2016;
RaNery 2013; Sandborn 2013) used a disease-specific measure
of quality of life and two studies used a generic measure
(Therkelsen 2016a; Therkelsen 2016b). The most commonly used
generic quality of life questionnaire was the Short Form-36 (SF-36)
(Colombel 2007; Gasche 2015; Therkelsen 2016a; Therkelsen 2016b;
Vogelaar 2014), however, the EuroQual (EQ-5D) was also used
(Vogelaar 2014). The most common disease-specific quality of
life questionnaire used was the Inflammatory Bowel Disease
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Questionnaire (IBDQ) (Colombel 2007; Feagan 2013; Gasche 2015;
McNelly 2016; RaNery 2013; Sandborn 2013; Vogelaar 2014), the UK
IBDQ (Artom 2018) and the IBDQ-9 (Horta 2017).
Of the twelve studies, five studies presented total quality of life
scores (Artom 2018; Colombel 2007; Gasche 2015; Horta 2017;
McNelly 2016). Two studies reported not analysing total quality of
life scores (Therkelsen 2016a; Therkelsen 2016b), whereas other
studies did not publish summary data for quality of life (Colombel
2017; Feagan 2013; RaNery 2013; Sandborn 2013; Vogelaar 2014).
Adverse events
Adverse (AEs) were assessed in ten of the fourteen eligible studies
(Colombel 2007; Colombel 2017; Feagan 2013; Gasche 2015; Hetzel
2013a; Horta 2017; McNelly 2016; Sandborn 2013; Therkelsen
2016a; Therkelsen 2016b). Three non-pharmacological trials did
not assess adverse events (Artom 2018; García-Vega 2004; Vogelaar
2014), whereas most of the pharmacological and multimodular
trials reported adverse events. It is unclear if one pharmacological
study assessed adverse events as it was not presented in the
report and the information remains unavailable (RaNery 2013).
The assessment of adverse events varied considerably across the
studies, with methods including the MedDRA system organ class
and preferred terms (Colombel 2007; Colombel 2017; Feagan 2013;
Gasche 2015; Sandborn 2013), medication diaries (McNelly 2016)
and interviews (Horta 2017; Therkelsen 2016a; Therkelsen 2016b)
being employed. Specific predefined adverse events were reported
in one trial (Hetzel 2013a).
Other outcomes
Due to the diverse nature of the eligible trials included in
this review, other outcomes were also assessed in the trials.
For example, the iron therapy interventions assessed Hgb
concentration and transferrin saturation (Gasche 2015; Hetzel
2013a), along with serum ferritin concentration (Gasche 2015),
whereas the physical activity advice intervention assessed physical
activity and body composition (McNelly 2016). Disease activity
was assessed in a number of studies using established measures
(Artom 2018; Colombel 2007; Colombel 2017; Gasche 2015; McNelly
2016; RaNery 2013; Therkelsen 2016a; Therkelsen 2016b), and
faecal calprotectin levels (Colombel 2017; Therkelsen 2016a;
Therkelsen 2016b; Vogelaar 2014). Many of the pharmacological
trials assessed disease activity response and remission as primary
outcomes of interest (Colombel 2007; Colombel 2017; Feagan
2013; Sandborn 2013). Some of the studies assessed a number
of blood tests, such as inflammatory levels (CRP) (Colombel
2007; Colombel 2017; McNelly 2016; RaNery 2013; Sandborn 2013;
Vogelaar 2014), full blood count (RaNery 2013), ethylenediamine
tetraacetic acid (EDTA) (Therkelsen 2016a; Therkelsen 2016b), and
serum 25(OH)D (RaNery 2013). Psychological outcomes, such as
depression (Artom 2018; Colombel 2017; Horta 2017; Vogelaar
2014) and anxiety (Artom 2018; Horta 2017; Vogelaar 2014), and self-
reported outcomes including sleepiness (Artom 2018; Horta 2017),
sleep quality (Vogelaar 2014) and illness perception (Artom 2018)
were other outcomes assessed. Of these outcomes, only those
related to fatigue, quality of life and adverse events were extracted
for this review.
Excluded studies
Of the 91 reports reviewed, 34 citations were excluded. The
majority (n = 24) were excluded as fatigue was not assessed
as a primary or secondary outcome in the trial. These trials
assessed quality of life using generic or disease-specific measures,
so potentially they were eligible to be included. However, as
the subscale data on fatigue, loss of energy, vitality or vigour
were not reported, these were excluded (Boye 2011; Colombel
2010; Cosnes 2013; Dewint 2014; Feagan 2003; Leiper 2001;
Lichtenstein 2002; LoNus 2017; Maragkoudaki 2016; Mikocka-Walus
2017; Paramsothy 2017; Pena Rossi 2009; Reusch 2016; Sands 2008;
Sands 2013; Schmidt 2016; Schreiber 2007; Smith 2011; Smith 2013;
Steinhart 2002; Targan 2007; Valentine 2009; Van Assche 2012;
Vermeire 2017). Seven studies were excluded as a randomised
controlled trial design was not employed (LoNus 2009; Minderhoud
2007; NCT01991314; NCT02148718; NCT02162862; Persoons 2007;
Szigethy 2016). For example, trials were single-group assignment
open trials (NCT01991314; NCT02148718; Szigethy 2016) or non-
randomised trials (Minderhoud 2007; NCT02162862). Three studies
were excluded as data from IBD-specific participants were not
presented separately (Ford 2016; Hetzel 2013b; Scholten 2018).
Details of the 34 excluded studies are presented in the
Characteristics of excluded studies table.
Studies awaiting classification
Five studies are awaiting classification following the top-up search
conducted in October 2019 (Ghosh 2019; Louis 2019; O' Connor
2019; Sands 2018; Tew 2019). Two studies are presented in full
text and three are published as conference proceedings. Additional
information is needed from the study authors and these studies will
be assessed for inclusion at the next update of the review.
Risk of bias in included studies
Two of the fourteen included trials (Colombel 2007; Gasche 2015)
were judged as adequately meeting all criteria (Figure 2; Figure 3).
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
 
 
Interventions for fatigue in inflammatory bowel disease (Review)









Cochrane Database of Systematic Reviews
Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
 
Details on the risk of bias for each individual trial are located within
the 'Characteristics of included studies' table.
Allocation
All studies were randomised, however, for two studies, the method
of sequence generation could not be ascertained as suLicient
description of the process was not provided to confirm true
randomisation (Hetzel 2013a; RaNery 2013). Studies used sequence
generation methods such as random number tables (García-Vega
2004), interactive voice response system (Colombel 2007; Colombel
2017; Gasche 2015), computer-generated simple randomisation
(Artom 2018; Feagan 2013; Horta 2017; Sandborn 2013), computer-
generated block randomisation (McNelly 2016; Vogelaar 2014),
or manual block randomisation (Therkelsen 2016a; Therkelsen
2016b).
Studies also applied measures to conceal allocation using an
interactive voice response system (Colombel 2007; Colombel 2017;
Gasche 2015), sequential named drug containers of identical
appearance provided by a pharmacy (capsule assignment)
(McNelly 2016) or sealed opaque envelopes (Artom 2018; Horta
2017). Other studies employed open allocation (high risk of
bias) (García-Vega 2004; McNelly 2016) or physical activity advice
intervention (Therkelsen 2016a; Therkelsen 2016b). Concealment
of allocation was unclear for the remaining five studies (Feagan
2013; Hetzel 2013a; RaNery 2013; Sandborn 2013; Vogelaar 2014)
due to insuLicient information available. These studies were
described as randomised, however convenience allocation may
have been employed.
Blinding
With regards to performance bias, studies varied from double-
blinded (Colombel 2007; Feagan 2013; Gasche 2015; Sandborn
2013), single-blinded (Horta 2017; Therkelsen 2016a; Therkelsen
2016b) to part-blinded (McNelly 2016) and unblinded (Artom 2018;
Colombel 2017; García-Vega 2004; Vogelaar 2014). It remained
unclear from two studies (Hetzel 2013a; RaNery 2013) if blinding
occurred due to limited information provided, although one
study stated that the trial was double-blinded, however, further
information was not provided (RaNery 2013). Most drug trials
were double-blinded (Colombel 2007; Feagan 2013; Gasche 2015;
Sandborn 2013), resulting in a low risk of bias classification.
Participants, sponsors, clinical researchers and clinical staL were
blinded to the treatment allocation in these studies, whereas only
the participants were blinded (single-blinded) in three studies
(Horta 2017; Therkelsen 2016a; Therkelsen 2016b). Personnel
administering the intervention were not blinded resulting in an
unclear risk of bias classification (Therkelsen 2016a; Therkelsen
2016b). However, in another study, the participants and evaluators,
but not the therapist, were blinded to group assignment, therefore,
deemed at low risk of bias (Horta 2017). A high risk of bias was
observed in one study which blinded participants and researchers
to the capsule (supplement) type, however, were unable to blind
personnel to the consultation type due to the nature of the
physical activity advice intervention (McNelly 2016). Three studies
were unblinded due to the inherent psychosocial nature of the
interventions (Artom 2018; García-Vega 2004; Vogelaar 2014).
Although one study (García-Vega 2004) tried to blind outcome
assessment undertaken by a gastroenterologist, all studies were
judged to have a high risk of bias.
The primary outcome of interest, fatigue, is a subjective outcome
self-reported in all studies, therefore, the unblinded (Artom 2018;
Colombel 2017; García-Vega 2004; Vogelaar 2014) and part-blinded
(McNelly 2016) studies were classified as at high risk of detection
bias. Participants were blinded in the remaining double-blinded
(Colombel 2007; Feagan 2013; Gasche 2015; Sandborn 2013) and
single-blinded (Horta 2017; Therkelsen 2016a; Therkelsen 2016b)
studies, therefore, these studies were judged to have a low risk
of detection bias. An unclear risk of bias was recorded for two
studies (Hetzel 2013a; RaNery 2013), as no explicit statement
about blinding status of participants, healthcare providers, data
collectors and outcome adjudicators was presented.
Incomplete outcome data
There was a relatively low dropout rate for the psychosocial
intervention trials (Artom 2018; García-Vega 2004; Horta 2017;
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McNelly 2016; Vogelaar 2014) and loss to follow-up was balanced
across groups with reasons comparable to the pharmacological
trials (Colombel 2007; Colombel 2017; Feagan 2013; Gasche 2015;
McNelly 2016; Sandborn 2013; Therkelsen 2016a; Therkelsen
2016b), yielding a low risk of bias classification. One study had
no loss to follow-up (García-Vega 2004). The remaining two trials
provided insuLicient information on missing outcome data (Hetzel
2013a; RaNery 2013).
Selective reporting
Most studies were judged as having a low risk of bias in terms of
selective outcome reporting as all information on outcomes was
presented and outcomes assessed were reported or provided upon
request (Colombel 2007; García-Vega 2004; Gasche 2015 McNelly
2016; Therkelsen 2016a; Therkelsen 2016b). However, selective
outcome reporting was an issue in the remaining studies, where
the results were presented for subgroups only or certain outcomes
were not reported. For example, two trial authors provided
information on the outcomes upon request (Artom 2018; Horta
2017). However, the findings are only published as conference
abstracts at present, therefore, we rated these studies as having
unclear risk of bias for selective reporting. One study presented
data comparing the intervention group with the overall placebo
population control group rather than an IBD placebo control group
(Hetzel 2013a). Also, one study did not report the fatigue and quality
of life scores for the intervention and control groups, but rather,
data for a subgroup based on the 25-hydroxyvitamin D (25OHD)
levels were presented (RaNery 2013). Another study presented only
percentages for fatigue scores, with no eLect sizes or P values
reported (Vogelaar 2014). Additional information requested was
not provided by trial authors, therefore, these five trials were all
classified as having high risk of bias (Feagan 2013; Hetzel 2013a;
RaNery 2013; Sandborn 2013; Vogelaar 2014). Fatigue and quality of
life data were not published for one trial (Colombel 2017), however,
we are awaiting outcome data from the trial author, so this trial,
therefore, was judged as having unclear risk of bias for selective
outcome reporting.
Other potential sources of bias
Selection bias
Ten studies reported similar baseline characteristics between
treatment groups (Artom 2018; Colombel 2007; Colombel 2017;
Feagan 2013; Gasche 2015; McNelly 2016; Sandborn 2013;
Therkelsen 2016a; Therkelsen 2016b; Vogelaar 2014) minimising
the potential for selection bias. Unbalanced groups at baseline
were noted in one study only (García-Vega 2004), so this study was
rated as having a high risk of selection bias. It remained unclear
from two studies if baseline characteristics of groups diLered due to
limited or no information reported and so selection bias was rated
as being unclear for these studies (Hetzel 2013a; RaNery 2013).
Use of validated assessment instruments
Ten studies used a validated fatigue assessment instrument to
measure fatigue (Artom 2018; Colombel 2007; Colombel 2017;
Feagan 2013; Gasche 2015; Hetzel 2013a; McNelly 2016; RaNery
2013; Sandborn 2013; Vogelaar 2014), however, in three trials,
fatigue was assessed as a subscale or subcomponent of a broader
quality of life scale only (Feagan 2013; Gasche 2015; Sandborn
2013). One study assessed the average frequency and severity
of 'tiredness' (fatigue) as a single item from a 10-item disease
symptom diary (García-Vega 2004). The validity of single-item or
subscale measures of fatigue are unknown, hence, the reliability of
the study findings need to be interpreted with caution.
E:ects of interventions
See: Summary of findings for the main comparison
Electroacupuncture compared to no treatment for participants
with quiescent IBD; Summary of findings 2 Electroacupuncture
compared to sham electroacupuncture for participants with
quiescent IBD; Summary of findings 3 CBT with therapist support
compared to fatigue information leaflet only for participants with
IBD; Summary of findings 4 Physical activity advice plus omega
3 compared to no physical activity advice plus omega 3 for
participants with quiescent IBD; Summary of findings 5 Physical
activity advice plus placebo compared to no physical activity
advice plus placebo for participants with quiescent IBD; Summary
of findings 6 Physical activity advice plus placebo compared to
no physical activity advice plus omega 3 for participants with
quiescent IBD
The eLects of 'pharmacological versus placebo'; 'pharmacological
versus pharmacological', 'non-pharmacological versus usual or
standard care', 'non-pharmacological versus non-pharmacological'
and 'pharmacological versus non-pharmacological' were the
comparisons included. No trial made the remaining comparisons
considered eligible for this review. See Summary of findings 3;
Summary of findings 2; Summary of findings 4; Summary of
findings 6; Summary of findings 5; Summary of findings for the
main comparison; Table 1; Table 2; Table 3; Table 4; Table 5; Table
6; Table 7. The summary of eLects of the interventions on the
predefined outcomes (fatigue, quality of life and adverse events) of
the included trials are presented below.
Pharmacological interventions versus placebo
Eight trials made this comparison (Colombel 2007; Feagan
2013; Gasche 2015; Hetzel 2013a; RaNery 2013; Sandborn 2013;
Therkelsen 2016a; Therkelsen 2016b), however fatigue data were
only available for four of the trials (Colombel 2007; Gasche
2015;Therkelsen 2016a; Therkelsen 2016b). In four trials, the mean
diLerence in the primary and secondary outcomes could not
be calculated, as data were not available. These comparisons
included ferumoxytol versus placebo (Hetzel 2013a); vedolizumab
maintenance versus placebo (Feagan 2013; Sandborn 2013); and
vitamin D3 versus placebo (RaNery 2013).
a. Adalimumab versus placebo
The eLect of adalimumab therapy was assessed in one trial
(Colombel 2007). Adalimumab was administered either 40 mg
every other week (eow) or 40 mg weekly. In this review,
dichotomous data were presented for both dosing regimens
individually and also combined (adalimumab maintenance
therapy). Continuous data were presented for the adalimumab
maintenance therapy group and the adalimumab 40 mg eow group
only, to avoid a unit of analysis error with multi-arm trials. As it was
not possible to calculate a mean and standard deviation for each
placebo comparator, the adalimumab 40 mg eow was selected as
the dose group that reflects clinical practice.
Primary outcome - Fatigue
Fatigue, as measured using the FACIT-F and SF-36 vitality subscale,
was assessed in one trial (Colombel 2007). The mean diLerence
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between adalimumab maintenance therapy and the placebo
groups could not be calculated for FACIT-F, as summary data were
not published or available upon request. However, fatigue data,
as measured using the FACIT-F, were available for randomised
responders (participants who had previously responded [achieved
clinically meaningful change in disease activity by week 4] to
open-label adalimumab induction therapy) only. Although fatigue
was also assessed for all randomised participants, data were not
available upon request. Furthermore, the FACIT-F data represented
the last-observation-carried-forward when a participant had a
missing value, dropped out, or switched to open-label therapy.
A diLerence was found in fatigue levels between adalimumab 40
mg eow, compared to the placebo at the 56-week follow-up, as
measured by the FACIT-F. The mean fatigue score aNer 56 weeks
of treatment was 36.8 in the in the adalimumab 40 mg eow group
compared to 32.5 in the placebo group (MD 4.30, 95% CI 1.75 to 6.85,
very low-certainty evidence) (Analysis 2.1).
Fatigue, as measured using the SF-36 vitality subscale, revealed
no diLerence between adalimumab maintenance therapy and the
adalimumab 40 mg eow group, compared to the placebo group, for
all randomised participants or for randomised previous responders
(low-certainty evidence) (Analysis 1.1; Analysis 2.2).
Secondary outcomes - Quality of life and adverse events
Quality of life data, as measured using the SF-36 and IBDQ, were
reported in one trial (Colombel 2007). There was no diLerence
in quality of life scores, as measured by the SF-36 between the
adalimumab maintenance therapy group and adalimumab 40 mg
eow group, compared to the placebo group, for all randomised
participants or randomised previous responders (low-certainty
evidence) (Analysis 1.2; Analysis 1.3; Analysis 2.3; Analysis 2.4).
However, when quality of life was measured using the disease-
specific IBDQ, the mean quality of life score aNer 56 weeks of
treatment was 187.1 in the adalimumab maintenance therapy
group compared to 173.3 in the placebo group for randomised
responders (MD 13.80, 95% CI 1.99 to 25.61, low-certainty evidence)
(Analysis 1.4).
The treatment-emergent adverse events during double-blind
treatment for the intention-to-treat subjects revealed that there
was no diLerence in adverse events for adalimumab maintenance
therapy, adalimumab 40 mg eow and adalimumab 40 mg weekly
compared to placebo (Analysis 1.5; Analysis 2.6; Analysis 3.6).
Serious adverse events and withdrawal due to adverse events were
reported in 9% (24/260) and 7% (18/260) of participants in the
adalimumab 40 mg eow group compared to 15% (20/130) and
13% (17/130) in the placebo group, respectively (OR 0.56, 95% CI
0.30 to 1.06 and OR 0.49, 95% CI 0.25 to 1.00, moderate-certainty
evidence) (Analysis 2.7; Analysis 2.8). However, the adalimumab
maintenance and adalimumab 40 mg weekly groups were less
likely to experience serious adverse events and withdrawal due
to adverse events compared to placebo. Serious adverse events
were reported in 8.7% (45/517) and 8.2% (21/257) of participants
in the treatment groups compared to 15.3% (40/261) and 15.4%
(20/130) of participants in the placebo groups, respectively (OR
0.53, 95% CI 0.33 to 0.83 and OR 0.49, 95% CI 0.25 to 0.94, moderate-
certainty evidence) (Analysis 1.6; Analysis 3.7). Withdrawal due to
adverse events was reported in 5.8% (30/517) and 4.7% (12/257) of
participants in the treatment groups compared to 13.4% (35/261)
and 13.1% (17/130) of participants in the placebo groups for the
adalimumab maintenance therapy and the adalimumab 40 mg
weekly groups, respectively (OR 0.40, 95% CI 0.24 to 0.66 and OR
0.33 95% CI 0.15 to 0.70, moderate-certainty evidence) (Analysis 1.7;
Analysis 3.8).
b. AndoSanTM versus placebo
Primary outcome - Fatigue
Fatigue data, as measured using the Fatigue Questionnaire and
SF-36 vitality subscale, were available in two trials (Therkelsen
2016a; Therkelsen 2016b). Data from these trials were pooled
as they were assessed as clinically homogenous with regards to
participants, interventions, and outcomes, with I2 = 0% for total
fatigue score and I2 = 61% for SF-36 vitality. At 21 days post-
intervention, there was no diLerence in fatigue, as measured by the
Fatigue Questionnaire, between the AndoSanTM group compared
to the placebo group for those with ulcerative colitis (MD -1.80,
95% CI -4.39 to 0.79, low-certainty evidence) (Therkelsen 2016a)
or Crohn's disease (MD -1.36,95% CI -4.07 to 1.35, low-certainty
evidence) (Therkelsen 2016b) (Analysis 4.1). Similar results were
found when fatigue was measured using the SF-36 vitality
subscale (Therkelsen 2016a; Therkelsen 2016b). At 21 days post-
intervention, there was no diLerence in fatigue scores between
AndoSanTM and the placebo group for those with ulcerative colitis
(MD 8.60, 95% CI -1.09 to 18.29, low-certainty evidence) (Therkelsen
2016a) and those with Crohn's disease (MD -3.72, 95% CI -15.31 to
7.87, low-certainty evidence) (Therkelsen 2016b) (Analysis 4.2).
Secondary outcomes - Quality of life and adverse events
Quality of life was assessed using the SF-36, however, total physical
component summary scores and mental component summary
scores were not calculated. Rather, findings from the eight health
dimensions of the scale were presented (author information).
Adverse events were assessed by the trial author via interviews
with participants at all visits. Although participants tolerated
AndoSanTM well, the trial authors did not record AEs (author
information).
c. Ferric maltol versus placebo
Primary outcome - Fatigue
Fatigue data, as measured using the SF-36 vitality subscale, were
available in one trial (Gasche 2015). At 12 weeks post-intervention,
there was a diLerence in the mean vitality scores between the ferric
maltol and placebo groups. The mean vitality score was 43.92 in
the treatment group compared to 53.23 in the placebo group, with
higher scores indicating better vitality (less fatigue) (MD -9.31, 95%
CI -17.15 to -1.47, low-certainty evidence) (Analysis 5.1).
Secondary outcomes - Quality of life and adverse events
Quality of life data, as measured using the IBDQ, were available in
one trial (Gasche 2015). At 12 weeks post-intervention, there was no
diLerence in quality of life scores between the ferric maltol group
and the placebo group (MD 3.70, 95% CI -7.89 to 15.29, low-certainty
evidence) (Analysis 5.2).
Adverse events were reported in 51% (35/60) of participants in the
ferric maltol group compared to 71% (43/60) of participants in the
placebo group (OR 0.55, 95% CI 0.26 to 1.18, low-certainty evidence)
(Analysis 5.3). Serious adverse events were reported in 8% (8/60) of
participants in the ferric maltol group compared to 13% (6/60) of
participants in the placebo group (OR 1.00,95% CI 0.14 to 7.34, low-
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certainty evidence) (Analysis 5.4). No diLerence in withdrawal due
to adverse events was found between the groups (OR 1.69, 95% CI
0.52 to 5.51, low-certainty evidence) (Analysis 5.5).
Pharmacological interventions versus pharmacological
interventions
One trial made this comparison, however, the mean diLerence in
the primary and secondary outcomes could not be calculated as
data were not available (Colombel 2017).
Non-pharmacological interventions versus usual or standard
care
Three trials made this comparison (García-Vega 2004; Horta 2017;
Vogelaar 2014).
a. Electroacupuncture versus no treatment
Primary outcome - Fatigue
Fatigue data, as measured using the FACIT-F, were available in one
trial (Horta 2017). There was a diLerence in fatigue levels found
between the electroacupuncture group, compared to the control
group. The mean fatigue score aNer eight weeks of treatment was
33.2 in the electroacupuncture group compared to 25.2 in the
control group, with higher scores indicating better vitality (less
fatigue) (MD 8.00, 95% CI 6.45 to 9.55, low-certainty evidence)
(Analysis 6.1). The diLerence in fatigue levels at the week 16 follow-
up could not be calculated. The summary data for the control group
were not available at follow-up, as the group was oLered open-label
electroacupuncture treatment.
Secondary outcomes - Quality of life and adverse events
Quality of life data, as measured using the IBDQ-9, were available
in one trial (Horta 2017). At the week eight follow-up, there was
a diLerence in IBDQ-9 scores between the electroacupuncture
group compared to the control group. The mean quality of life
score aNer eight weeks of treatment was 61.5 in the treatment
group, compared to 57.0 in the control group (MD 4.50, 95% CI
3.37 to 5.63, low-certainty evidence) (Analysis 6.2). The IBDQ-9
summary data were not available at the week 16 follow-up to
calculate the mean diLerence, as the group was oLered open-label
electroacupuncture treatment. No adverse events, serious adverse
events and withdrawal due to adverse events were reported by
participants in the electroacupuncture or control groups.
b. Electroacupuncture versus sham electroacupuncture
Primary outcome - Fatigue
Fatigue data, as measured using the FACIT-F, were available in one
trial (Horta 2017). At the week eight and 16 follow-up, there was a
diLerence in fatigue scores between the electroacupuncture group
and the sham electroacupuncture group. The mean vitality score
aNer eight weeks of treatment was 33.2 in the electroacupuncture
group compared to 28.1 in the sham electroacupuncture group,
with higher scores indicating better vitality (less fatigue) (MD
5.10, 95% CI 3.49 to 6.71, low-certainty evidence) (Analysis
7.1). At 16-week follow-up, the mean vitality score was 31.4 in
the electroacupuncture group compared to 28.8 in the sham
electroacupuncture group (MD 2.60, 95% CI 0.74 to 4.46, low-
certainty evidence) (Analysis 7.1).
Secondary outcomes - Quality of life and adverse events
Quality of life data, as measured using the IBDQ-9, were available
in one trial (Horta 2017). A mean diLerence was found in the quality
of life scores following treatment at week eight and at the week
16 follow-up. The mean quality of life score aNer eight weeks of
treatment was 61.5 in the electroacupuncture group compared to
57.8 in the sham electroacupuncture group (MD 3.70, 95% CI 2.66 to
4.74, low-certainty evidence) (Analysis 7.2). At 12-week follow-up,
the mean quality of life score was 60.8 in the electroacupuncture
group compared to 58.6 in the sham electroacupuncture group (MD
2.20, 95% CI 0.98 to 3.42, low-certainty evidence) (Analysis 7.2).
One adverse event was reported in the sham electroacupuncture
group (Analysis 7.3). No serious adverse events were reported
by participants in either group (Analysis 7.4). There was one
withdrawal due to adverse events in the sham electroacupuncture
group (Analysis 7.5).
c. Guided stress management programme versus conventional
medical treatment
Primary outcome - Fatigue
Fatigue data, measured as the average frequency of tiredness and
the severity of tiredness, were available in one trial (García-Vega
2004). At post-intervention and 12-month follow-up, there were
no diLerences in the average frequency of tiredness in the guided
stress management programme compared to the conventional
medical treatment group (MD -22.10, 95% CI -55.47 to 11.27 and
MD 0.00, 95% CI -30.77 to 30.77, respectively, very low-certainty
evidence) (Analysis 8.1). Likewise, the severity of tiredness was not
diLerent in the guided stress management group, compared to
the conventional medical treatment group post-intervention or at
12-month follow-up (MD -0.40, 95% CI -1.18 to 0.38 and MD 0.30,
95% CI -0.39 to 0.99, very low-certainty evidence) (Analysis 8.2),
respectively.
Secondary outcomes - Quality of life and adverse events
Quality of life and adverse events were not assessed in this trial
(García-Vega 2004). The author stated that no adverse events were
reported (author information).
d. Self-directed stress management programme versus
conventional medical treatment
Primary outcome - Fatigue
Fatigue data, measured as the average frequency of tiredness
and the severity of tiredness, were available in one trial (García-
Vega 2004). At post-intervention, there was no diLerence in the
average frequency of tiredness between the self-directed stress
management group and the conventional medical treatment group
(MD -17.20, 95% CI -50.91 to 16.51, very low-certainty evidence),
However, at 12 months follow-up, a diLerence in the average
frequency of tiredness was found. The average frequency of
tiredness scores was 21.8 in the self-directed stress management
group compared to 51.4 in the conventional medical treatment
group (MD -29.60, 95% CI -58.68 to -0.52, very low-certainty
evidence) (Analysis 9.1). There was no diLerence in the severity of
tiredness post-intervention (MD -0.20, 95% CI -1.01 to 0.61, very
low-certainty evidence), or at 12-month follow-up (MD -0.30, 95%
CI -0.98 to 0.38, very low-certainty evidence) (Analysis 9.2).
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Secondary outcomes - Quality of life and adverse events
Quality of life and adverse events were not assessed in this trial
(García-Vega 2004). The author stated that no adverse events were
reported (author information).
e. Solution-focused therapy versus care-as-usual
Primary outcome - Fatigue
Fatigue data, as measured using the CIS-F and FSS-9, were
available in one trial (Vogelaar 2014). The mean diLerence in fatigue
between the solution-focused therapy and care-as-usual groups
could not be calculated because standard summary data were not
reported. However, when data from the CIS-F were presented as a
dichotomous variable, the solution-focused therapy group showed
a greater reduction in fatigue across the first six months compared
with the CAU group (P < 0.001). No significant diLerences between
the two groups were found at nine months.
Secondary outcomes - Quality of life and adverse events
Quality of life was assessed in one trial (Vogelaar 2014). However,
the mean diLerence in quality of life scores between the solution-
focused therapy and care-as-usual groups could not be calculated
because summary data were not reported. Adverse events were not
assessed in this trial (Vogelaar 2014).
Non-pharmacological interventions versus non-
pharmacological interventions
One trial made this comparison (Artom 2018).
a. Cognitive behavioural therapy with therapist support versus
fatigue information leaflet
Primary outcome - Fatigue
Fatigue data, as measured using the IBD-F, were available in
one trial (Artom 2018). At month three follow-up, there was no
diLerence in IBD-F section I scores and IBD-F section II scores
between the cognitive behavioural therapy with therapist support
group and the fatigue information leaflet group. The mean fatigue
level score was 7.29 in the treatment group compared to 9.45 in
the control group (MD -2.16, 95% CI -6.13 to 1.81, very low-certainty
evidence) (Analysis 10.1). The mean impact of the fatigue score was
25.71 in the cognitive behavioural therapy with therapist support
group compared to 47.33 in the fatigue information leaflet group
(MD -21.62, 95% CI -45.02 to 1.78, very low-certainty evidence)
(Analysis 10.2).
Secondary outcomes - Quality of life and adverse events
Quality of life data, as measured using the UK-IBDQ, were available
in one trial (Artom 2018). No diLerence in quality of life scores
were found between the cognitive behaviour therapy with therapist
support group, compared to the fatigue information leaflet group,
at the month three follow-up (MD 0.19, 95% CI -9.32 to 9.70, very
low-certainty evidence) (Analysis 10.3). Adverse events were not
assessed in this trial (Artom 2018).
Multimodular intervention
One trial used multimodular comparisons (McNelly 2016). This 2 x
2 factorial RCT examined six comparisons, namely:
1. No physical activity advice plus omega 3 versus no physical
activity advice plus placebo;
2. Physical activity advice plus omega 3 versus no physical activity
advice plus omega 3;
3. Physical activity advice plus placebo versus no physical activity
advice plus placebo;
4. Physical activity advice plus omega 3 versus physical activity
advice plus placebo;
5. Physical activity advice plus omega 3 versus no physical activity
advice plus placebo;
6. Physical activity advice plus placebo versus no physical activity
advice plus omega.
In order to avoid a unit of analysis error, it was not possible
to calculate mean and standard deviations for each placebo
comparator, therefore the following three key comparisons were
selected:
a. Physical activity advice plus omega 3 versus no physical
activity advice plus omega 3
Primary outcome - Fatigue
Fatigue data, as measured using the FACIT-F, MFI and IBD-F, were
available in one trial (McNelly 2016). At the 12-week follow-up, there
was no diLerence in fatigue levels between the physical activity
advice plus omega 3 group, compared to the no physical activity
advice plus omega 3 group, as measured using the FACIT-F (MD 6.40,
95% CI -1.80 to 14.60, very low-certainty evidence) (Analysis 11.1) or
the MFI (MD - 0.50, 95% CI -3.88 to 2.88, very low-certainty evidence)
(Analysis 11.2). Likewise, there was no diLerence between the
groups when fatigue was measured using the disease-specific IBD-
F scale section I (MD - 3.10, 95% CI -6.67 to 0.47, very low-certainty
evidence) (Analysis 11.3) and section II (MD -13.10, 95% CI -29.37 to
3.17, very low-certainty evidence) (Analysis 11.4).
Secondary outcomes - Quality of life and adverse events
At the 12-week follow-up, there was no diLerence in quality of life
scores between the physical activity advice plus omega 3 group,
and the no physical activity advice plus omega 3 group (MD 4.00,
95% CI -18.46 to 26.46, very low-certainty evidence) (Analysis 11.5).
At the 12-week follow-up, there were five reported adverse events in
the physical activity advice plus omega 3 group, namely, epigastric
pain (n = 1), bloating (n = 1), headache (n = 1), leg pain (n = 1) and
feeling unwell (n = 1). There were fourteen reported adverse events
in the no physical activity advice plus omega 3 group, namely,
epigastric pain (n = 1), diarrhoea (n = 1), bloating (n = 2), nausea and
vomiting (n = 3), IBD flare (n = 1), pins and needles (n = 1), joint pain
(n = 1), ankle injury (n = 1), rash (n = 1) and feeling unwell (n = 2).
Serious adverse events and withdrawal due to adverse events were
not reported.
b. Physical activity advice plus placebo versus no physical
activity advice plus placebo
Primary outcome - Fatigue
Fatigue data, as measured using the FACIT-F, MFI and IBD-F, were
available in one trial (McNelly 2016). At the 12-week follow-up, there
was no diLerence in fatigue levels between the physical activity
advice plus placebo group, and the no physical activity advice plus
placebo group, as measured using the FACIT-F (MD 2.70, 95% CI
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-2.48 to 7.88, very low-certainty evidence) (Analysis 12.1), however
a diLerence was identified when measured using the MFI. The mean
fatigue score was 12.7 in the treatment group compared to 15.3 in
the control group, with higher scores indicating greater fatigue (MD
- 2.60, 95% CI -4.70 to -0.50, very low-certainty evidence) (Analysis
12.2). There was no diLerence between the groups when fatigue
was measured using the disease-specific IBD-F scale section I (MD
- 1.70, 95% CI -4.04 to 0.64, very low-certainty evidence) (Analysis
12.3) and section II (MD -8.50, 95% CI -21.57 to 4.57, very low-
certainty evidence) (Analysis 12.4).
Secondary outcomes - Quality of life and adverse events
At the 12-week follow-up, there was no diLerence in quality of life
scores between the physical activity advice plus placebo group and
the no physical activity advice plus placebo group (MD 9.00, 95% CI
-15.72 to 33.72, very low-certainty evidence) (Analysis 12.5).
At the 12-week follow-up, there were four reported adverse
events in the physical activity advice plus placebo group, namely,
epigastric pain (n = 1), diarrhoea (n = 1), bloating (n = 1), and nausea
and vomiting (n = 1). There were five reported adverse events in the
no physical activity advice plus placebo group, namely epigastric
pain (n = 2), diarrhoea (n = 1), headache (n = 1), and molluscum (n
= 1). Serious adverse events and withdrawal due to adverse events
were not reported.
c. Physical activity advice plus placebo versus no physical
activity advice plus omega 3
Primary outcome - Fatigue
At the 12-week follow-up, a diLerence in fatigue levels was found
between the physical activity advice plus placebo group, and the no
physical activity advice plus omega 3 group, as measured using the
FACIT-F. The mean vitality scores aNer 12 weeks of treatment was
41.1 in the physical activity advice plus placebo group compared
to 32.1 in the no physical activity advice plus omega 3, with higher
scores indicating greater vitality (less fatigue) (MD 9.00, 95% CI 1.64
to 16.36, very low-certainty evidence) (Analysis 13.1). No diLerence
was identified when fatigue was measured using the MFI (MD -1.40,
95% CI -4.39 to 1.59, low-certainty evidence) (Analysis 13.2). There
was no diLerence between the groups when fatigue was measured
using the disease-specific IBD-F scale section I, however, the mean
level of fatigue scores aNer 12 weeks of treatment was 6.8 for
the physical activity advice plus placebo group compared to 9.6
for the no physical activity advice plus omega 3 group (MD -2.80,
95% CI -5.93 to 0.33, very low-certainty evidence) (Analysis 13.3).
A diLerence was evident between the groups when measured by
section II of the IBD-F. The mean impact of the fatigue scores was
19.4 for the physical activity advice plus placebo group compared
to 34.8 in the no physical activity advice plus omega 3 group (MD
-15.40, 95% CI -30.51 to -0.29, very low-certainty evidence) (Analysis
13.4).
Secondary outcomes - Quality of life and adverse events
At the 12-week follow-up, there was no diLerence in quality of life
scores between the physical activity advice plus placebo group, and
the no physical activity advice plus omega 3 group (MD 4.00, 95% CI
-18.20, to 26.20, very low-certainty evidence) (Analysis 13.5).
At the 12-week follow-up, there were four reported adverse
events in the physical activity advice plus placebo group, namely,
epigastric pain (n = 1), diarrhoea (n = 1), bloating (n = 1), and nausea
and vomiting (n = 1). There was fourteen reported adverse events
in the no physical activity advice plus omega 3 group, namely,
epigastric pain (n = 1), diarrhoea (n = 1), bloating (n = 2), nausea and
vomiting (n = 3), IBD flare (n = 1), pins and needles (n = 1), joint pain
(n = 1), ankle injury (n = 1), rash (n = 1) and feeling unwell (n = 2).
Serious adverse events and withdrawal due to adverse events were
not reported.
D I S C U S S I O N
Summary of main results
This systematic review included fourteen randomised controlled
trials (3741 participants) that evaluated the eLicacy and
safety of diLerent pharmacological and non-pharmacological
interventions on fatigue in IBD. The fourteen trials in the review
included nine pharmacological, four non-pharmacological and one
multimodular trial. Only four trials assessed fatigue as a primary
outcome (Artom 2018; Horta 2017; McNelly 2016; Vogelaar 2014).
Outcome data on fatigue were not available for analysis from all
fourteen trials, therefore, the findings of this review are based
on 1344 participants in nine trials. Only two of the studies were
pooled, due to the diversity and limited number of studies for each
intervention.
Given the high prevalence and burden of fatigue in IBD, there
is very limited evidence on interventions that help fatigue. In
the Colombel 2007 trial, at week 56 the mean fatigue scores
were lower in the adalimumab 40 mg administered every other
week group (36.8) than in the placebo group (32.5) in participants
with Crohn's disease who were already known to respond to
adalimumab treatment, with higher scores indicating less fatigue.
The mean diLerence between the groups was 4.30 points and this
is likely to be a clinically meaningful improvement in fatigue levels
(Cella 2005; Cella 2002). However, the GRADE analysis indicated
that the overall certainty of the evidence for this outcome was
very low due to due to serious inconsistency and very serious
imprecision as the confidence interval was wide and the fatigue
data measured using the FACIT-F represented the last-observation-
carried-forward when a participant had missing values, dropped
out or switched to open-label therapy. No diLerence in fatigue was
evident for adalimumab maintenance therapy or adalimumab 40
mg administered every other week in all randomised participants.
Results must be interpreted with caution as the fatigue findings
diLer when measured using the FACIT-F and the SF-36 vitality
subscale, and the indication for the intervention was disease
activity, rather than the primary outcome of this review. Further
research is needed before any firm conclusions can be drawn about
potential fatigue benefits with adalimumab 40 mg administered
every other week in patients with Crohn's disease.
The evidence suggests that ferric maltol results in a slight increase
in fatigue in patients with Crohn's disease or ulcerative colitis,
in remission or with mild-to-moderate disease activity (Gasche
2015). Mean fatigue scores were lower in the ferric maltol group
(43.92) compared to placebo (53.23), with higher scores indicating
better vitality (less fatigue). The mean diLerence between ferric
maltol and placebo groups was 9.31 points and this is likely to
be a minimally important diLerences in fatigue in people with
Crohn's disease (Coteur 2009). However, these results should be
interpreted with caution as the GRADE analysis indicated that the
overall certainty of the evidence was low due to sparse data and a
wide confidence interval, therefore, further research is needed.
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Results from one trial on self-directed stress management
intervention suggest that the average frequency of tiredness is
lower compared to the standard care group, with a mean diLerence
of 29.6 points found at 12 months (García-Vega 2004). However,
there was no diLerence in the severity of tiredness between the self-
directed stress management group and those receiving standard
care. The assessment measure used has not been validated and
it is unclear whether observed improvements in the frequency of
tiredness are clinically meaningful. Thus, we are very uncertain
about the eLects of self-directed stress management on fatigue.
There is evidence to suggest that electroacupuncture may result
in a large reduction in fatigue and increase in quality of life
compared to no treatment aNer eight weeks of treatment and
also compared to sham electroacupuncture post-treatment and
eight weeks following treatment (Horta 2017). The mean diLerence
between electroacupuncture and control groups post-treatment
was 8 points and this is likely to be a clinically meaningful
improvement in fatigue levels (Cella 2005; Cella 2002). The scores
were not available for the control group to calculate the mean
diLerence between the groups at week 16, as participants reporting
no improvement in fatigue (FACIT-F score < 40) at week eight were
oLered open electroacupuncture in this cross-over design trial.
Mean fatigue scores were also higher in the electroacupuncture
group compared to the sham electroacupuncture group both at
week eight and week 16 follow-up, with higher scores indicating
less fatigue. A mean diLerence of 5.10 points and 2.60 points was
found at week eight and week 16, respectively. This suggests a
likely clinically meaningful improvement in fatigue post-treatment,
however, the diLerence may not be clinically important eight weeks
following treatment (Cella 2002; Cella 2005). The GRADE analysis
indicated that the overall certainty of the evidence supporting
these results were low due to sparse data and wide confidence
intervals. Further research is needed before any strong conclusions
can be drawn on the eLicacy of electroacupuncture on fatigue.
We found that physical activity advice may also reduce fatigue but
the evidence is very uncertain. One 2 x 2 factorial RCT (McNelly
2016) examined six comparisons, therefore, in order to avoid a unit
of analysis error, only three key comparisons were selected. The
mean diLerences in fatigue scores between the physical activity
advice plus omega 3 and no physical activity advice plus omega 3
groups using the diLerent fatigue scales (FACIT-F 6.40; MFI -0.50;
IBDF Section I -3.10; IBDF Section II -13.10) were not statistically
significant, however, may be clinically meaningful for the FACIT-F
scale (Cella 2002; Cella 2005). It is unclear whether the observed
improvements in fatigue for the IBDF scale are important, due to the
lack of clearly defined minimally important thresholds. In contrast,
the mean diLerence scores were lower for the physical activity
advice plus placebo and no physical activity advice plus placebo
comparison across the FACIT-F (MD 2.7), MFI (-2.6), IBDF Section I
(-1.70) and IBDF Section II (-8.50) scales. Although, a statistically
significant diLerence was found, as measured by the MFI scale, the
mean diLerence may not be clinically important (Goligher 2008;
Pouchot 2008). For the third comparison, it was found that the
mean fatigue scores were higher in the physical activity advice
plus placebo group (41.1) than the no physical activity advice plus
omega 3 group (32.1) using the FACIT-F scale, with higher scores
indicating less fatigue. The mean fatigue scores were lower in the
physical activity advice plus placebo group (MFI 12.7; IBDF Section
I 6.8; IBDF Section II 19.4) than the no physical activity advice group
plus omega 3 group (MFI 14.1; IBDF Section I 9.6; IBDF Section II
34.8), with lower scores indicating less fatigue. The mean diLerence
for the FACIT-F scale (MD 9.00) is likely to be clinically meaningful
(Cella 2002; Cella 2005), however not important based on the MFI
mean diLerence (MD - 1.40) (Goligher 2008; Pouchot 2008) and
unclear for the IBDF scale (IBDF Section I MD - 2.80; IBDF Section II
MD - 15.40). Results must be interpreted with caution as the fatigue
findings diLer when measured using diLerent fatigue scales and the
overall GRADE analysis indicated that the certainty of the evidence
supporting these results is low due to high risk of bias, sparse data
and wide confidence intervals.
Partial data were available from some of the fatigue outcomes
assessed in the solution-focused therapy (SFT) trial (Vogelaar
2014). There is evidence to suggest that SFT shows a greater
reduction in fatigue at six months follow-up compared with care-as-
usual, however, data were reported in a non-standard way and the
study rated as high risk of bias for selective reporting, therefore, we
are very uncertain about the eLicacy and safety of solution-focused
therapy on fatigue,
No diLerence in fatigue levels were found for any of the other
comparisons, including adalimumab 40 mg weekly (Colombel
2007), AndoSanTM (Therkelsen 2016a; Therkelsen 2016b), guided
stress management (García-Vega 2004), physical activity advice
and/or omega 3 (McNelly 2016) and cognitive behavioural therapy
with therapist support (Artom 2018).
Fatigue data were not available for the trials investigating the eLect
of customised combination therapy (tight control management)
(Colombel 2017), vedolizumab maintenance therapy (Feagan 2013;
Sandborn 2013), vitamin D3 (RaNery 2013) or ferumoxytol (Hetzel
2013a). This was primarily due to fatigue not being a primary
outcome in these trials.
Secondary outcomes relevant to our review, namely quality
of life and adverse events, were both assessed in nine trials
(Colombel 2007; Colombel 2017; Feagan 2013; Gasche 2015; Horta
2017; McNelly 2016; Sandborn 2013 Therkelsen 2016a; Therkelsen
2016b). One trial (Hetzel 2013a) assessed adverse events only;
three trials assessed quality of life only (Artom 2018; RaNery
2013; Vogelaar 2014) and one trial (García-Vega 2004) assessed
neither secondary outcomes relevant to our review. There was
no diLerence in physical or mental quality of life, as measured
using a generic quality of life scale, for adalimumab maintenance
therapy or adalimumab 40 mg administered every other week
compared to placebo (Colombel 2007). In contrast, when quality
of life was measured using a disease-specific measure, results
suggest a diLerence in scores for the adalimumab maintenance
therapy and adalimumab 40 mg administered every other week
compared to placebo, for randomised previous responders only.
Mean fatigue scores were higher in the adalimumab maintenance
group (187.1) and the adalimumab 40 mg administered every
other week group (187.9) than in the placebo group (173.3) at
56 weeks in participants with Crohn's disease who were already
known to respond to adalimumab treatment, with higher scores
indicating better quality of life. However, the mean diLerences
between the groups were 13.80 and 14.60 points, respectively,
and this is likely to not be a clinically meaningful improvement
in quality of life (Cella 2005; Cella 2002). The evidence suggests
that electroacupuncture may result in a large increase in quality of
life, compared to control and sham electroacupuncture. The mean
quality of life scores were higher in the electroacupuncture group
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(61.5) than the control group (57) and sham electroacupuncture
(57.8) at week eight. The mean quality of life scores were also higher
in the electroacupuncture group (60.8) compared to the sham
electroacupuncture group (58.6) at week 16. However, it is unclear
whether the observed improvements in quality of life are clinically
important, due to the lack of clearly defined minimally important
diLerence thresholds for the IBDQ-9 scale. The GRADE analysis
indicated that the overall certainty of the evidence supporting
these results on quality of life was low due to sparse data and wide
confidence intervals. Further research is needed before any strong
conclusions can be drawn on the eLicacy and safety of adalimumab
maintenance therapy, adalimumab 40 mg administered every
other week and electroacupuncture on quality of life.
No diLerences in quality of life were found for ferric maltol (Gasche
2015), cognitive behavioural therapy with therapist support (Artom
2018), and the physical activity advice and omega 3 comparisons
(McNelly 2016). Although assessed, quality of life data were not
available for the trials investigating the eLect of customised
combination therapy (tight control management) (Colombel 2017),
vedolizumab maintenance therapy (Feagan 2013; Sandborn 2013),
vitamin D3 (RaNery 2013), solution-focused therapy (Vogelaar
2014), and guided and self-directed stress management (García-
Vega 2004). Total physical and mental component quality of
life scores were not reported in two trials (Therkelsen 2016a;
Therkelsen 2016b).
In terms of safety, there was no diLerence in adverse events
reported in the three adalimumab treatment groups compared to
placebo, however, the adalimumab maintenance and adalimumab
40 mg weekly groups were significantly less likely to experience
serious adverse events and withdrawal due to adverse events,
compared to control, for all randomised participants (Colombel
2007). The multimodular trial (McNelly 2016) reported a range
of adverse events, including epigastric pain, diarrhoea, bloating,
nausea and vomiting, IBD flare, headache, pins and needles, joint
pain, ankle injury, leg pain, rash, molluscum and feeling unwell.
Adverse events varied across groups, with the no physical activity
advice plus omega 3 group reporting more adverse events (n
= 14), compared to the other three groups (n = 4 or n = 5).
These adverse events were considered to be mild in nature. This
study did not report serious adverse events or withdrawal due
to adverse events. There was no diLerence in adverse events
reported for any of the other trials. Additional information from
the trial authors revealed that there were no adverse events
reported by participants involved in the guided and self-directed
stress management (García-Vega 2004) and the AndoSanTM trials
(Therkelsen 2016a; Therkelsen 2016b). Adverse events were not
reported in the solution-focused therapy trial (Vogelaar 2014),
cognitive behavioural therapy with therapist support trial (Artom
2018) or for the randomised responders in the adalimumab trial
(Colombel 2007).
The evidence presented in this review is limited due the diversity of
interventions, missing data, low or very low evidence of certainty
due to single studies, small sample sizes, and unclear or high risk of
bias in trials (see 'Characteristics of included studies'). The results
reported in this review must therefore be interpreted with caution.
Most studies included in this review were published in the last five
years, with a large number of ongoing trials (n = 30) also identified
as potentially eligible in future updates, indicating the growing
interest in IBD fatigue.
Overall completeness and applicability of evidence
This review included fourteen studies (3741 participants), however,
as outcome data on fatigue were not available for all included
trials, the findings are based on 1344 participants in nine trials,
so completeness of evidence is a concern. Due to insuLicient
and non-standard reporting, fatigue data were available for
analysis from only eight of the 14 eligible trials. Data on the two
secondary outcomes were presented in five of the trials. Although
some additional information was obtained from the trial authors,
insuLicient data was a diLiculty in this review. For example,
data on the primary outcome relevant to this review, although
assessed, were not available for analysis in four trials (Feagan
2013; Hetzel 2013a; RaNery 2013; Sandborn 2013). Furthermore,
one trial presented fatigue data as estimates and eLect sizes for
the intervention and control groups at each time point, rather
than standard reporting of mean and standard deviation scores
(Vogelaar 2014). Pharmacological companies have ownership of
data for one of the large pharmacological trials and a data
request has been submitted and is awaited (Colombel 2017). Three
of the nine eligible trials did not present baseline participant
characteristics for the groups (Hetzel 2013a; RaNery 2013; Vogelaar
2014). However, most studies did present suLicient baseline
information on age, gender, disease type, disease activity or disease
duration.
The studies tended to include participants with Crohn's disease
only, or both ulcerative colitis or Crohn's disease, whereas the
focus of trials on only individuals with ulcerative colitis remains
limited (Feagan 2013; Therkelsen 2016a). Crohn's disease is a
more complex disease and it has been previously suggested that
this disease type may be more responsive to therapy, as Crohn's
disease is associated with higher levels of fatigue and greater
impairment in quality of life. Studies with mixed populations
did not report subgroup analysis according to disease type. As
most interventions were not specifically targeted at IBD fatigue,
there was no subgroup analysis on those with other pre-existing
fatigue related comorbidities, for example, depression and anxiety.
Furthermore, subgroup analysis was not possible in this review due
to the small sample sizes and diversity across trials.
As most participants were not recruited because of fatigue, it seems
likely in some studies that participants experienced low levels
of fatigue at baseline and perhaps may have had limited scope
for improvement in fatigue levels. For example, in the two trials
investigating the eLect of AndoSanTM on fatigue in participants
with ulcerative colitis (Therkelsen 2016a) and Crohn's disease
(Therkelsen 2016b), the baseline total fatigue scores were relatively
low.
There is some evidence of the eLect of pharmacological
interventions on IBD fatigue, however, there were fewer studies
examining the eLicacy of non-pharmacological interventions. The
cost implications and potential side eLects of pharmacological
therapies suggest there may be diLiculty using such type of
treatment specifically for managing IBD fatigue. In contrast, four
of the five non-pharmacological interventions were specifically
designed and developed for managing IBD fatigue (Artom 2018;
Horta 2017; McNelly 2016; Vogelaar 2014). More research is
needed, in particular, studies specifically developed and targeted
at managing IBD fatigue in well-defined patient groups. For
example, a specific type of therapy may work best for participants
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with Crohn's disease, rather than those with ulcerative colitis, in
improving fatigue.
The duration of interventions ranged from 21 days to 56 weeks.
Given the multidimensional nature of fatigue and the complexities
of IBD, the potential benefit of longer intervention periods should
also be explored. More research is needed to be able to draw any
firm conclusions about the eLicacy and safety of pharmacological
and non-pharmacological interventions on fatigue in individuals
with IBD.
Quality of the evidence
The quality of evidence presented in this review is limited. Two
studies were assessed as high quality on all criteria (Figure 2; Figure
3). Our assessment of risk of bias was considerably compromised
by insuLicient publication of information. Most studies used
adequate procedures for random sequence generation. Methods
of allocation concealment was rated low risk in only five trials.
Most pharmacological trials were either double-blinded (Colombel
2007; Feagan 2013; Gasche 2015; RaNery 2013; Sandborn 2013) or
single-blinded (Therkelsen 2016a; Therkelsen 2016b). In contrast,
most non-pharmacological interventions were unblinded, due to
the inherent nature of the type of intervention (Artom 2018; García-
Vega 2004; McNelly 2016; Vogelaar 2014). Therefore, the trend of
positive eLect found in these studies may have been as a result of a
placebo response. Standard care or care-as-usual were frequently
used as the control, however, limited information on the care
received or the visits schedule was typically provided. There is little
evidence if and to what extent conditions between the intervention
and control groups were kept similar in non-pharmacological trials,
in order to reduce the risk of performance bias.
The primary outcome of this review was a subjective, self-
reported outcome, therefore, detection bias was rated high for
all unblinded trials and low for double- and single- (participant)
blinded trials. There were no concerns over attrition bias in
most studies, however, the small sample size in many trials
was problematic. Selection bias was not an issue in terms of
comparable baseline characteristics of groups. This may be as
a result of the random sampling strategies used in trials. There
were concerns over the quality of reporting in six trials, where
data were presented insuLiciently (Colombel 2017; Feagan 2013;
Hetzel 2013a; RaNery 2013; Sandborn 2013) and reported in a
non-standard way (Vogelaar 2014). Overall, our assessment, based
on GRADE analyses, suggests that the certainty of the evidence
supporting the outcomes of this review ranges was low or very
low. As a result of this uncertainty, no firm conclusions can be
drawn regarding the eLicacy and safety of pharmacological and
non-pharmacological interventions on fatigue in IBD.
Potential biases in the review process
We performed a comprehensive literature search to minimise
bias related to study selection. We are confident that our search
strategy has identified all eligible pharmacological and non-
pharmacological randomised controlled trials assessing fatigue
or loss of energy as a primary or secondary outcome in IBD
published up until October 2019. Our search was limited to
English, therefore, there may be a language bias. Two authors
reviewed the studies for inclusion and exclusion, extracted data
independently, and reviewed study quality. Additional information
was retrieved from authors for eight of the 14 eligible trials
(Artom 2018; Colombel 2007; García-Vega 2004; Gasche 2015; Horta
2017; McNelly 2016; Therkelsen 2016a; Therkelsen 2016b), with
one request for additional information still outstanding (Colombel
2017) and five studies identified from the top-up search run in
October 2019 awaiting assessment needing additional information
from the trial authors. Some studies where insuLicient data were
reported were included in the review demonstrating presence of
reporting bias (Feagan 2013; Hetzel 2013a; RaNery 2013; Sandborn
2013; Vogelaar 2014). However, as data on the primary outcome
remain unavailable, these studies did not contribute to the overall
findings of the review.
Limitations of this systematic review include the diversity of
interventions, the limited number of studies with a small number
of participants and sparse data. Only one pooled analysis was
undertaken. The small sample sizes in the trials may have been
insuLicient to detect a small eLect. All studies that assessed
fatigue or loss of energy as a primary or secondary outcome
using a generic or disease-specific fatigue scale, a subscale of
a broader questionnaire or as a single question were deemed
eligible for inclusion. All generic and disease-specific measures
used in the trials demonstrated adequate psychometric properties,
however, caution needs to be exercised when interpreting findings
measured using non-validated subscales or single-item measures.
For example, one trial assessed the average frequency and severity
of tiredness using a single item on a Crohn's disease symptom
diary (García-Vega 2004). In future updates of this review, further
consideration needs to be given to the inclusion of studies that use
subscales or single-item measures of fatigue. As there are a lack of
clearly defined minimal clinically important diLerences (MCID) for
some fatigue measures established in the IBD literature, this limits
the interpretation of results and conclusions drawn. Three review
authors (WCD, MA, CN) were involved in two eligible trials included
in this review. These authors were not involved in extracting data or
conducting 'Risk of bias' assessments for these trials (Artom 2018;
McNelly 2016).
Agreements and disagreements with other studies or
reviews
A review has appraised the management of fatigue in IBD (Czuber-
Dochan 2013a). Similar to the present review, a paucity of evidence
was found. It supported the findings regarding the potential
benefit of adalimumab, stress management and solution-focused
therapy for fatigue in IBD. Furthermore, the evidence from this
review is broadly in agreement with some other Cochrane reviews
on fatigue management in other chronic illnesses. For example,
Cochrane reviews suggest that exercise therapy may be an eLective
and safe treatment for reducing fatigue in adults with chronic
fatigue syndrome (Larun 2017), multiple sclerosis (Heine 2015),
rheumatoid arthritis (Cramp 2013) and people with breast and
prostate cancer both during and aNer cancer treatment (Cramp
2012), which supports the findings of this review in relation to
the potential benefit of physical activity advice (McNelly 2016).
A Cochrane review evaluating the eLect of biologic therapies
on fatigue in adults with rheumatoid arthritis found a small to
moderate improvement (Almeida 2016), which is in agreement with
the findings of this review on adalimumab treatment (Colombel
2007). Other Cochrane reviews have found no specific drugs can be
recommended as an eLective treatment of fatigue in palliative care
patients with advanced chronic diseases (Mücke 2015) and multiple
sclerosis (Pucci 2007; Tejani 2012).
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Cochrane reviews have also demonstrated the benefit of
psychosocial interventions in managing fatigue in rheumatoid
arthritis (Cramp 2013) and people with cancer receiving active
treatment (Goedendorp 2009). In particular, cognitive behavioural
therapy (Price 2008) and educational interventions (Bennett 2016)
have shown an eLect on fatigue in adults with chronic fatigue
syndrome and cancer, respectively. There is no evidence in
this review suggesting that cognitive behavioural therapy may
be beneficial in managing fatigue, however this trial (Artom
2018) was a pilot with a limited sample size. Furthermore,
there is no evidence available from our review regarding the
eLectiveness of educational interventions on fatigue in IBD,
which may be a useful strategy that could be incorporated into
routine care of individuals with IBD, if proven eLective. Similar to
our review, Cochrane reviews investigating the eLectiveness and
safety of pharmacological and non-pharmacological interventions
on fatigue in the area of primary brain tumours (Day 2016),
amyotrophic lateral sclerosis (Gibbons 2018) and Parkinson's
disease (Elbers 2015) have found insuLicient and low-quality
evidence, resulting in no firm conclusion being reached. This
suggests that further research also needs to be conducted in
the area of fatigue management across other chronic illnesses.
Due to the complex nature of fatigue, it appears likely that the
optimal management of fatigue would require a multidimensional
approach.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The data were not suLicient or of high enough quality to identify
specific interventions that might be associated with a positive
eLect on fatigue management in individuals with IBD. Limited
available data, the heterogeneity of studies and fatigue not being
the primary endpoint of most studies are limitations of the
evidence base. Furthermore, the optional duration and suitability
of interventions remains unclear. Biologic therapy (adalimumab 40
mg administered every other week only for those known to respond
to adalimumab induction therapy) may reduce fatigue and iron
therapy (ferric maltol) may result in a slight increase in fatigue,
however the evidence is very uncertain. Non-pharmacological
treatments, such as electroacupuncture and physical activity may
reduce fatigue in individuals with IBD. The small sample sizes
and high risk of bias in these trials means the benefit of these
treatments is uncertain and suggests that further research is
needed.
Implications for research
Research aimed at managing fatigue as a major IBD burden is
lacking and hopefully, this review will act as a catalyst to initiate
these studies. To date, there is a lack of high-quality research
evaluating the eLect of interventions on fatigue in IBD, despite
the high prevalence and burdensome nature of this symptom.
The evidence in this review applies to a broad range of therapies
(pharmacological and non-pharmacological). Further investigation
is warranted. Reporting in some of the trials was insuLicient to
assess the eLicacy and safety of some therapies. This review
focused on presenting clinically important findings, however, at
times, it was diLicult to determine if the observed improvements
in fatigue on some scales (IBDF, total fatigue score, average
frequency of tiredness, average severity of tiredness) were clinically
meaningful. There is need for clearly defined minimal clinically
important diLerence thresholds for fatigue measures in the IBD
population.
There is a need for considerably more robust, well-designed
randomised controlled trials to identify eLective treatments for
fatigue in IBD. Further research is required to test interventions
specifically designed to manage fatigue in patients with IBD. In
order to identify the types and specific elements of interventions
that are eLective in improving fatigue, there should be more
research targeted at selected IBD populations. This will identify
subgroups of patients most likely to benefit from certain
interventions. Alternative non-pharmacological treatments found
to be eLective in other chronic illnesses, such as educational
interventions, warrant investigation in the IBD population. Future
research needs to use validated generic and/or disease-specific
measures of fatigue and measure the long-term eLects of
interventions. Trials should recruit a suLicient sample size, as
predetermined by a power calculation, in order to be adequately
powered to detect diLerences between intervention and control
groups. Methodological standards of clinical trials, particularly for
non-pharmacological interventions, need to be improved.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Pilot RCT with nested qualitative study
Participants Adults (aged 18 years old and over) with a diagnosis of IBD (record of diagnostic endoscopy in patient
clinical notes) and reported currently experiencing fatigue
Exclusion criteria: Currently experiencing bowel symptoms they would associate with a relapse of their
disease; received CBT for fatigue in the last year; enrolled in a trial involving a non-licensed pharmaco-
logical intervention; pregnant women or planning a pregnancy or were unable to give informed con-
sent
A total of 31 participants were randomised to the CBT group (n = 15) or information leaflet group (n =
16).
Age [Mean(SD) years]: CBT group 37.00 (8.71); Information leaflet 39.13 (10.49)
Gender: CBT group (33.3% Male, 67.7% female); Information leaflet (37.5% male; 62.5% female)
Disease duration [Mean(SD) years]:CBT group 14.26 (18.19); information leaflet 18.08 (20.18)
Loss to follow-up: n = 9; CBT group (n = 5); information leaflet (n = 4)
Interventions CBT manual about the management of fatigue with the support of a qualified CBT therapist
Mode of delivery: Telephone/Skype sessions with a therapist
Duration: 60-minute session and seven 30-minute sessions over an eight-week period
Setting of trial: Single centre in the UK
Setting of intervention: Participants home
Comparision treatment: The Crohn’s and Colitis UK (IBD charity) "Fatigue in IBD" Information Sheet
without therapist assistance
Co-interventions: none
Outcomes Fatigue was assessed using the Inflammatory Bowel Disease-Fatigue (IBD-F) scale.
Quality of life was assessed using the UK IBDQ and adverse events were not assessed.
Other outcomes: Disease activity, illness perceptions, daytime sleepiness, anxiety and depression
Assessment time points: Baseline and month 3
Notes Information provided by trial author. Full-text paper submitted for publication to Pilot and Feasibility
Studies
Data analysed with per protocol analyses
No power calculation conducted, however a pilot study
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were randomised at the individual level using a random num-









High risk Participants and therapists not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Loss to follow-up relatively similar across the groups
Selective reporting (re-
porting bias)
Unclear risk All information provided by trial author on outcomes were transparent, how-
ever, findings published as a conference abstract at present





Methods Phase III, RCT, double-blinded
Participants Crohn's disease, moderately to severely active disease (CDAI 220-450). History of having received TNF-
anatagonist therapy but discontinued at least 12 weeks before study entry; other stable dosages of
concurrent treatment
Exclusion criteria: Ulcerative colitis; symptomatic obstructive disease; bowel resection within the past
6 months; an ostomy; extensive small bowel resection or short bowel syndrome; currently receiving to-
tal parenteral nutrition; history of cancer, listeria, human immunodeficiency virus, central nervous sys-
tem demyelinating disease, or untreated tuberculosis; had received investigational chemical agents
within 30 days or investigational biologic therapy within 3 months before screening; had received
antibiotic treatment for non-CD-related infections within 3 weeks before screening; were pregnant
or breastfeeding; had a history of significant drug or alcohol abuse within the past years; had poorly
controlled medical conditions; had received treatment with adalimumab or participated in an adali-
mumab clinical study; had received enema therapy within 2 weeks before screening; had received cy-
closporine, mycophenolate mofetil, or tacrolimus within 8 weeks of screening; had a positive clostridi-
um difficile stool assay; or had clinically significant deviations in prespecified laboratory parameters
A total of 854 participants enrolled in the study and received open-label adalimumab 80 mg subcuta-
neously followed by a 40 mg dose at week 2. At week 4, participants were assessed for response and
randomised (n = 778) to one of the three treatment arms (adalimumab 40 mg every other week (eow) (n
= 260), adalimumab 40 mg weekly (n = 257), or placebo weekly (n = 261)). Participants who experienced
a decrease in CDAI scores of 70 or more points from baseline were considered responders (n = 499). A
total of 170 participants were placebo randomised responders; 172 participants were adalimumab 40
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mg every other week (eow) randomised responders; 157 participants were adalimumab 40 mg weekly
randomised responders
Participant characteristics for all randomised participants (Rubin 2009):
Age [Mean(SD) years): placebo: 36.9 (11.43); adalimumab maintenance therapy (40 mg eow): 36.8
(11.48); adalimumab maintenance therapy (40 mg weekly): 37.8 (12.09)
Gender: placebo (99 males, 162 females); adalimumab maintenance therapy (40 mg eow) (97 males;
163 females); adalimumab maintenance therapy (40 mg weekly) (100 males, 157 females)
Disease status [Mean(SD) CDAI score]: placebo: 315.8 (65.72); adalimumab maintenance therapy (40 mg
eow): 309.6 (60.70); adalimumab maintenance therapy (40 mg weekly): 308.2 (55.26) (author informa-
tion)
Loss to follow-up: placebo (n = 114; 43.7%); adalimumab maintenance therapy (40 mg eow) (n = 94;
36.2%); adalimumab maintenance therapy (40 mg weekly) (n = 65; 25.3%)
Participant characteristics for randomised responders (Loftus 2008):
Age [Mean(SD) years]: placebo: 36.9 (11.9); adalimumab maintenance therapy (40 mg eow): 36.4 (11.1);
adalimumab maintenance therapy (40 mg weekly): 36.9 (11.8)
Gender: placebo (65 males, 105 females); adalimumab maintenance therapy (40 mg eow) (61 males;
111 females); adalimumab maintenance therapy (40 mg weekly) (62 males, 95 females)
Disease status [Mean(SD) CDAI score]: placebo: 321.1 (67.1); adalimumab maintenance therapy (40 mg
eow): 315.7 (61.5); adalimumab maintenance therapy (40 mg weekly): 312.6 (58.3)
Loss to follow-up: placebo (n = 60; 35.3%); adalimumab maintenance therapy (40 mg eow) (n = 57;
33.1%); adalimumab maintenance therapy (40 mg weekly) (n = 26; 16.6%)
Interventions Adalimumab maintenance therapy
Dosing regimen: a) 40 mg every other week; b) 40 mg weekly
Mode of delivery: Subcutaneously administered
Duration: Four weeks open-label adalimumab followed by up to 52 weeks of randomised study drug.
Setting of trial: 92 centres in the United States, Europe, Canada, Australia, and South Africa
Comparison treatment: placebo weekly (open-label 80 mg adalimumab at baseline (week 0) and 40 mg
adalimumab at week 2, plus placebo sc injections following randomisation (week 4)
Co-interventions: Not reported
Outcomes Fatigue was assessed using the FACIT-F and the SF-36 vitality subscale.
Quality of life was assessed using the IBDQ and the SF-36.
Adverse events were assessed for each Medical Dictionary for Drug Regulatory Affairs (MedDRA) system
organ class and preferred term.
Other outcomes assessed: Disease activity (CDAI), CRP concentration, number of cutaneous fistulas
draining, concomitant medication
Assessment time points: Baseline, week 4, week 12, week 26, week 56 (AE also assessed at week 2,
week 6, week 8, week 16, week 20, week 32, week 40, week 48, week 60)
Notes 3-arm trial (2 experimental, 1 control)
The secondary publication (Rubin 2009) presented data from all randomised participants regardless
of week 4 response status to pre-trial dose of adalimumab (n = 778). The secondary publication (Loftus
Colombel 2007  (Continued)
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2008) presented data from a subgroup of participants who responded to pre-trial dose of adalimumab
(n = 499).
The study was funded and supported by Abbot Laboratories.
Additional study information was supplied by AbbVie (formally Abbot Laboratories).
Data analysed with intention-to-treat analyses, however, FACIT-F data represented the last-observa-
tion-carried-forward when a participant had a missing value, dropped out, or switched to open-label
therapy.
Adalimumab maintenance group represented data from both the 40 mg every other week and 40 mg
weekly groups combined.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk At week 4, all subjects were randomised to either adalimumab 40 mg eow,
adalimumab 40 mg weekly or placebo, stratified by responder status and pre-
vious anti-TNF use. The subject's number and treatment regimen of each stra-
tum was assigned by a central randomisation schedule, utilising an interac-
tive voice response system. The randomisation schedule was prepared by the
Statistics Department of Abbott (author information).
Allocation concealment
(selection bias)






Low risk "Patients, study coordinators, and study investigators were blinded to treat-
ment assignment throughout the blinded portion of the study".
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Loss to follow-up relatively similar across the groups and reasons comparable
Selective reporting (re-
porting bias)
Low risk All information on outcomes were transparent and outcomes assessed were
reported/provided upon request.





Methods Phase III, RCT, open-label
Participants Ileal, colonic (including rectal), or ileocolonic Crohn's disease (not more than 6 years prior to baseline).
Moderately-to-severely active disease (CDAI 220 - 450 if not receiving prednisone; CDAI 220 - 450 if re-
ceiving prednisone ≤ 20 mg; CDAI 150 - 450 if receiving prednisone > 20 mg greater than or equal to 7
days before baseline); active endoscopic disease (CDEIS > 6; sum of CDEIS subscores of > 6 in one or
more segments with ulcers); CRP of 5 mg/L or more, fecal calprotectin of 250 μg/g or more, or both
Colombel 2017 
Interventions for fatigue in inflammatory bowel disease (Review)









Cochrane Database of Systematic Reviews
Exclusion criteria: Previous or current use of biologic or immunomodulators; more than two previous
courses of corticosteroids, or current use of corticosteroids for more than 3 months before screening;
fibrotic stricture/draining perianal fistulas/non-perianal fistula; poorly controlled medical conditions;
positive C. difficile stool assay at screening
A total of 255 participants enrolled in the study and received the prednisone induction therapy. A total
of 244 participants were randomly allocated to the tight control (n = 122) or clinical management (n =
122) groups.
Age [Mean(SD) years]: clinical management group 31.1 (11.4); tight control group 32.1 (12.0)
Gender: clinical management group (53 males, 69 females); tight control group (50 males, 72 females)
Disease status [Mean(SD) CDAI score]: clinical management group 267.7 (58.4); tight control group
273.3 (59.5)
Disease duration [Mean (SD) years]: clinical management group 0.9 (1.7); tight control group 1.0 (2.3)
Loss to follow-up: clinical management group (n = 29); tight control management group (n = 32)
Interventions Tight Control Management - customised therapy (after prednisone induction therapy, management es-
calated in a stepwise manner, from no treatment, to adalimumab induction followed by adalimumab
every other week, adalimumab every week, and lastly to both weekly adalimumab and daily azathio-
prine) based on disease activity (CDAI, high sensitivity C-reactive protein, fecal calprotectin, and corti-
costeroid use)
Dosing regimen:
(i) Prednisone 40 mg/day for 2 weeks (max dose), followed by a taper with a schedule that was set by
each investigator at his or her discretion for 6 weeks, however prednisone treatment could continue on
the basis of the rapidity and tolerance of the taper
(ii) Adalimumab 160 mg induction dose at week 0, followed by 80 mg at week 3 and 40 mg eow as a
maintenance dose (participants who met any of the failure criteria 1 week before group allocation). In-
crease to 40 mg weekly if response inadequate and de-escalated to 40 mg eow in participants who did
not meet the treatment failure criteria
(iii) Azathioprine 2.5 mg/kg/day (normal thiopurine methyltransferase [TPMT])/1.25 mg/kg/day oral
(intermediate TMPT). Dose-adjusted according to abnormalities of white blood cell (WBC) count,
platelet count, liver function tests (LFTs; i.e. alanine transaminase [ALT], aspartate transaminase [AST],
phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine. Therapy was escalated based
on meeting treatment failure criteria, which differed between groups (tight control group before and
after random assignment: faecal calprotectin ≥ 250 µg/g, CRP ≥ 5 mg/L, CDAI ≥ 150, or prednisone use
in the previous week; clinical management group before random assignment: CDAI decrease of 200;
clinical management group after random assignment: CDAI decrease of < 100 points compared with
baseline or CDAI ≥ 200, or prednisone use in the previous week). Participants who did not meet the
treatment failure criteria stayed on their previously assigned treatment option.
Mode of delivery: (i) sc (ii) oral (iii) oral
Duration: 56 weeks (8 weeks of prednisone induction treatment and 48 weeks of intervention/active
control treatment)
Setting of trial: 22 countries at 74 hospitals and outpatient centres
Comparision treatment: Clinical Management - customised therapy (as per intervention group) based
on disease activity (CDAI and corticosteroid use). Therapy was escalated according to prespecified fail-
ure criteria using less stringent criteria: CDAI decrease ≥ 70 (CR-70) compared to baseline at visit 1 or
CDAI < 200 at 1 week prior to visit 1; CDAI decrease of ≥ 100 (CR-100) compared to baseline or CDAI <
200, and absence of prednisone during the preceding week at visit 3, 4, and 5
Co-intervention: Not reported
Outcomes Fatigue was assessed using the FACIT-F.
Colombel 2017  (Continued)
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Quality of life was assessed using the IBDQ and the SF-36.
Adverse events were assessed for each Medical Dictionary for Drug Regulatory Affairs (MedDRA) system
organ class and preferred term.
Other outcomes assessed: Mucosal healing and no deep ulcerations; deep remission; biologic remis-
sion; endoscopic response; endoscopic disease activity; clinical disease activity; Crohn's disease flare;
clinical remission; steroid-free remission; hospitalisation; length of stay in hospital; CD-related surg-
eries; Crohn's disease behaviour; High Sensitivity CRP; fecal calprotectin; total dose of prednisone;
work productivity; depression;
Assessment time points: Baseline, week 12, week 24, week 48
Notes The study was funded and supported by AbbVie.
Awaiting additional study information from AbbVie via the Vivli Platform
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "At week 9 (earlier if active disease present), patients were randomly assigned
to the tight control or clinical management group in a 1:1 ratio, stratified by
smoking status (yes or no), weight (< 70 kg or ≥ 70 kg) and disease duration (≤
2 years or > 2 years). The patient number and group of each stratum were as-
signed by a central randomisation schedule generated by AbbVie (Chicago,
IL, USA) using WebRando software for randomisation and ClinPhone, an inter-
active voice and web response system for patient allocation. The subject ran-
domisation schedule was generated by a designated person in the AbbVie sta-
tistics department who was not involved in the rest of the study".
Allocation concealment
(selection bias)






High risk Treatments were open-label - unblinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Loss to follow-up relatively similar across the groups and reasons comparable
Selective reporting (re-
porting bias)
Unclear risk Fatigue and quality of life outcomes assessed but not reported. Awaiting out-
come data from trial authors





Methods Phase III, RCT, double-blinded
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Participants Ulcerative colitis, moderately-to-severely active disease (Mayo Clinic score of 6 to 12, with a sigmoi-
doscopy subscore of at least 2, and disease that extended ≥ 15 cm or more from the anal verge). No re-
sponse to or unacceptable side effects from ≥ 1 of the following: glucocorticoids, immunosuppressive
agents, or TNF antagonists
Exclusion criteria: previously treatment with vedolizumab, natalizumab, efalizumab, or rituximab; re-
ceived TNF antagonists within 60 days before enrollment or cyclosporine, thalidomide, or investiga-
tional drugs within 30 days before enrollment; participants with toxic megacolon, abdominal abscess,
symptomatic colonic stricture, stoma, a history of colectomy, an increased risk of infectious compli-
cations, clinically meaningful laboratory abnormalities, pregnancy or lactation, an unstable or uncon-
trolled medical disorder, an anticipated requirement for major surgery, colonic dysplasia or adenomas,
and malignant neoplasms
A total of 895 participants enrolled in the study and were randomised in a 3:2 ratio to received DB
placebo (n = 149), DB vedolizumab (n = 225) or open-label vedolizumab (n= 521) 300 mg at week 0 and
week 2. At week 6, participants who demonstrated clinical response (reduction in Mayo Clinic score of
≥ 3 and a decrease of ≥ 30% from baseline, with an accompanying decrease in the rectal bleeding sub-
score of ≥ 1 or an absolute rectal bleeding subscore of 0 or 1) were then randomly assigned in a 1:1:1 ra-
tio to receive DB vedolizumab every 8 weeks (n = 122), vedolizumab every 4 weeks (n = 125), or placebo
(n = 126), for up to 52 weeks. Participants who did not have a clinical response at week 6 to vedolizum-
ab induction therapy received vedolizumab at a dose of 300 mg every 4 weeks, for up to 52 weeks (n =
330).
Age [Mean(SD) years): placebo 41.2 (12.5); vedolizumab DB induction therapy 40.1(13.1); vedolizumab
open-label induction therapy 40.1(13.3)
Gender: placebo (92 males, 57 females); vedolizumab DB induction therapy (132 males; 93 females);
vedolizumab open-label induction therapy (301 males; 220 females)
Disease duration [Mean(SD) years]: placebo 7.1 (7.2); vedolizumab DB induction therapy 6.1 (5.1);
vedolizumab open-label induction therapy 7.2 (6.6)
Disease status [Mean(SD) Mayo Clinical score]: placebo 8.6 (1.7); vedolizumab DB induction therapy 8.5
(1.8); vedolizumab open-label induction therapy 8.6 (1.8)
Loss to follow-up for maintenance phase: placebo (n = 78); vedolizumab maintenance therapy (300 mg
every 8 weeks) (n = 45); vedolizumab maintenance therapy (300 mg every 4 weeks) (n = 41)
Interventions Vedolizumab maintenance therapy
Dosing regimen: a) 300 mg every 8 weeks; b) 300 mg every 4 weeks
Mode of delivery: Intravenous infusion
Duration: Six weeks DB or open-label vedolizumab, followed by up to 52 weeks of randomised
vedolizumab.
Setting of trial: 211 medical centres (15 centres discontinued enrollment) in 34 countries worldwide
Comparision treatment: placebo (double-blind placebo intravenous infusions at week 0 and week 2,
followed by every 4 weeks from week 6)
Co-interventions: Not reported
Outcomes Fatigue was assessed using the IBDQ subcomponent 'fatigue' and 'energy level' (Rubin 2018).
Quality of life was assessed using the IBDQ.
Adverse events were assessed according to the Medical Dictionary for Regulatory Activities, version 15.
Other outcomes assessed: Clinical remission, CRP, clinical response, glucocorticoid-free clinical remis-
sion; durable clinical remission
Feagan 2013  (Continued)
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Assessment time points: Baseline, week 2, week 4, week 6 in the trial of induction therapy and every 4
weeks thereafter during the trial of maintenance therapy until week 52. IBDQ was assessed at week 6,
week 30 and week 52.
Notes 3-arm trial (2 experimental, 1 control)
The study was supported by Millennium Pharmaceuticals.
Additional study information request from Takeda Oncology (formally Millennium Pharmaceuticals)
via the Vivli Platform, was declined as fatigue was considered a tertiary endpoint in the study, thus, not
meeting the eligibility criteria for this review (primary or secondary outcome).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk "Participant, Care Provider and Investigator were blinded to treatment assign-
ment throughout the maintenance phase of the study".
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Loss to follow-up relatively similar across the groups and reasons comparable
Selective reporting (re-
porting bias)
High risk Fatigue and quality of life outcomes assessed but not reported in full-text pub-
lication or available upon request
Other bias Low risk "No clinically important differences in baseline characteristics". No apparent




Methods RCT, not blinded
Participants Crohn’s disease, in remission (HBI < 5). All receiving sulfasalazine or 5 ASA
Exclusion criteria: dietary restrictions
A total of 45 participants were randomised to one of three treatment groups, two intervention groups
(guided stress management n = 15 and self-directed stress management n = 15) and a control group
(conventional medical treatment n = 15)
Age [Mean(SD) years]: guided stress management group 28.7 (6.4); self-directed stress management
group 31.0 (5.7); control group 35.3 (9.1)
Gender: guided stress management group (5 males, 10 females); self-directed stress management
group (5 males, 10 females); control group (6 males, 9 females)
García-Vega 2004 
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Disease duration [Mean(SD) years]: guided stress management group 5.6 (6.0); self-directed stress man-
agement group 5.7 (4.8); control group 8.2 (5.7)
Loss to follow-up: No loss to follow-up (author information)
Interventions Stress management programme: a) guided stress management (relaxation practice, problem-solving,
coping in everyday life) b) self-directed stress management (personal planning skills, autogenic train-
ing)
Mode of delivery: a) face to face; delivered by psychotherapist, b) introduction by psychotherapist, writ-
ten guide and audiotape
Duration: a) 2 sessions, followed by weekly sessions over 6 weeks, daily practice, b) 2 sessions, daily
practice for 8 weeks
Setting of trial: Single centre in Spain, gastroenterology department
Setting of intervention: Participants home
Comparision treatment: none (standard medical therapy - salicylates [author information])
Co-interventions: 5 - ASA compounds
Outcomes Fatigue was assessed using a self-reported daily diary (recorded between evening dinner and retiring).
Tiredness (a subjective feeling of tiredness) was one of the 10 Crohn's disease symptoms assessed for
presence or absence and rated for severity (according to the scale: 1 = mild, 2 = moderate and 3 = se-
vere).
Quality of life and adverse events were not assessed, however, the author reported that there were no
adverse events.
Other outcomes: "Symptom reduction score" for individual symptoms assessed in those afflicted only
Assessment time points: Baseline, post-intervention, month 6, month 12
Notes 3-arm trial (2 experimental, 1 control)
No evidence of power calculation statistical analysis
Non-validated fatigue measure
Additional information was supplied by the author.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number table was used (author information).
Allocation concealment
(selection bias)





High risk Due to the psychosocial nature of this intervention, participants and personnel
could not be blinded to the intervention receiving/delivering.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Subjective outcome and participants were not blinded.
A gastroenterologist performed the blind evaluation (authors information).
García-Vega 2004  (Continued)
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Low risk All participants included in the analysis (author information)
Selective reporting (re-
porting bias)
Low risk All information on outcomes were transparent and outcomes assessed were
reported.
Other bias High risk Some diversity in baseline characteristics of groups
Tiredness was assessed using a single item of a Crohn's disease symptom out-




Methods Phase III, RCT, double-blinded
Participants Crohn's disease or ulcerative colitis, in remission or mild-to-moderate disease activity (CDAI < 220; SC-
CAI < 4). All required to have a mild-to-moderate iron-deficiency anaemia (IDA) (Hb concentration ≥ 9.5
g/dL and < 12.0 g/dL for females and ≥ 9.5 g/dL and < 13.0 g/dL for males and serum ferritin levels < 30
ug/L) and previously failed on treatment with oral ferrous products (OFP). Participants receiving pro-
tocol-allowed immunosuppressive and immunomodulatory agents at screening were required to have
been on a stable dose for ≥ 4 weeks before randomisation.
Exclusion criteria: patients with anaemia unrelated to iron deficiency or who had received depot iron
preparations, erythropoietin, or blood transfusions within 12 weeks of screening; oral iron treatment
within 4 weeks of randomisation; treatment with immunosuppressants known to induce anaemia; fo-
late deficiency; uncorrected vitamin B12 deficiency; serum creatinine > 2.0 mg/dL (176 ųmol/L); abnor-
mal liver function tests and pregnancy
A total of 128 participants were randomised to the ferric maltol group (n = 64) or placebo group (n = 64)
Age [Mean(SD) years]: ferric maltol group 40.1 (13.5); placebo group 38.5 (12.3)
Gender: ferric maltol group (24 males, 40 females); placebo group (21 males, 43 females)
Disease type: ferric maltol group (35 CD, 29 UC); placebo group (35 CD, 29 UC)
Disease duration [Mean(SD) years]: ferric maltol group UC 9.0 (8.28)/CD 11.25 (9.3); placebo group UC
10.99 (11.43)/CD 11.01 (8.09) (author information)
Loss to follow-up: n = 20 in total. Ferric maltol group (n = 9); due to adverse event (n = 5), participant
withdrawal (n = 3), physician decision (n = 1); Placebo group (n = 11); due to adverse event (n = 4), pro-
tocol violation (n = 1), participant withdrawal (n = 5), physician decision (n = 1)
Interventions Ferric maltol
Dosing regimen: 231.5 mg of ferric maltol (equivalent to 30 mg of elemental iron) twice daily
Mode of delivery: Oral
Duration: 12 weeks
Setting of trial: 4 centres in Austria, Germany, Hungary and the UK
Setting of intervention: IBD clinic (author information)
Comparision treatment: Placebo - the capsules had the same excipients as ferric maltol without the ac-
tive ingredient (author information)
Gasche 2015 
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Co-interventions: Study participants did not receive any additional co-interventions during the trial,
apart from the ones they were already on (author information).
Outcomes Fatigue was assessed using the SF-36 vitality subscale.
Quality of life was assessed using the SF-36 and the IBDQ.
Adverse events were recorded according to MedDRA preferred terms. Treatment-emergent adverse
events assessed were the following: abdominal pain, diarrhoea, constipation, nasopharyngitis, flatu-
lence, abdominal discomfort, rectal haemorrhage, arthralgia, abdominal distension, gastroesophageal
reflux disease, fatigue, worsening of CD, headache, worsening of UC, vomiting, upper respiratory tract
infection, oropharyngeal pain, Hb decreased, seasonal allergy, pruritis, nausea
Other outcomes assessed: change in Hb concentration; serum ferritin concentration; percentage trans-
ferrin saturation (TSAT); clinical symptoms (SCCAI; CDAI)
Assessment time points: Randomisation (baseline) and week 12
Notes Funders were Iron Therapeutics (UK) Ltd, now Shield TX (UK) Ltd (author information).
Additional information was supplied by the author.
Data analysed with intention-to-treat analyses
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation codes were used to randomise participants. Generation of
randomisation codes and drug packaging were performed by independent
providers (ALMAC, AXIO and Piramal, respectively). The subject and kit ran-




Low risk "Randomisation to either ferric maltol or placebo was conducted through an
interactive voice response system (IXRS system - author information) accord-





Low risk "Patients and all sponsors, clinical research and clinical staL were blinded to
the randomisation code until all randomized trial processes were complete".
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Low risk All information on outcomes were transparent and outcomes assessed were
reported.
Other bias Low risk Baseline demographics and disease characteristics were generally compara-
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Methods Two studies, Phase III, RCTs
Participants Patients with inflammatory bowel disease and iron deficiency (baseline haemogloblin (Hgb) < 10g/dL
and > 7g/dL and transferrin saturation (TSAT) < 20%)
Exclusion criteria: Not reported
A total of 116 participants were included in the analysis of Study 1. Participants were randomised to the
ferumoxytol group (n = 79; Study 1 n = 47), iron sucrose group (n = 25) and placebo group (n = 12).
Loss to follow-up: Not reported
Interventions Ferumoxytol
Dosing regimen: 2 injections each 510 mg, 3-8 days apart
Mode of delivery: Intravenous
Duration: 5 weeks
Setting: Not reported
Comparision treatment: Study 1 - placebo (comparator)
Co-interventions: Not reported
Outcomes Fatigue was assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)
Quality of life was not assessed
Adverse events (AEs) were assessed as follows: all AEs; related AEs; serious AEs; related serious AEs,
AEs of special interest – protocol defined (included protocol defined signs and symptoms of hypoten-
sion and hypersensitivity); cardiovascular AE composite endpoint (included myocardial infarctions,
heart failure, moderate to severe hypertension, and hospitalisation due to any cardiovascular cause);
AEs resulting in study discontinuation; death
Other outcomes assessed: Change in Hgb, transferrin saturation
Assessment time points: Baseline, week 2, week 3, week 4, week 5
Notes No additional information supplied by the author
Study 2 (active comparator - iron sucrose) excluded as fatigue not assessed
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information on the methods used to generate a sequence provided
Allocation concealment
(selection bias)





Unclear risk No information on whether the study personnel, participant, clinical staL were
blinded
Blinding of outcome as-
sessment (detection bias) 
Unclear risk Subjective outcome but unclear if blinding occurred
Hetzel 2013a 
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Unclear risk The number of participants randomised to each group and the number includ-
ed in the analysis for study one was unclear. No information on the number of
withdrawals and exclusion following randomisation and the reasons for this
Selective reporting (re-
porting bias)
High risk Presented data on change from baseline in FACIT-F score for the intervention
group and the overall placebo population, but not the IBD placebo group
Other bias Unclear risk No information presented on the baseline characteristics of the interventions
and placebo groups in study one or no information of the disease activity sta-




Methods RCT, single-blinded, cross-over design
Participants Diagnosis of IBD (CD or UC) and clinically quiescent disease (HBI < 5 for CD or Mayo score ≤ 2 for UC; ab-
sence of biochemical markers of disease activity) for at least six months, experiencing persistent fa-
tigue (defined as 2 consecutive FACIT-F scores (4 weeks apart) lower than 40 points)
Exclusion criteria: previous or active neoplasia; pregnancy or lactation; anaemia, defined as haemo-
globin lower than 12 g/dL in women and < 14g/dL in men; previous treatment with acupuncture; con-
traindications for acupuncture; participation in other therapeutic trials; concomitant chronic diseases
not related to IBD that might contribute to the presence or the severity of fatigue. Participants who pre-
sented clinical relapse during the study period were withdrawn from the study.
A total of 52 participants were randomised to the electroacupuncture (EAc: n = 18), sham acupuncture
(ShaEAc: n = 18) or control group (WL: n = 16).
Age [Mean(SD) years): EAc: 44.6 (12.1); ShaEAc: 38.6 (8.3); control: 42.6 (10.7)
Gender: EAc (10 males, 8 females); ShaEAc (13 males; 5 females); control (11 males, 15 females)
Disease type: EAc (17 CD, 1 UC); ShaEAc (17 CD; 1 UC); control (12 CD, 4 UC)
Disease duration [Mean(SD) years]: EAc: 10.6 (4.8); ShaEAc: 11.4 (5.4); control: 10.5 (4.7)
Loss to follow-up: EAc (n = 3; 17%); ShaEAc (n = 3; 17%); control (n = 4; 25%)
Interventions Participants in EAC and sham EAC groups performed a total of 9 acupuncture sessions during eight
weeks (2 sessions/first week and one session per week during 7 weeks).
(a) Electroacupuncture; (b) sham EAc
Mode of delivery: (a) 20 acupoints were selected, needles were inserted to a depth of 20 mm and con-
nected to a 6-channel electroacupuncture device (ITO® ES-160, Japan). A pulsed electrical stimulation
(asymmetric balanced, rectangular shape, 8 to 100 Hz frequency) was used and needles were leN in
place connected to the electroacupuncture device for 20 minutes. (b) 8 'non-acupuncture' points were
selected, needles were inserted to a depth of 20 mm and connected to a 6-channel electroacupuncture
device (ITO® ES-160, Japan), but electric stimulation was not applied and needles were leN in place for
20 minutes.
The sessions for both groups was delivered by 3 senior acupuncturists with at least five years of experi-
ence.
Duration: 9 sessions during eight weeks (2 sessions during the first week and one session per week dur-
ing 7 weeks)
Setting of trial: Single centre in Spain, outpatient clinic of a Digestive Diseases department
Horta 2017 
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Setting of intervention: IBD unit in separate rooms
Comparision treatment: none (waiting-list group was offered an open EAc treatment at the end of fol-
low-up)
Co-interventions: Usual pharmacological treatments were maintained and drug dosage unchanged
during the study.
Outcomes Fatigue was assessed using the FACIT-FS.
Quality of life was assessed using the IBDQ-9.
Adverse events, including acupuncture abnormalities such as bleeding, haematoma, pain in the
acupuncture sites, increased blood pressure, fainting during acupuncture and other adverse reactions
were evaluated (during the treatment period).
Other outcomes assessed: depression, anxiety and sleepiness
Assessment time points: baseline, week 4, week 8 and week 16
Notes Additional information was supplied by author. Full-text paper submitted for publication
3-arm trial (1 experimental, 2 control)
Cross-over of participants who had no improvement in fatigue (FACIT-FS score < 40) after 8 weeks post-
treatment occurred (participants from EAc group to ShEAc group and vice versa) and also the control
group started EAc. However, due to loss to follow-up and dropouts, data analysis was not performed.
Data analysed with per protocol analyses.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Simple randomisation was performed by generating a random number table
using the SPSS 20.0 software. The first number in the random number table
was used as a starting point to create random assignment cards, which were
then sealed in opaque envelopes. The envelopes were numbered and kept se-
cure by one of the authors (AF) (author information).
Allocation concealment
(selection bias)
Low risk The acupuncturists were given randomly generated treatment allocations





Unclear risk Participants and evaluators were blinded to group assignment. Personnel ad-
ministering the intervention were not blinded (author information).
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Loss to follow-up relatively similar across the groups (author information)
Selective reporting (re-
porting bias)
Unclear risk All information provided by trial author on outcomes was transparent, howev-
er, findings published only as a conference abstract at present
Other bias Low risk Baseline demographics were generally comparable between groups (author
information).
Horta 2017  (Continued)
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Methods RCT, 2 x 2 factorial design, part-blinded
Participants Diagnosed with Crohn's disease or ulcerative colitis in remission (CRP < 5 mg/dL and HBI < 5/SCCI < 3),
who are self-reporting fatigue, willing to increase current activity levels and able to take medication
with ingredients derived from animal or fish sources.
Exclusion criteria: At least 60 minutes of moderate-to-vigorous exercise performed per week; concur-
rent course of anticoagulant medications; concurrent participation in another randomised control tri-
al; concurrent pregnancy; consumption of oily fish at least twice per week or eight times per month;
Omega-3 fatty acid supplements taken in the 12 weeks before screening; fatigue-related comorbidities.
A total of 74 participants were randomised (n = 52 completed the trial according to protocol) to one of
four treatment groups (No physical activity advice (PAA) and omega 3 n = 14; PAA and omega 3 n = 11;
No PAA and placebo n = 12; PAA and placebo n = 15).
Age [Median(IQR) years] : No PAA with omega 3: 45 (36, 51); PAA with omega 3: 31 (29, 55); No PAA and
placebo: 31 (27, 51); PAA and placebo: 35 (28, 43)
Gender: No PAA and omega 3 (7 males, 7 females); PAA and omega 3 (6 males and 5 females); No PAA
and placebo (4 males, 8 females); PAA and placebo (8 males and 7 females)
Disease type: No PAA and omega (7 CD, 7 UC); PAA and omega 3 (6 CD and 5 UC); No PAA and placebo (6
CD, 6 UC); PAA and placebo (6 CD, 8 UC, 1 unclassified)
Loss to follow-up: n = 8; No PAA and omega 3 n = 0; PAA and omega 3 n = 4; no PAA and placebo n = 2;
PAA and placebo n = 2 (author information). Reasons included clinically active disease (n = 3), pregnan-
cy (n = 2), anaemia (n = 1); musculoskeletal injury (n = 1) and lack of time (n = 1).
Interventions a) Physical activity advice - received advice about initiating and maintaining motivation (using tech-
niques of imagery, goal-setting [for each week and the whole programme]) and discussed overcoming
barriers to exercise (physical limitations and fears of worsening symptoms of IBD)
b) Active supplementation - two capsules containing a total of 2970 mg of omega-3 fatty acids (EPA,
2250 mg; DHA, 150 mg)
Mode of delivery a) face-to-face individual consultation with a personal trainer and one researcher b)
orally with food
Duration: a) 15 minutes b) daily for 12 weeks
Setting of trial: Single-centre London tertiary referral hospital (author information)
Setting of delivery: IBD outpatient clinic. The exercise programme was undertaken either at home or at
a gym.
Comparision treatment: a) Placebo (capsules containing capric and caprylic acid) b) No physical activi-
ty advice (15 minute face-to-face individual consultation with the researcher discussing current dietary
habits and general health)
Co-interventions: None
Outcomes Fatigue was assessed using the FACIT-F; MFI and IBD-F.
Quality of life was assessed using the IBDQ.
Adverse events were recorded in the medication diary and assessed by the researcher during the 6 fol-
low-up contact time points.
Other outcomes assessed: Depression; physical activity (diary and accelerometer), disease activity
(HBI; SCCAI); body composition; Hgb; CRP
McNelly 2016 
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Assessment time points: Baseline and week 12. All groups were contacted by the researcher on six oc-
casions (a week following their second study visit, and then every two weeks) using email, text or tele-
phone to discuss progress.
Notes 4-arm trial
Additional information was supplied by the author.
The study was supported by the Big Lottery Fund [grant number GFTTAFR] and Crohn's and Colitis UK
was the fund holder.
No power calculation undertaken
Data analysed with per protocol analyses
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomisation using computer-generated random numbers
Allocation concealment
(selection bias)
Unclear risk For the capsule assignment, sequentially named drug containers of identical
appearance were provided by UCHL pharmacy. The first author performed the
randomisation and enrollment of the participants for the physical activity ad-





High risk Participants and researchers were blinded to capsule type, but could not be
blinded to the consultation type due to the nature of the intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes









Low risk All information on outcomes were transparent and outcomes assessed were
reported.






Participants Crohn’s disease, in remission and on stable drug therapies for at least 1 month at study entry
Exclusion criteria: Symptomatic CD (CDAI > 150); pregnancy; previous extensive small bowel research;
presence of an ileostomy or colostomy; known hypersensitivity to vitamin D; hypercalcaemia; those
currently using supplemental vitamin D > 800 IU/D; diagnosis of any of the following: active tuberculo-
sis, sarcoidosis, hyperparathyroidism, renal failure, pseudohyperparathyroidism, malignancy, active
lymphoma, short bowel syndrome; antibiotic use in the 4 weeks prior to enrollment; current use of bis-
RaLery 2013 
Interventions for fatigue in inflammatory bowel disease (Review)









Cochrane Database of Systematic Reviews
phosphonates; renal impairment, diabetes mellitus; participants participating in a concurrent RCT; al-
cohol dependency
A total of 27 participants were randomised to the intervention (vitamin D3, n = not reported) or control
group (placebo, n = not reported)
Loss to follow-up: Not reported
Interventions Vitamin D3
Dosing regimen: 2000 IU per day
Mode of delivery: Oral
Duration: 3 months
Setting: 2 centres in the Republic of Ireland
Comparision treatment: Placebo (soya bean oil)
Co-interventions: None
Outcomes Fatigue was assessed using the MFI.
Quality of life was assessed using the IBDQ.
Adverse events were not assessed.
Other outcomes assessed: Change in hand grip strength; disease activity (CDAI), FBC, CRP, serum
25OHD
Assessment time points: Baseline and month 3
Notes No additional information supplied by the author
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information provided
Allocation concealment
(selection bias)





Unclear risk Double-blind but no further information provided
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk The number of participants included in the analysis was not reported.
Selective reporting (re-
porting bias)
High risk Reported only the difference in muscle strength scores for the intervention
and control groups. Changes in fatigue and quality of life scores from baseline
RaLery 2013  (Continued)
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to month 3 presented for those who achieved 25OHD levels ≥ 75nmol/L com-
pared to those with 25OHD levels < 75nmol/L only.




Methods Phase III, RCT, double-blinded
Participants Crohn's disease, moderately-to-severely active disease (CDAI 220-450) and one of the following: a
serum CRP > 2.87 mg/L, colonoscopic findings showing ≥ 3 large ulcers or ≥ 10 aphthous ulcers, or fecal
calprotectin > 250 μg/g of stool plus evidence of ulcers on CT or MRI, small-bowel radiography, or cap-
sule endoscopy. No response to or unacceptable side effects from ≥ 1 of the following: glucocorticoids,
immunosuppressive agents, or TNF antagonists
Exclusion criteria: previous treatment with vedolizumab, natalizumab, efalizumab, or rituximab; treat-
ment with adalimumab within 30 days before enrollment and treatment with infliximab or certolizum-
ab pegol within 60 days before enrollment; participants with a stoma, ≥ 3 small-bowel resections,
short-bowel syndrome, extensive colonic resection, intestinal stricture, abdominal abscess, active or
latent tuberculosis, or cancer
A total of 1115 participants enrolled in the study and were randomised in a 3:2 ratio to receive DB
placebo (n = 148), DB vedolizumab (n = 220) or open-label vedolizumab (n= 748) 300 mg at week 0
and week 2. At week 6, participants who demonstrated clinical response (≥ 70-point decrease in the
CDAI score) were then randomly assigned, in a 1:1:1 ratio to continue in a blinded fashion to receive
vedolizumab every 8 weeks (n = 154), vedolizumab every 4 weeks (n = 154), or placebo (n = 153), for up
to 52 weeks. Participants who did not have a clinical response at week 6 to vedolizumab induction ther-
apy received vedolizumab at a dose of 300 mg every 4 weeks, for up to 52 weeks (n = 412).
Age [Mean(SD) years): placebo 38.6 (13.2); vedolizumab DB induction therapy 36.3 (11.6); vedolizumab
open-label induction therapy: 35.6 (12.0)
Gender: placebo (69 males, 79 females); vedolizumab DB induction therapy (105 males; 115 females);
vedolizumab open-label induction therapy (346 males, 401 females)
Disease duration [Mean(SD) years]: placebo 8.2 (7.8); vedolizumab DB induction therapy 9.2
(8.2);vedolizumab open-label induction therapy 9.2 (7.6)
Disease status [Mean(SD) CDAI score]: placebo: 325 (78); vedolizumab DB induction therapy 327 (71) ;
vedolizumab open-label induction therapy 322 (67)
Loss to follow-up in maintenance phase: placebo (n = 89); vedolizumab maintenance therapy (300 mg
every 8 weeks) (n = 81); vedolizumab maintenance therapy (300 mg every 4 weeks) (n = 72)
Interventions Vedolizumab maintenance therapy
Dosing regimen: a) 300 mg every 8 weeks; b) 300 mg every 4 weeks
Mode of delivery: Intravenous infusion
Duration: Six weeks DB or open-label vedolizumab, followed by up to 52 weeks of randomised
vedolizumab
Setting of trial: 285 medical centres (15 centres discontinued enrollment) in 39 countries worldwide
Comparision treatment: placebo (double-blind placebo intravenous infusions at week 0 and week 2,
followed by every 4 weeks from week 6)
Co-interventions: Not reported
Sandborn 2013 
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Outcomes Fatigue was assessed using the IBDQ subcomponent 'fatigue' and 'energy level' (Rubin, 2008).
Quality of life was assessed using the IBDQ.
Adverse events were assessed according to the Medical Dictionary for Regulatory Activities, version 15.
Other outcomes assessed: Clinical remission, CRP, clinical response, glucocorticoid -free clinical remis-
sion; durable clinical remission
Assessment time points: Baseline, week 2, week 4, week 6 in the trial of induction therapy and every 4
weeks thereafter during the trial of maintenance therapy until week 52. IBDQ was assessed at week 6,
week 30 and week 52.
Notes 3-arm trial (2 experimental, 1 control)
The study was supported by Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Phar-
maceuticals.
Additional study information request from Takeda Oncology (formally Millennium Pharmaceuticals) via
the Vivli Platform, was declined as fatigue was considered a tertiary endpoint in the study, thus deem-
ing it not to meet the eligibility criteria for this review (primary or secondary outcome).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk Participant, Care Provider and Investigator were blinded to treatment assign-
ment throughout the maintenance phase of the study.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Loss to follow-up relatively similar across the groups and reasons comparable
Selective reporting (re-
porting bias)
Unclear risk Fatigue and quality of life outcomes assessed but not reported in full-text pub-
lication or available upon request
Other bias Low risk "Baseline disease characteristics were similar across groups". No apparent





Participants Ulcerative colitis, mild-to-moderate disease activity (CAI ≥ 3)
Therkelsen 2016a 
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Exclusion criteria: Pregnancy, biological treatment with antibodies to TNFα, daily use of more than
5 mg of prednisolone, change of medication and/or consumption of mushroom products from two
weeks before till end of the study
A total of 62 participants were randomised to the intervention (AndoSan™, n = 31) or control group
(placebo, n = 31).
Age [Mean(SD) years]: AndoSan™ group 41.6 (12.8); placebo group 38.5 (8.9) (author information)
Gender: AndoSan™ group (13 males, 11 females); placebo group (12 males, 14 females)
Disease duration [Mean(SD) years]: AndoSan™ group: 8.7 (7.3); placebo group: 7.2 (6.6) (author informa-
tion)
Loss to follow-up: AndoSan™ group (n = 7): due to 3 with change of medication, 2 with missing labora-
tory data and 2 with missing attendance. Placebo group (n = 5): due to 2 with change of medication, 2
with missing laboratory data, and 1 with missing attendance
Interventions Agaricus blazei Murill- based mushroom extract (AndoSan™)
Dosing regimen: 30 mL twice daily (60 mL/day)
Mode of delivery: Oral
Duration: 21 days
Setting: Single centre in Oslo, Norway
Comparison treatment: Placebo (colour-like drink with ionised water containing 0.5 mL per litre of
caramel colour [E150c] with salt)
Co-interventions: None (author information)
Outcomes Fatigue was assessed using an 11-item total fatigue score (Fatigue Questionnaire) and the vitality sub-
scale of the SF-36 (IQOLA SF-36 Norwegian Version 1.2).
Quality of life was assessed using the SF-36 (IQOLA SF-36 Norwegian Version 1.2).
Adverse events were assessed during an interview between the first author and participant at all visits.
Other outcomes assessed: EDTA blood test; faecal calprotectin; CAI
Assessment time point: Baseline, day 14 and day 21
Notes Sample size was calculated for prospective differences of 20% between the experimental and placebo
group and assumed standard deviation of 20% for the different parameters with a significant level of
5% and a power of 90% (ß = 0.10), demanded about 25 participants per randomised arm (calculated in
cooperation with Oslo Center for Biostatistics and Epidemiology, Oslo University Hospital).
Two of the authors (GH and EJ) had patent/patent applications and financial interests relating to ma-
terial (AndoSan™) pertinent to this article: i) WO2005065063 A2, Appl. No.:10/ 585600, NO- and PCT-
filed Jan 2004 and Jan 2005 respectively, by Inventor Hetland Geir, and ii) NO20090003383, Appl. No.:
NO20090003383 20091119, by Inventors Hetland Geir and Johnson Egil and filed by Applicant Im-
munopharma AS in Nov 2009 and financial interest of Geir Hetland as shareholder in Immunopharma
AS of Norway, commercialising AndoSan™.
Grants received from the University of Oslo (author information)
Additional information was supplied by the author.
SF-36 PCS and MCS not calculated (author information)
Data analysed with per protocol analyses
Therkelsen 2016a  (Continued)
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "50 patients were divided into 13 groups and manually randomised with the
overall allocation ratio of one to one. Block randomisation was done after the
phone interview, with uneven and even numbers given for AndoSan™ or place-
bo respectively. The patients, one by one, were placed in one pile, and the
group affiliations were placed in another pile, both anonymized".
Allocation concealment
(selection bias)
High risk "The first author performed the randomisation, enrolled the participants, and





Unclear risk Single-blinded trial (participants). Personnel administering the intervention
were not blinded (author information).
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk 7 lost to follow-up from intervention group, 5 from placebo group. Missing da-
ta balanced across groups with similar reasons. The included 50 symptomatic
participants had no missing data.
Selective reporting (re-
porting bias)
Low risk All information on outcomes were transparent and outcomes assessed were
reported.
Other bias Unclear risk Baseline characteristics similar between treatment groups. Mixed models cor-
rected for baseline values were used for measuring P values between the study
groups.
Two authors (GH and EJ) had patent/patent applications and financial interest
relating to material (AndoSan™) pertinent to these articles. Therkelsen 2016a
and Therkelsen 2016b published as two distinct trials, however, the trials have
the same ethical approval number. No mention of subjects being stratified ac-





Participants Crohn's disease, mild-to-moderate disease activity (SCDAI ≥ 3), aged 18 years old and older
Exclusion criteria: Pregnancy, biological treatment with antibodies to TNFα, daily use of more than
5 mg of prednisolone, change of medication and/or consumption of mushroom products from two
weeks before till end of the study
A total of 76 participants were randomised to the intervention (AndoSan™: n = 37) or control group
(placebo: n = 39)
Age [Mean(SD) years]: AndoSan™ group: 44.92 (13.96) years; placebo group: 43.28 (13.74) years (author
information)
Gender: AndoSan™ group (11 males, 14 females); placebo group (10 males, 15 females)
Therkelsen 2016b 
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Disease duration [Mean(SD) years]: AndoSan™ group: 9.7 (0.5 - 46) years; placebo group: 8.0 (0.5 - 42)
years
Loss to follow-up: AndoSan™ group (n = 12): due to 11 with missing report for symptoms and 1 with
missing laboratory data. Placebo group (n = 14): due to 9 with missing report for symptoms, 4 missing
laboratory data, and 1 with missing attendance
Interventions Agaricus blazei Murill- based mushroom extract (AndoSan™)
Dosing regimen: 30 mL twice daily (60 mL/day)
Mode of delivery: Oral
Duration: 21 days
Setting: Single centre in Oslo, Norway
Comparison treatment: Placebo (colour-like drink with ionised water containing 0.5 mL per litre of
caramel colour [E150c] with salt)
Co-interventions: None (author information)
Outcomes Fatigue was assessed using an 11-item total fatigue score (Fatigue Questionnaire) and the vitality sub-
scale of the SF-36 (IQOLA SF-36 Norwegian Version 1.2).
Quality of life was assessed using the SF-36 (IQOLA SF-36 Norwegian Version 1.2).
Adverse events were assessed during an interview between the first author and participant at all visits,
however, such events were not registered (author information).
Other outcomes assessed: EDTA blood test; faecal calprotectin; SCDAI
Assessment time point: Baseline, day 14 and day 21
Notes Sample size was calculated for prospective differences of 20% between the experimental and placebo
group and assumed standard deviation of 20% for the different parameters with a significant level of
5% and a power of 90% (ß = 0.10), demanded about 25 participants per randomised arm (calculated in
cooperation with Oslo Center for Biostatistics and Epidemiology, Oslo University Hospital).
Two of the authors (GH and EJ) had patent/patent applications and financial interests relating to ma-
terial (AndoSan™) pertinent to this article: i) WO2005065063 A2, Appl. No.:10/ 585600, NO- and PCT-
filed Jan 2004 and Jan 2005 respectively, by Inventor Hetland Geir, and ii) NO20090003383, Appl. No.:
NO20090003383 20091119, by Inventors Hetland Geir and Johnson Egil and filed by Applicant Im-
munopharma AS in Nov 2009 and financial interest of Geir Hetland as shareholder in Immunopharma
AS of Norway, commercialising AndoSan™.
Grants received from the University of Oslo (author information)
Additional information was supplied by the author.
SF-36 PCS and MCS not calculated (author information).
Data analysed with per protocol analyses
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Block randomization was done after the phone interview, with uneven and
even numbers given for AndoSan™ or placebo respectively. The patients, one
by one, were placed in one pile, and the group affiliations were placed in an-
other pile. The randomization was performed by combining one selection
from each pile, both anonymized."
Therkelsen 2016b  (Continued)
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Allocation concealment
(selection bias)
High risk "The first author performed the randomization, enrolled the participants, and





Unclear risk Single-blinded trial (participants). The first author (SPT) was responsible for
the inclusion and randomisation of participants, the implementation of the
practical aspects of and in meeting with the participants and also in the analy-
sis of the results.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk 12 lost to follow-up from intervention group, 14 from placebo group. Missing
data balanced across groups with similar reasons. The included 50 sympto-
matic participants had no missing data.
Selective reporting (re-
porting bias)
Low risk All information on outcomes transparent and outcomes assessed were report-
ed.
Other bias Unclear risk Baseline characteristics similar between treatment groups. Mixed models cor-
rected for baseline values were used for measuring P values between the study
groups.
Two authors (GH and EJ) had patent/patent applications and financial interest
relating to material (AndoSan™) pertinent to these articles. Therkelsen 2016a
and Therkelsen 2016b published as two distinct trials, however, the trials have
the same ethical approval number. No mention of subjects being stratified ac-




Methods RCT, not blinded
Participants Inflammatory bowel disease, in remission (CDAI < 150 or CAI < 10) and CRP < 10) experiencing fatigue
(CIS-fatigue score of ≥ 35).
Exclusion criteria: Pregnant or breastfeeding women; history of lymphoproliferative disease or cancer,
other than skin basocellular carcinoma; other gastrointestinal disease than IBD; listeriosis; HIV infec-
tion; immunodeficiency syndrome; CNS demyelinating disease; chronic hepatitis B or C virus infection
or untreated tuberculosis; poorly controlled medical conditions, including anaemia, low iron levels, di-
abetes mellitus, kidney disease, liver disease and unstable Ischaemic heart disease; a known pre-exist-
ing condition that could interfere with the participant’s participation such as psychiatric conditions or
CNS trauma or active seizure disorders; surgery in the past 12 weeks prior to the screening visit; history
of clinically significant drug or alcohol abuse in the last 2 years
A total of 98 participants were randomised to the intervention group (SFT: n =48 [1 participant declined
further participation after randomisation]) or control group (CAU n = 49)
Baseline characteristics for each treatment group were not presented.
Loss to follow-up: One participant declined further participation after randomisation.
Interventions Solution-focused therapy (psychotherapy/coping styles for fatigue)
Mode of delivery: 6 face-to-face group sessions during 3 months and a final booster session at 6
months. Each group consisted of 7 participants. In the fiNh session, a partner, family member or close
relative participated.
Vogelaar 2014 
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Duration: 7 sessions, 1.5 hours per session
Setting: 2 centres in the Netherlands
Comparision treatment: none (care-as-usual)
Co-interventions: Not reported
Outcomes Fatigue was assessed using the CIS and the FSS-9.
Quality of life was assessed using the IBDQ, SF-36 and EQ-5D.
Adverse events were not reported.
Other outcomes assessed: faecal calprotectin; depression and anxiety; sleep quality; disease activity;
medication use; side effect of medication and laboratory parameters (CRP, leucocytes and haemoglo-
bin)
Assessment time point: Baseline, month 3, month 6, month 9
Notes Baseline characteristics were reported to be similar between the two groups, however, the data were
not presented.
No additional information supplied by the author
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Patients were randomised to the treatment or control arm in blocks of 14




Unclear risk Randomisation was conducted by the second author. The randomisation lists





High risk Participants were informed about the study and the design of the treatment.
Due to the psychosocial nature of this intervention, participants and personnel
could not be blinded to the intervention receiving/delivering.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Self-reported outcomes and participants were informed about the study and




Low risk Only one participant was excluded from the analysis after randomisation due
to participant declining further participation.
Selective reporting (re-
porting bias)
High risk Non-standard reporting of CIS, FSS-9, IBDQ, SF-36 and EQ-5D scores. Only
fixed mixed models and estimates and effect sizes presented
Other bias Low risk Baseline characteristics similar between the treatment groups, however, the






BUN: Blood urea nitrogen
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CAI: Clinical Activity Index
CAU: Care-as-usual
CBT: Cognitive behavioural therapy
CD; Crohn's disease
CDAI: Crohn's Disease Activity Index
CDEIS: Crohn's Disease Endoscopic Index of Severity
CIS: Checklist of Individual Strength







eow: every other week
EPA: Eicosapentanoic acid
EQ-5D: EuroQol 5 dimensions
FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue
FACIT-FS: Functional Assessment of Chronic Illness Therapy-Fatigue Scale
FBC: Full blood count
FSS-9: 9-item Fatigue Severity Scale
g/dL: grams per decilitre
Hb: Haemogloblin
HBI: Harvey Bradshaw Index
Hgb: Haemoglobin
HIV: Human immunodeficiency viruses
IBD: Inflammatory bowel disease
IBD-F: Inflammatory Bowel Disease Fatigue scale
IBDQ: Inflammatory Bowel Disease Questionnaire
IBDQ-9: 9-item Inflammatory Bowel Disease Questionnaire
IDA: Iron deficiency anaemia
IL: Illinois
IQOLA: International Quality of Life Assessment
IU/D: International unit of Vitamin D
IXRS: Interactive voice response system
kg: Kilogram
LFT: Liver Function Test
MCS: Mental component summary
MedDRA: Medical Dictionary for Regulatory Activities
MFI: Multidimensional Fatigue Inventory
mg: milligrams
mg/kg/day: milligrams per kilograms per day
ml/L: millilitres per Liters
MRI: Magnetic Resonance Imaging
OFP: Oral ferrous products
PAA: Physical Activity Advice
PCS: Physical component summary
RCT: Randomised controlled trial
SAS: Statistical Analysis System
sc: Subcutaneous
SCCAI : Simple Clinical Colitis Activity Index
SCCI: Simple Clinical Colitis Index
SCDAI: Short Crohn's Disease Activity Index
SD: Standard deviation
SF-36: 36-Item Short Form
SFT: Solution-focused therapy
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ShaEAc: Sham electroacupuncture
SPSS: Statistical Package for the Social Sciences
SSCAI: Simple Clinical Colitis Activity Index




UCHL: University College London Hospitals
UK: United Kingdom
UK IBDQ: British version of the Inflammatory Bowel Disease Questionnaire
USA: United States of America
WBC: White blood cells
WL: Waiting list
μg/g: microgram per gram
ųmol/L: micromole/litre
25OHD: 25-hydroxycholecalciferol or 25-hydroxyvitamin D
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Boye 2011 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ not reported
Colombel 2010 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ not reported
Cosnes 2013 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ not reported
Dewint 2014 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ not reported
Feagan 2003 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ and SF-36
not reported
Ford 2016 Participants: Data from patients with IDA and underlying gastrointestinal disorders - IBD-specific
data not presented
Hetzel 2013b Participants: Data from patients with IDA and underlying gastrointestinal disorders - IBD-specific
data not presented
Leiper 2001 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the inflammatory
bowel disease quality of life index not reported
Lichtenstein 2002 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ not reported
Loftus 2009 Type of study: Not a RCT. Only presented data from baseline to week 4 prior to commencement of
RCT
Loftus 2017 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ or SF-36 not
reported
Maragkoudaki 2016 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IMPACT-III scale
not reported
Mikocka-Walus 2017 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the WHOQoL not re-
ported
Minderhoud 2007 Type of study: Not a RCT
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Study Reason for exclusion
NCT01991314 Type of study: Not a RCT
NCT02148718 Type of study: Not a RCT
NCT02162862 Type of study: Not a RCT
Paramsothy 2017 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ not reported
Pena Rossi 2009 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ not reported
Persoons 2007 Type of study: Not a RCT
Reusch 2016 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the Short Form-12
Health Survey not reported
Sands 2008 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ and SF-36
not reported
Sands 2013 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ and SF-36
not reported
Schmidt 2016 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ and SF-36
not reported
Scholten 2018 Participants: Data from patients with IBS and IBD not analysed separately
Schreiber 2007 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ not reported
Smith 2011 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ and SF-36
not reported
Smith 2013 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IMPACT-III survey
not reported
Steinhart 2002 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ not reported
Szigethy 2016 Type of study: Not a RCT
Targan 2007 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ and SF-36
not reported
Valentine 2009 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ and SF-36
not reported
Van Assche 2012 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ not reported
Vermeire 2017 Outcome: Data on fatigue, loss of energy, vigour and vitality as a subscale of the IBDQ or SF-36 not
reported
IBD: Inflammatory bowel disease
IBDQ: Inflammatory Bowel Disease Questionnaire
IBS: Irritable bowel syndrome
IDA: Iron deficiency anemia
RCT: Randomised controlled trial
SF-36: 36-Item Short Form
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WHOQoL: World Health Organisation Quality of Life
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods A phase 3, double-blind RCT
Participants Adults (aged 16 years and older) with a diagnosis of active ulcerative colitis (adapted Mayo score of
5 to 9 points and endoscopic subscore of 2 to 3) who have demonstrated an inadequate response
to, loss of response to, or intolerance to at least one of the following treatments including: oral
aminosalicylates, corticosteroids, immunosuppressants, and/or biologic therapies in the opinion
of the investigator
Interventions Experimental: Extended-release updacitinib 7.5, 15, 30, 45 mg orally, once daily for 8 weeks
Comparator: Placebo, orally, once daily for 8 weeks
Outcomes Patient-reported outcomes utilising the newly developed 17-item Ulcerative Colitis Symptom
Questionnaire (UC-SQ). Overall scores of UC-SQ range from 17 to 85; higher scores indicate greater
symptom burden. Participants at selected study sites completed the UC-SQ at baseline (BL) and
week 2, 4, and 8.
Notes Data from the Phase 2b study U-ACHIEVE (NCT02819635)
110 participants completed the UC-SQ questionnaire.




Methods A phase II, multicentre, randomised, double-blind, multiple dose, placebo-controlled, paral-
lel-group study
Participants Adults (aged 18 - 75 years) with a diagnosis of moderate-to-severe active Crohn' disease (CDAI ≥
220 and ≤ 450) with mucosal ulcers and CDEIS >= 7 (or >= 4 in participants with isolated ileitis on
ileocolonoscopy). Patients who are naive or experienced to 1 or more TNF antagonists (infliximab,
adalimumab, or certolizumab pegol) at a dose approved for CD were included.
Interventions Experimental: Risankizumab (200 mg or 600 mg) or placebo IV Q4W for 12 weeks as induction ther-
apy. In the extended induction/washout phase (weeks 14-26, period 2), those not in deep remission
at week 12 received open-label RZB 600 mg IV Q4W for 12 weeks and those in deep remission at
week 12 entered a washout phase until week 26. Patients in clinical remission at week 26 entered
the maintenance phase and received open-label RZB 180 mg SQ Q8W for 26 weeks (weeks 26-52,
period 3); those not in clinical remission discontinued. In period 2 and 3, only participants who re-
ceived open-label RZB treatment were analysed.
Outcomes Percentages of participants with IBDQ response (increase in IBDQ total score >= 16); IBDQ remis-
sion (IBDQ total score >= 170); and mean change from baseline (BL) in IBDQ total, domain, and se-
lected individual item scores were calculated at weeks 12, 26, and 52.
Notes Data from phase 2 trial of risankizumab in Crohn's disease (NCT02031276)
121 participants were analysed in period 1.
Recent conference proceeding - additional information on individual item scores for fatigue to be
requested
Louis 2019 
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Methods A single-centred randomised, placebo-controlled, open trial
Participants 40 adults (aged 18 years and older) with IBD (20 adults with Crohn's disease and 20 adults with ul-
cerative colitis) in clinical and biochemical remission with no other obvious identifiable explana-
tion for their fatigue. Remission for CD will be defined as HBI < 5 and CRP < 5. For UC, it will be de-
fined as partial Mayo score ≤ 2 and CRP < 5. For both groups a faecal calprotectin (FC) of > 250 ug/
g will be regarded as indicating active disease and will exclude participants from the study. Partici-
pants will also be excluded if they are anaemic (Hb < 14g/dL for males, 11.5g/dL for females). In the
CD arm, participants will be assessed for Vitamin B12 and Vitamin D status and excluded if B12 is
less than 300 pmol/L or Vitamin D less than 30 ng/mL.
Interventions Experimental: Structured psychoeducational intervention centred around a self-management
booklet and group work (3 small group sessions over 6 months)
Comparator: Standard care
Outcomes Primary outcome: Fatigue severity and impact (CCUK fatigue score at 20 weeks)
Secondary outcomes:
Anxiety/depression (HADS at 20 weeks)
Somatisation (PHQ15 at 20 weeks)
IBS symptoms (Rome III at 20 weeks)
Quality of life (SIBDQ and SF-36 at 20 weeks)
Disease activity (HBI/Mayo score; CRP and FC)
Activity diaries (for four weeks)
Fatigue scores and disease activity (as measured by HBI/Mayo score, CRP, FC), quality of life (as
measured by SF-36 & SIBDQ), anxiety and depression (HAD) or somatisation (PHQ15)
Notes Estimated enrollment: 40 participants




Methods A phase 3, randomised, double-blind, placebo-controlled, parallel-group multicentre study
Participants Adults (aged 18 years and older) with moderately-to-severely active CD (CDAI 220-450) who had in-
adequate response or intolerance to TNF antagonists (UNITI-1, N = 741) or to conventional therapy
(UNITI-2, N = 627) were randomised 1:1:1 to receive Ustekinumab (UST) ˜6 mg/kg, UST 130 mg or
placebo (PBO) intravenously (IV) at week 0 and the IBDQ score was assessed at baseline and week
8.
Interventions Experimental: Ustekinumab ˜6 mg/kg or 130 mg intravenously at week 0
Active comparator: Placebo intravenously at week 0
Outcomes Specific items of quality of life (IBDQ assessed at baseline and week 8)
Sands 2018 
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Notes Post hoc analysis of the UNITI- I & 2 phase 3 trials. Participants included those who had an inad-
equate response or intolerance to TNF antagonists (UNITI-1, N = 741) or to conventional therapy
(UNITI-2, N = 627).





Methods A multicentred RCT
Participants Adults (aged between 16 and 65 years) with a clinical diagnosis of Crohn's disease (for at least 4
weeks before the screening visit) with mildly active (150 to 219 on Crohn’s Disease Activity Index
[CDAI]) or inactive (< 150 on CDAI) disease. Faecal calprotectin < 250 mcg/g recorded no greater
than 4 weeks before the screening visit. Stable medications for at least 4 weeks before the screen-
ing visit. Able to provide written informed consent and complete the study questionnaires. Able to
travel to the research centre for assessment visits and exercise sessions.
53 participants were assessed for eligibility and 36 (68%) were randomised.
Interventions Experimental: High-intensity training group - participants will be invited to complete three exercise
sessions each week for 12 consecutive weeks. All exercise will be performed on a stationary upright
cycle ergometer. Each session will begin with a 5-minute warm-up of easy cycling. The main body
of each session will involve ten, 1-minute bouts of hard cycling, interspersed with 1-minute bouts
of easy cycling. The session will end with a 3-minute cool-down of easy cycling. The resistance level
on the cycle ergometers will be progressed after 4 and 8 weeks of training.
Experimental: Moderate-intensity training group - participants will be invited to complete three
exercise sessions each week for 12 consecutive weeks. All exercise will be performed on a station-
ary upright cycle ergometer. Each session will begin with a 5-minute warm-up of easy cycling. The
main body of each session will involve 30 minutes of cycling at a moderate intensity. The session
will end with a 3-minute cool-down of easy cycling. The resistance level on the cycle ergometers
will be progressed after 4 and 8 weeks of training.
Comparator: Participants continue as normal, and do not undertake any additional activity.
Outcomes Primary outcomes: Recruitment rates and intervention adherence rates (calculated when interven-
tion delivery period is complete). Missing data rates and retention rates are calculated when fol-
low-up is complete.
Secondary outcomes: Blood markers of inflammation (e.g. IL-6, CRP) are measured at baseline and
13 week in all participants, and week 7 in exercise group participants. Body mass, cardiorespiratory
fitness (ventilatory threshold and peak oxygen uptake), disease symptoms (CDAI), bowel inflamma-
tion (faecal calprotectin), resting blood pressure, resting heart rate and waist circumference is de-
termined at baseline and 13 weeks.
Health status (EuroQol EQ-5D-5L), anxiety and depression (Hospital Anxiety and Depression Scale),
fatigue (Inflammatory Bowel Disease Fatigue Scale), quality of life (Inflammatory Bowel Disease
Quality of Life Questionnaire) and physical activity (International Physical Activity Questionan-
naire) is measured using the questionnaire at baseline, 13 and 26 weeks.
Notes Findings from pilot study recently published
Tew 2019 
BL: Baseline
CCUK: Crohn's & Colitis UK
CD: Crohn's disease
CDAI: Crohn's Disease Activity Index
CDEIS: Crohn's Disease Endoscopic Index of Severity
Interventions for fatigue in inflammatory bowel disease (Review)









Cochrane Database of Systematic Reviews
CRP: C-reactive protein
CT: Computed tomography
FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue
FC: Faecal calprotectin
HADS: Hospital Anxiety and Depression Scale
Hb: Haemogloblin
HBI: Harvey Bradshaw Index
IBD: Inflammatory bowel disease
IBDQ: Inflammatory Bowel Disease Questionnaire
IBS: Irritable bowel syndrome
IL: Interleukin
IV: intravenous
MD: Doctor of Medicine
PHQ15: Patient Health Questionnaire 15
PI: Principal Investigator
Q4W: Every 4 weeks
R CT: Randomised controlled trials
RZB: Risankizumab
SF-36: 36-Item Short Form
SIBDQ: Short Inflammatory Bowel Disease Questionnaire
SQ: Subcutaneous
TNF: Tumor necrosis factor
UC: Ulcerative colitis
UC-SQ: Ulcerative Colitis Symptom Questionnaire
UST: Ustekinumab
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title A prospective randomised multicentre study to evaluate the effect of intravenous iron infusion
compared to oral iron supplementation on the quality of life in inflammatory bowel disease with
non-anaemia hypoferritinanaemia
Methods A phase 4 multicentre RCT
Participants 58 adults (aged 17 - 80 years) with a diagnosis of IBD for at least 3 months, disease in remission for
at least 3 months, ferritin equal or less than 30 ug/L and haemoglobin equal or greater than 13 0g/L
in males and equal or greater than 120 g/L in females
Interventions Experiment: one oL visit for administration of intravenous Ferric Carboxymaltose (Ferrinject) 1000
mg
Comparator: oral ferrous sulphate 1 x 325 mg tablet once daily for 6 weeks
Outcomes Quality of life (Shortened IBD Questionnaire and SF-36 at week 6)
Fatigue (IBD-F at week 6)
Disease Activity (HBI and SCCAI at 6 weeks)
Starting date May 2017
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Contact person: Dr Sylvia Wu
+6445666999
sylvia.wu@huttvalleydhb.org.nz
Notes Anticipated date of last participant enrollment: May 2018
No published data identified in latest search




Trial name or title Influence of extra virgin olive oil intake on disease activity and gut microbiota profile of community
dwelling adults with ulcerative colitis in comparison to healthy subjects
Methods RCT, parallel, open allocation
Participants Individuals with ulcerative colitis (aged >= 18 years) for > 3 months duration of any extent. Non-IBD
subjects (aged >= 18 years) with stable medication and willing to be randomised into one of the
two study arms and participate in the intervention prescribed
Interventions Experimental: total replacement of all free dietary fats with extra virgin olive oil (EVOO)
Active comparator: usual care, no dietary replacement
Outcomes Primary outcomes: Ulcerative colitis disease activity (partial Mayo scoring Index); gut microbiota
variety and richness (faecal samples)
Secondary outcomes: Diet quality (3-day weighted food record submitted and Food Frequency
Questionnaire); malnutrition risk (Mini-Nutritional Assessment); Food Frequency Questionnaire;
medication intake; fatty acid profile; polyphenol content; diet Inflammatory Index (3-day food di-
ary as determined by FoodWorks); plasma oleic acid levels; faecal short chain fatty acid content;
plasma hydroxityrosol sulfate (gas chromatography–mass spectrometry); self-reported symptoms
(weekly status check); bone density in the lumbar spine and hip (dual-energy X-ray absorptiome-
try); serum levels of Tumour Necrosis Factor Alpha (enzyme-linked immunosorbent assays ELISA);
blood C-Reactive Protein; Erythrocyte Sedimentation Rate (sedimentation rate test); faecal IgA
(ELISA); blood lipopolysaccharides (LPS); serum levels of folate; serum levels of calcium; Serum lev-
els of vitamin D; Quality of life (IBDQ and SF-36); Depressive Symptoms (patient health question-
naire - 9); Depression and Anxiety (HADS); Fatigue (IBD-F); 7-day physical activity (Axivity MEMS
3-axis accelerometer); adverse events ( weekly status check); plasma tyrosol (gas chromatogra-
phy–mass spectrometry); IgA coating bacteria in stool analysis (16S rRNA sequencing); faecal levels
of Interleukin (IL) 1, IL6, IL10, IL12 (ELISA); faecal LPS (Pro Q Emerald 300 Gel Staining kit); food-re-
lated quality of life (FR-QoL-29)
Starting date April 2019
Contact information Principal investigator: Prof Maria A. Fiatarone Singh, MD, FRACP
University of Sydney Cumberland Campus
Building K, Room K221
ACTRN12619000150145 
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+61 2 9351 9755
maria.fiataronesingh@sydney.edu.au
Contact Person: Mr Kenneth Daniel
University of Sydney Cumberland Campus






Notes Anticipated date of data collection: April 2020
Trial forms part of a PhD programme
No published data identified in latest search




Trial name or title The effectiveness and tolerability of GlobiFer (haem iron) tablets compared to ferrous sulphate
tablets in inflammatory bowel disease: a randomised-controlled trial
Methods A phase 2, multicentre RCT
Participants Adolescents and adults (> 12years) with established inactive IBD (defined by CDAI < 150 with nor-
mal CRP or SCCAI < 4 for patients with Crohn's colitis or colitis and terminal ileal disease and ulcer-
ative colitis respectively) and iron deficiency anaemia (haemoglobin levels at least 1 g/dL below
the sex-specific lowest value [13 g/dL for men and 12 g/dL for women] and either mean cell volume
≤ 80 fl or ferritin ≤100 g/L or transferrin saturation < 20%)
Interventions Experimental: Oral GlobiFer Forte (iron-integrated haemoglobin powder equal to 18 mg Fe++)
Active comparator: Oral ferrous sulphate 65 mg iron ++ per tablet
Outcomes Primary outcome: 1 g/dL increase in haemoglobin over baseline at 12 weeks
Secondary outcomes: Clinical assessment at each visit: FBC, serum ferritin, transferrin saturation,
CRP, ESR, disease activity (CDAI or SCCAI); quality of life (IBDQ); fatigue (10-point visual analogue
scale); analysis of faecal microbiota at baseline, week 12, week 24; safety of treatment - symptoms
and side effects (weekly diary card); adverse and serious adverse events
Starting date Starting date not reported
EudraCT Number: 2008-004277-17 
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Contact information Globifer International bvba, Belgium
Notes No published data identified in latest search
The study was initiated but never completed as there were not enough participants. Findings from
the data retrieved were not published, however, a small internal report was completed. 21 partici-
pants were enrolled (11 with GlobiFer Forte, 10 with ferrous sulphate) and the conclusion was that
GlobiFer Forte seemed to be better tolerated than ferrous sulphate. But it was a small number of
participants and a non-homogeneous data situation so difficult to make a strong conclusion (per-




Trial name or title Iron therapy in IBD patients with normal levels of haemoglobin and chronic fatigue
Methods A multicentre, randomised, placebo-controlled, double-blinded trial
Participants Adults (aged > 18 years) with IBD and chronic fatigue (MFI-20 > 13). At least 12-month history of IBD.
Inactive Crohn's disease or ulcerative colitis (HBI: < 5, Mayo clinical score: ≤ 2) for at least 6 months.
Concurrent stable doses of 5-aminosalicylate, azathioprine, methotrexate or anti-tumour necrosis
factor alpha. Iron deficiency (ferritin < 100 ng/mL or ferritin 100-300 ng/mL when transferring satu-
ration < 20%)
Interventions Experimental: Ferric carboxymaltose 50 mg/mL
Comparator: Placebo
Outcomes Primary outcome: chronic fatigue remission at week 24 (MFI-20 < 13)
Secondary outcomes: clinical response at week 24, defined as decrease in MFI-20 of at least 4
points, but with a score > 13
Starting date Not reported
Contact information Instituto Clinico Humanitas, via Manzoni 56, Rozzano, Italy, 20089
Telephone number: 02 82244033
Fax number: 02 82247208
Email: francesco.minuti@humanitas.it
Notes No published data identified in latest search
Study is still ongoing - personal correspondence with Francesco Minuti (July 2018)




Trial name or title Prospective Open label study of Parenteral vs Enteral iron in Young IBD patients and Effect on phys-
ical fitness - POPEYE study
Methods A randomised, placebo-controlled, multicentre trial
EudraCT Number: 2012-005644-26 
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Participants 150 children (aged 8 - 18 years) with a diagnosis of CD, UC or IBDU
Interventions Experiment: Ferric Carboxymaltose 50 mg/mL intravenous
Comparator: Ferrous Fumarate 100 mg oral
Outcomes Primary outcome:
Exercise capacity (6-minute walk test at week 4, month 3 and month 6)
Secondary outcomes:
Haemoglobin levels (Hbg at week 4, month 3 and month 6)
Quality of life (IMPACT-III at week 4, month 3 and month 6)
Fatigue (PedsQL Multidimensional Fatigue Scale at week 4, month 3 and month 6)
Disease activity (PCDAI and PUCAI at week 4, month 3 and month 6)
Iron stores (Ht, cell indices, thrombocytes, ferritin, transferrin, serum iron level, transferrin satura-
tion, reticulocytes/retHb , sTfR (soluble transferrin receptor), soluble transferrin receptors to log
ferritin (sTfR-F ratio), transferrin/log ferritin ratio, hepcidin at week 4, month 3 and month 6)
Side effects of IV iron therapy on liver functioning (AST, ALT, AF, total protein, albumin at week 4,
month 3 and month 6)
Side effects on electrolyte homeostasis (phosphate at week 4, month 3 and month 6)
Daily Activity and sleep (IV accelerometers at week 4, month 3 and month 6)
Starting date February 2018







Notes No published data identified in latest search




Trial name or title Effects of a 6-month practical resistance training programme on muscle function and bone miner-
al density in adults with inactive or mildly active Crohn’s disease: study protocol for a randomised
controlled trial
Methods A mulitcentre RCT
ISRCTN11470370 
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Participants Adults (aged 16 years and older) diagnosed with Crohn's disease with inactive (CDAI < 150) or mild
disease (CDAI 150 - 219) and faecal calprotectin < 250 mcg/g
Interventions Experimental: A six-month resistance training programme involving a combination of supervised
and unsupervised exercise sessions.
Comparator: Usual care
Outcomes Primary outcomes: Bone mineral density (dual energy X-ray absorptiometry); maximum volun-
tary isometric and isokinetic strength (isokinetic dynamometry); handgrip strength (handgrip dy-
namometer); lower limb muscle endurance (30-second chair sit-to-stand test); upper limb muscle
endurance (30-s arm bicep curl test)
Secondary outcomes: Quality of life (Inflammatory Bowel Disease Quality of Life Questionnaire);
health status (EuroQol 5-dimensions, 5-level questionnaire); fatigue (IBD-F); body mass (balance
beam scales); stature (stadiometer); disease activity (CDAI); bowel inflammation (faecal calpro-
tectin); blood markers of inflammation; physical activity (Scottish Physical Activity Questionnaire);
feasibility and acceptability outcomes
Starting date October 2016
Contact information Dr Garry Tew










Notes Estimated enrollment: 50 participants
No published data identified in latest search




Trial name or title Assessing the tolerability of oligosaccharide supplementation in patients with Crohn's disease: a
randomized, controlled trial
Methods RCT
Participants Adults (aged >/= 19 years) with a diagnosis of Crohns disease for >/= 6 months, currently in remis-
sion (HBI score </= 4 points and CRP < 5 mg/L)
NCT02193750 
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Interventions Experimental: Moderate Oligosaccharide Group - 1 placebo muesli bar and 1 serving intervention
muesli per day (3.25 g total fructans/GOS)
Experimental: High Oligosaccharide Group - 1 intervention muesli bar and 1 serving intervention
muesli per day (5.43 total fructans/GOS)
Comparator: Placebo Group - 1 placebo muesli bar and 1 serving placebo muesli per day (0.55 g to-
tal fructans/GOS)
Outcomes Primary Outcome: Overall GI symptoms (VAS in diet diaries) at baseline and study completion
Secondary Outcomes: Tolerability (individual gastrointestinal symptoms (abdominal bloating, ab-
dominal pain, gut rumbling, flatulence) quantified by the VAS), fatigue (Fatigue Impact Scale), qual-
ity of life (Physical Component Summary and Mental Component Summary), mood (STPI), disease
activity, adherence assessment at baseline and study completion
Starting date August 2015
Contact information Cherry E. Galorport
Telephone: 604-806-9440
Email: cgalorport@gmail.com
PI: Brian Bressler, MD, Division of Gastroenterology, Department of Medicine St. Paul's Hospital,
Vancouver, BC Cananda
PI: Peter Gibson, MD, Department of Gastroenterology Alfred Hospital, Melbourne, Australia
Notes Estimated study completion date: December 2017
Estimated Enrollment: 48 participants
No published data identified in latest search




Trial name or title A randomised controlled trial of high-dose vitamin D in Crohn's disease
Methods A multicentre RCT
Participants Adults (aged 18-75 years) with a diagnosis of Crohn's disease and vitamin D deficiency or insuffi-
ciency (serum 25-hydroxyvitamin D < 30 ng/mL)
Interventions Experimental: High dose vitamin D - cholecalciferol 10,000 IU daily for 30 days. At that point, if their
vitamin D levels remain below 50 ng/mL, the 30-day course will be repeated. For participants who
enrol in the summer, levels will be rechecked in March and if < 50 ng/mL, a 30-day course will be
administered.
Active comparator: Low dose vitamin D - cholecalciferol 400 IU once daily for 30 days. To maintain
the blind, a random few will be given another round at the 30-day mark. For participants who enrol
in the summer, a random few will again receive 400 IU cholecalciferol in March.
Outcomes Primary outcomes: Primary composite outcome at year 1 - Crohn's disease(CD)-related hospitali-
sations, CD-related surgeries, CD-related ER visits, steroid prescriptions; hypercalcaemia at year 1
(calcium > 10.8 mg/dL); incidence of nephrolithiasis associated with hypercalcaemia at year 1 (doc-
umented by imaging)
NCT02208310 
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Secondary outcomes: Crohn's related hospitalisation at year 1; steroid prescriptions at year 1;
Crohn's disease-related surgeries at year 1; change in modified HBI at year 1; change in CRP at year
1; change in fecal calprotectin at year 1 ; percent with escalation of therapy at year 1; quality of life
measure changes at year 1 (IBDQ and CD-PRO); change in fatigue measurements at year 1 (FACIT-F);
Crohn's related ED visits at year 1
Starting date April 2015
Contact information Principal Investigator: Peter Higgins MD, PhD, MSc, University of Michigan
Contact name: Kelli Porzondek
Telephone number: 007346470507
Email: kporzond@med.umich.edu
Notes No published data identified in latest search. The clinical trial registers webpage (https://clinicaltri-
als.gov/ct2/show/NCT02208310) stated that the study has been terminated, unable to enroll at rate





Trial name or title Effects of iron therapy in patients with chronic fatigue and IBD
Methods A phase 2, randomised, placebo-controlled trial
Participants Adults (aged 18 - 75 years) with a diagnosis of Crohn's disease or ulcerative colitis for a least 6
months prior to day 1 by endoscopy and/or imaging. At least 6 months of clinical remission (HBI ≤
5; Mayo clinical score ≤ 2). Therapy with mesalamine, immunosuppressors or anti-tumour necro-
sis factor alpha at stable doses for at least 3 months prior to enrollment; steroids are not permitted
from 6 months prior to baseline. Chronic fatigue symptoms (MFI-20 > 13). Iron deficiency (ferritin <
100 microg/L or < 300 microg/L in case of transferrin-iron saturation percentage < 20%
Interventions Experimental: Ferric carbxymaltose 200 mg in normal saline 100 mL administered IV at day 0 and
then every 4 weeks up to week 24
Comparator: Placebo - normal saline 100 mL administered IV at day 0 and then every 4 weeks up to
week 24
Outcomes Primary outcome: chronic fatigue remission at week 24 (MFI-20 < 13)
Secondary outcomes: chronic fatigue reduction at week 24 (MFI-20 reduction of at least 4 points.
Absolute MFI-20 > 13)
Chronic fatigue remission at week 12 (MFI-20 < 13)
Anxiety evaluation (State-Trait Anxiety Inventory (STAI) at week 4, week 12, week 24)
Depression evaluation (BDI-II at week 4, week 12, week 24)
Quality of life (IBDQ at week 4, week 12, week 24)
Starting date October 2014
Contact information Silvio Danese, MD, PhD
IBD Center, Rozzano, MI, Italy, 20089
NCT02517151 
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Telephone number: 0039028224 ext 5555
Email: IBDclinicaltrials@humanitas.it or sdanese@hotmail.com
Notes No published data identified in latest search
Study is still ongoing (personal correspondence with Dr. Danese July 2018)




Trial name or title The impact of serum vitamin D and calcium levels on the body composition, bone mineral density,
muscle strength, exercise tolerance, fatigue and inflammatory activity in patients with Crohn's dis-
ease: a randomized controlled trial
Methods A single-centred randomised, placebo-controlled, double-blinded trial
Participants 110 adults (aged 18 - 50 years) with a clinical diagnosis of Crohn's disease, with remission of
Crohn's activity and reduced blood levels of vitamin D
Interventions Experimental: Tablets with 50000 IU cholecalciferol (vitamin D3) will be administered, weekly, for
six months and nutritional instructions from an experienced nutritionist regarding the consump-
tion of vitamin D and calcium rich foods.
Placebo Comparator: The participants selected for the placebo group will receive inert content
tablets without therapeutic effect, weekly, for six months.
Outcomes Primary outcome: Grip strength after 6 months of supplementation with vitamin D
Secondary outcomes:
Mineral bone density (DXA at 6 months)
Fecal calprotectin levels (at 6 months)
Inflammatory biomarkers (TNF-α; IL6; IL17; CRP at 6 months)
Exercise capacity (shuttle walk test at 6 months)
Lean body mass (DXA at 6 months)
Fatigue (Chalder Fatigue Questionnaire at 6 months)
Starting date December 2016
Contact information Lorena NO Pinto, Lecturer
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Principal Investigator: Júlio MF Chebli, Professor Federal University of Juiz de Fora
Notes No published data identified in latest search
Estimated study completion date: February 2020




Trial name or title Quality Of LIfe Tool for IBD (QOLITI): pilot testing of a self-administered intervention to target psy-
chological distress in inflammatory bowel disease
Methods A single-centred randomised, placebo-controlled, open trial
Participants 62 adults (aged 18 years and older) with a clinical diagnosis of inflammatory bowel disease
Interventions Experimental: QOLITI
Intervention group receives the QOLITI ('Quality Of LIfe Tool for IBD') manual immediately to work
with over the course of several weeks along with 3 x 30 minutes of telephone support by a trained
healthcare professional. Telephone calls will occur at two, four and six weeks post-randomisation.
Comparator: Waiting-List Control group (WLC)
Waiting-list control group waits until after the study finishes to receive the same manual, but with-
out telephone support sessions.
Outcomes Primary outcomes:
Depression (Patient Health Questionnaire - 9 at 10 weeks post-intervention)
Anxiety (Generalised Anxiety Disorder - 7-item scale at 10 weeks post-intervention)
Generic quality of life (EQ-5D-5L at 10 weeks post-intervention)
Specific quality of life (IBDQ at 10 weeks post-intervention)
Secondary outcomes:
Semi-structured qualitative Interviews: Participants will be invited to discuss their experiences af-
ter the end of the actual study. These interviews are no obligatory part of the QOLITI study.
Fatigue (Chalder Fatigue Scale at 10 weeks post-intervention)
Illness perception (Illness Preception Questionnaire at 10 weeks post-intervention)
Disease activity (Patient-Modified Simple Clinical Colitis Activity Index or Crohns Disease Activity In-
dex for research surveys)
Starting date January 2016
Contact information Lyndsay D Hughes, PhD
Kings College London
Email: Lyndsay.hughes@kcl.ac.uk
Notes The study has been completed however no fatigue data published yet (personal correspondence
July 2018).
NCT02707068 
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Trial name or title A randomized, double-blind, placebo-controlled, multi-center pragmatic clinical trial to evaluate
the effectiveness of low dose oral methotrexate In patients with pediatric Crohn's disease initiating
anti-TNF therapy
Methods A randomised, double-blind, placebo-controlled, multicentre trial
Participants 425 paediatric Crohn's disease (PCD) patients, < 21 years of age, ≥ 20 kg, initiating anti-TNF therapy
with infliximab or adalimumab (including biosimilars)
Interventions Experiment: Methotrexate (10, 12.5, or 15 mg), once weekly. Weight-based dosing. Ondansetron (4
mg), twice weekly, 1 hour prior to methotrexate dose and the morning after methotrexate dose.
Folic Acid (1 mg) daily
Comparator: Placebo (sugar pill) for methotrexate, once weekly. Placebo for ondansetron, twice
weekly, 1 hour prior to methotrexate placebo dose and the morning after methotrexate placebo
dose. Folic Acid (1 mg) daily
Outcomes Primary outcomes
Time to treatment failure (Short Pediatric Crohn's Disease Activity Index (SPCDAI) through week
104); hospitalisation for active irritable bowel disease or abdominal surgery after week 25; use
of oral prednisone or prednisolone, enteral release budesonide, or intravenous (IV) methylpred-
nisolone for over 10 weeks cumulatively, beyond week 16 (not inclusive of steroids used as premed
for anti-TNF administration or steroids used for conditions other than CD); or discontinuation of
anti-TNF or study drug for lack of effectiveness or toxicity)
 
Secondary outcomes:
Pain (patient-reported outcome measurement and Information system pain interference T score at
week 52 and 104)
Fatigue (patient-reported outcome measurement and information system fatigue T score at week
52 and 104)
Positive anti-TNF antibody status (between week 91 and week 104)
Starting date October 2016
Contact information Michael D Kappelman, MD, University of North Carolina, Chapel Hill
Notes Estimated study completion date: December 2020




Trial name or title Pre-habilitation exercise intervention for patients scheduled for colorectal surgical resection
Methods RCT
Participants Adults (18 years and older) with a primary diagnosis of colon/rectal cancer or IBD or diverticular
disease who are scheduled for elective (non-emergent) surgery. Patients with approval from their
treating physician, study physician, or physician's designee to participate in maximal physiologi-
NCT02849717 
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cal fitness testing and a low-to-moderate home-based walking and progressive resistance exercise
programme and those who are able to read English are eligible to participate.
Interventions Experiment: A standardised, daily, home-based, progressive exercise programme (walking and re-
sistance exercise treatment)
Comparator: Standard care
Outcomes Primary outcome: Fatigue (FACIT-F fatigue subscale) at baseline and 12 weeks
Secondary Outcomes: aerobic capacity (VO2 maximum testing), skeletal muscle mass (bio-electri-
cal impedance assessment of muscle mass and CT assessment of muscle mass), pro-inflammatory
cytokines (IL-6, IL-8,IL-10, IL-1B,and IFN-y), TNFr1 cytokine receptor, postoperative complications
(Clavien-Dindo classification of surgical complications), quality of life (Profile of Mood States and
Spielberg State/Trait Anxiety Inventory) at baseline and 12 weeks
Starting date Pilot trial start date: March 2016
Contact information PI Fergal Fleming, MD from the University of Rochester
fergal.fleming@urmc.rochester.edu)
Notes This study will be eligible to be included in future updates of the review if sufficient numbers of IBD
participants are included to conduct a subgroup analysis (personal correspondence with the PI
Fergal Fleming, MD from the University of Rochester - fergal.fleming@urmc.rochester.edu). Data




Trial name or title Inflammatory bowel disease: could a regular physical activity reduce patients fatigue?
Methods A single-centre RCT
Participants Adults (18 - 45 years old) with IBD in remission (CRP < 5) with fatigue (FACIT score < 30). Patients
with haemoglobin dosage > 10 g/dL, BMI > 18 and < 30kg/m2, women with no risk of pregnancy
(menopausal women or with contraceptive drugs), affiliated to the social security and living not far
from the centre where the rehabilitation programme will be performed, are eligible to be included.
Interventions Experimental: Regular and moderate physical activity will be done 3 times per week more than
usual
Sham Comparator: No regular and moderate physical activity more than usual
Outcomes Primary Outcome: Fatigue (FACIT) at baseline and 3 months
Secondary Outcome: Quality of life (IBDQ and SF-36) at baseline and 3 months
Starting date September 2016
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Julien Blot - julien.blot@chu-rouen.fr
Notes Estimated study completion date: April 2018
Estimated enrollment: 10 participants
No published data identified in latest search




Trial name or title A phase 2, multicentre, randomized, parallel-arm, placebo-controlled study of LY3074828 in sub-
jects with active Crohn's disease (SERENITY)
Methods A Phase 2, multicentre, randomised, parallel-arm, placebo-controlled trial
Participants Adults (aged 18 -75 years) with active Crohn's disease (SES-CD and participant-reported stool fre-
quency and abdominal pain) and inadequate response or failure to tolerate at least one of the fol-
lowing: aminosalicylates; budesonide; systemic corticosteroids; immunosuppressants (e.g. aza-
thioprine, 6-mercaptopurine, or methotrexate); or prior exposure to biologics for the treatment of
CD
Interventions Experimental: Mirikizumab dose level 1
Period 1 (Weeks 0 -12) Mirikizumab dose level 1
Period 2 (Weeks 12 - 52) Mirikizumab dose level 1 or dose level 4 or dose level 3
Period 3 (Weeks 52 - 104) Mirikizumab dose level 4
Experimental: Mirikizumab dose level 2
Period 1 (Weeks 0 -12) Mirikizumab dose level 2
Period 2 (Weeks 12 - 52) Mirikizumab dose level 2 or dose level 4 or dose level 3
Period 3 (Weeks 52 - 104) Mirikizumab dose level 4
Experimental: Mirikizumab dose level 3
Period 1 (Weeks 0 -12) Mirikizumab dose level 3
Period 2 (Weeks 12 - 52) Mirikizumab dose level 3 or dose level 4
Period 3 (Weeks 52 - 104) Mirikizumab dose level 4
Comparator: Placebo
Period 1 (Weeks 0 -12) Placebo
Period 2 (Weeks 12 - 52) Mirikizumab dose level 3
Period 3 (Weeks 52 - 104) Mirikizumab dose level 4
Outcomes Primary outcome: Endoscopic disease activity (Simple Endoscopic Activity Score-Crohn's Disease
(SES-CD)) at baseline and week 12
Secondary outcomes: Discontinuation rate and pharmacokinetics (area under the curve Mirik-
izumab) at baseline through week 104. Endoscopic remission, patient-reported outcome remis-
sion, patient global rating (severity and change (PGR-S and PGR-C) Crohn's disease score), quality
of life (IBDQ and SF-36), fatigue (FACIT-F) at baseline and week 12
NCT02891226 
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Starting date December 2016
Contact information Eli Lilly and Company
Telephone: 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559
Notes Estimated study completion date: April 2021




Trial name or title Effects of a mindfulness therapy intervention for individuals with inflammatory bowel disease: a
randomized controlled trial
Methods RCT single-blinded
Participants Adults (18 -55 years) with a diagnosis of inflammatory bowel disease in remission (non-active dis-
ease symptoms in the last 3 months). Participants with access to the internet and basic informatics
knowledge are eligible to be included.
Interventions Experimental: Mindfulness-Based Cognitive Therapy (psychological programme designed to help
manage depressive and stress symptoms) for 12 months
Comparator: Treatment-as-usual control
Outcomes Primary Outcome: Quality of life (IBDQ-32) at baseline and 12 months
Secondary Outcome: Inflammation stress markers (CRP and FC) at baseline and 12 months
Starting date February 2017
Contact information Dr. Jose Miguel Soria Lopez (PI)
Professor, Cardenal Herrera University
Contact: Dr. Xavier Cortés or Dr Juan F Lisón
Telephone: 686774074 or 606503108
Email: xavier.cortes@uchceu.es orjuanfran@uchceu.es
Notes Eligible only if analysis of the subcomponents of IBDQ is undertaken
Estimated study completion date: March 2018
Actual enrollment: 60 participants
No published data identified in latest search




Trial name or title A multicenter, randomized, double-blind, placebo-controlled induction study to assess the effica-
cy and safety of risankizumab in subjects with moderately to severely active Crohn's disease who
failed prior biologic treatment
NCT03104413 
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Methods A multicentre, randomised, placebo-controlled, double-blinded trial
Participants Patients (aged 16 - 80 years - Where locally permissible, subjects 16 to < 18 years of age who meet
the definition of Tanner stage 5 for development at the baseline visit) with a diagnosis of Crohn's
disease for at least 3 months prior to baseline. A confirmed diagnosis of moderate-to-severe CD
as assessed by stool frequency (SF), abdominal pain (AP) score, and Simple Endoscopic Score for
Crohn's Disease (SES-CD). Demonstrated intolerance or inadequate response to biologic therapy
for CD. If female, subject must meet the contraception recommendations.
Interventions Placebo Comparator: Placebo (induction period 1) - Subjects randomised to receive placebo for
risankizumab in induction period 1.
Experimental: Risankizumab dose 1 and dose 2 in induction period 1
Experimental: Risankizumab dose 1 (induction period 2): Participants who received placebo in pe-
riod 1 and participants with inadequate response at week 12 in period 1 randomised to receive
risankizumab dose 1 administered by intravenous (IV) infusion in period 2.
Experimental: Risankizumab dose 2 (induction period 2)
Participants with inadequate response at week 12 in period 1 randomised to receive risankizumab
dose 2 administered by subcutaneous (SC) injection in period 2.
Experimental: Risankizumab dose 3 (induction period 2)
Participants with inadequate response at week 12 in period 1 randomised to receive risankizumab
dose 3 administered by subcutaneous (SC) injection in period 2.
Outcomes Primary outcomes:
Clinical remission (average daily SF and average daily AP at week 12)
Endoscopic response (SES-CD at week 12)
Secondary outcomes:
Clinical response (average daily SF and average daily AP at week 4 and week 12)
Clinical remission (CDAI at week 4 and week 12)
Clinical response and endoscopic response (at week 12)
Endoscopic healing (SES-CD at week 12)
Severity of Crohn's disease symptoms (Crohn's Symptom Severity at week 12)
Resolution of extra-intestinal manifestation (at week 12)
Hospitalisation (through to week 12)
Draining fistula (at week 12)
Fatigue (FACIT-F at week 12)
Overall health status (SF-36 at week 12)
Crohn's disease-related surgeries (through to week 12)
Starting date June 2017
Contact information AbbVie Call Center
Telephone: 8472838955
NCT03104413  (Continued)
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Email: abbvieclinicaltrials@abbvie.com
Notes Estimated study completion date: June 2019




Trial name or title A multicenter, randomized, double-blind, placebo controlled 52-week maintenance and an open-
label extension study of the efficacy and safety of risankizumab in subjects with Crohn's disease
who responded to induction treatment in M16-006 or M15-991
Methods The study consists of 3 substudies, as follows:
• Substudy 1 (randomised, double-blind, placebo-controlled trial) to evaluate the efficacy and safe-
ty of risankizumab versus placebo as maintenance therapy in subjects with moderately-to-se-
verely active Crohn's disease (CD) who responded to risankizumab induction treatment in study
M16-006 or study M15-991;
• Substudy 2 (randomised, exploratory maintenance study) to evaluate the efficacy and safety of
two different dosing regimens for risankizumab as maintenance therapy in subjects who respond-
ed to induction treatment in Study M16-006 or Study M15-991;
• Substudy 3 (open-label, long-term extension study) to evaluate long-term safety of risankizumab
in subjects who completed substudy 1 or 2.
Participants Adults (16 - 80 years) with Crohn's disease who have completed study M16-006 or study M15-991
and have achieved clinical response
Interventions Experimental: Double-blind risankizumab dose 1 (substudy 1) - Participants randomised to receive
double-blind risankizumab dose 1 for 52 weeks
Experimental: Double-blind risankizumab dose 2 (substudy 1) - Participants randomised to receive
double-blind risankizumab dose 2 for 52 weeks.
Placebo Comparator: Double-blind placebo for risankizumab (substudy 1) - Participants ran-
domised to receive double-blind placebo for risankizumab for 52 weeks
Experimental: Maintenance risankizumab dose 1 (substudy 2) - Participants randomised to receive
1 dose of double-blind risankizumab dose 1 followed by open-label risankizumab for 52 weeks
Experimental: Maintenance risankizumab dose 2 (substudy 2) - Participants randomised to receive
1 dose of double-blind risankizumab dose 2 followed by open-label risankizumab for 52 weeks
Experimental: Open-label risankizumab (substudy 3) - Participants who completed substudy 1 or
substudy 2 will receive open-label risankizumab beginning at Week 56
Outcomes Primary outcomes:
Clinical remission (average daily SF and average daily AP at week 52)
Endoscopic response (SES-CD at week 52)
Secondary outcomes:
Clinical remission (CDAI at week 52)
Discontinued corticosteroid use and achieved clinical remission (average daily SF and average dai-
ly AP score at Week 52)
Discontinued corticosteroid use (at week 52)
NCT03105102 
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Sustained clinical remission (average daily SF and average daily AP score at both week 0 and week
52)
Enhanced clinical response (decrease in average daily SF and/or decrease in average daily AP
score, and/or clinical remission per average daily SF and average daily AP score at week 52)
Clinical remission (average daily stool frequency and average daily abdominal pain score) and en-
doscopic response (SES-CD at week 52)
Endoscopic healing (SES-CD at week 52)
Severity of Crohn's disease symptoms (Crohn's Symptom Severity at week 52)
Resolution of extra-intestinal manifestation (at week 52)
Deep remission, both clinical remission (per average daily SF and average daily AP score) and endo-
scopic healing (SES-CD at week 52)
Hospitalisation (through to week 52)
Draining fistula (at week 52)
Fatigue (FACIT-F at week 52)
Overall health status (SF-36 at week 12)
Crohn's disease-related surgeries (through to week 12)
Starting date September 2017
Contact information AbbVie Call Center
Telephone: 8472838955
Email: abbvieclinicaltrials@abbvie.com
Notes Estimated completion date: September 2022




Trial name or title A multicenter, randomized, double-blind, placebo controlled induction study of the efficacy and
safety of risankizumab in subjects with moderately to severely active Crohn's disease
Methods A multicentre, randomised, double-blind, placebo-controlled induction trial
Participants Adults (aged 16 - 80 years - where locally permissible, subjects 16 to < 18 years of age who meet the
definition of Tanner stage 5 for development at the baseline visit) with a diagnosis of Crohn's dis-
ease for at least 3 months prior to baseline. Confirmed diagnosis of moderate-to-severe Crohn's
disease assessed by stool frequency, abdominal pain score and simple endoscopic score for
Crohn's disease (SES-CD). Demonstrated intolerance or inadequate response to conventional or to
biologic therapy for Crohn's disease. If female, subject must meet the contraception recommenda-
tions.
Interventions Placebo Comparator: Placebo (period 1)- Participants randomised to receive placebo for
risankizumab administered by intravenous (IV) infusion
Experimental: Risankizumab dose 1 (period 1) - Participants randomised to receive risankizumab
dose 1 administered by intravenous (IV) infusion
NCT03105128 
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Experimental: risankizumab dose 2 (period 1) - Participants randomised to receive risankizumab
dose 2 administered by intravenous (IV) infusion
Experimental: risankizumab dose 1 (period 2) - Participants who received placebo in period 1 and
participants with inadequate response at week 12 in period 1 randomised to receive risankizumab
dose 1 administered by intravenous (IV) infusion in period 2
Experimental: Risankizumab dose 2 (period 2) - Participants with inadequate response at week 12
in period 1 randomised to receive risankizumab dose 2 administered by subcutaneous (SC) injec-
tion in period 2
Experimental: Risankizumab dose 3 (period 2) - Participants with inadequate response at week 12
in period 1 randomised to receive risankizumab dose 3 administered by subcutaneous (SC) injec-
tion in period 2
Outcomes Primary outcomes:
Clinical remission (average daily SF and average daily AP at week 12)
Endoscopic response (SES-CD at week 12)
Secondary outcomes:
Clinical response (average daily SF and average daily AP score at week 4 and week 12)
Clinical remission (CDAI at week 12)
Clinical remission (average daily SF and average daily AP score at week 4)
Clinical response and endoscopic response (at week 12)
Endoscopic healing (SES-CD at week 12)
Severity of Crohn's disease symptoms (Crohn's Symptom Severity at week 12)
Resolution of extra-intestinal manifestation (at week 12)
Hospitalisation (through to week 12)
Draining fistula (at week 12)
Fatigue (FACIT-F at week 12)
Overall health status (SF-36 at week 12)
Crohn's disease-related surgeries (through to week 12)
Starting date May 2017
Contact information AbbVie Call Center
Telephone: 8472838955
Email: abbvieclinicaltrials@abbvie.com
Notes Estimated completion date: February 2020
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Trial name or title Study of treat to target versus routine care maintenance strategies in Crohn's disease patients
treated with ustekinumab
Methods RCT
Participants Adults (aged 18 years and older) with active moderate-to-severe Crohn's disease (CDAI score >/=
220 and </= 450 and endoscopic evidence of active Crohn's disease (SES-CD score >/= 3, excluding
the contribution of the narrowing component score). Patient who has had an inadequate response
with, lost response to, was intolerant to, or had medical contraindications to either conventional
therapy, or one previous biologic therapy approved for the treatment of Crohn's disease and are el-
igible according to tuberculosis (TB) infection screening criteria can participate.
Interventions Experimental: All participants
At week (wk) 0, all eligible participants will initiate intravenous (IV) induction treatment with ustek-
inumab (UST) on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/
kg). At week 8, all participants will receive a 90 milligram (mg) subcutaneous (SC) injection of
ustekinumab. At week 16, participants who do not achieve a Crohn's Disease Activity Index (CDAI)
improvement of greater than or equal to (>=) 70 points versus week 0 (CDAI 70) will leave the study.
Remaining participants will be randomised in a 1:1 ratio to either one of two arms for open-label
maintenance treatment up to week 48: the treat-to-target arm or the routine care arm.
Experimental: Routine care arm
In the routine care arm, assessment visits will be scheduled according to the timing of mainte-
nance treatment injections, which will be in compliance with the EU Summary of Product Charac-
teristics for ustekinumab for the treatment of Crohn's disease, in which dosing every 12 weeks is
recommended. At week 16, (that is, 8 weeks after the first SC dose) participants continuing in the
study will have demonstrated a CDAI-70 response. Nonetheless, participants who have not shown
adequate response based on the investigator's judgement may receive a second SC dose at week
16. During the routine care maintenance treatment period, in case of clinical worsening reported
by the participant, consistent with disease flare in the investigator's judgement, clinical assess-
ments of disease flare will be performed at the investigator's discretion.
Experimental: Treat-to-Target (T2T) arm
UST maintenance treatment assignment will be based on centrally-read colonoscopy (at wk 16).
Participants with < 25% improvement in SES-CD score at wk16 will be assigned to Q8 (8-weekly)
treatment and will receive UST 90 mg SC at wk 16. In contrast, participants with >= 25% improve-
ment in SES-CD score at wk 16 will be assigned to Q12 treatment and will receive the next UST
dose (90 mg SC) at wk 20. At assessment visits (from wk 24 for participants assigned to the Q8 reg-
imen or from wk 20 for the Q12 group) UST maintenance treatment will be directed by T2T assess-
ments. Participants meeting the target will continue on the same UST dosing frequency. The dos-
ing frequency will be optimised for all participants failing to meet the target at the assessment vis-
it. Those previously on Q12 regimens will be adjusted to Q8 dosing; those previously on Q8 regi-
mens will be adjusted to Q4 dosing. Participants subsequently failing to meet the target will not be
able to adjust further and will leave the study.
Outcomes Primary Outcome: Endoscopic response (reduction from baseline in simple endoscopic score for
Crohn's disease (SES-CD) of >/= 50%) at week 48
 
Secondary Outcomes: Endoscopic remission (SES-CD score </= 2), mucosal healing (complete
absence of mucosal ulcerations in any ileocolonic segment), clinical remission (CDAI score < 150
points), clinical response (>/= 100-point reduction from the baseline CDAI score, or a CDAI score <
150), corticosteroid-free clinical remission (CDAI score < 150), corticosteroid-free endoscopic re-
sponse (a reduction from baseline in SES-CD score of >= 50%), inflammation (serum CRP and fecal
calprotectin), quality of life (IBDQ), work productivity (Work Productivity and Activity Impairment
Questionnaire score), health-related quality of life (European Quality Of Life 5 Dimensions 5 Level),
fatigue (FACIT-F), depression and anxiety (Hospital Anxiety and Depression Scale), time lost from
NCT03107793 
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work (number of days lost from work due to Crohn's disease), adverse events at baseline and week
48
Starting date April 2017
Contact information Janssen Cilag Ltd.
844-434-4210
JNJ.CT@sylogent.com
Notes Estimated study completion date: April 2019




Trial name or title The possible beneficial effects of mindfulness-based cognitive therapy (MBCT) in fatigued adult pa-
tients with Inflammatory Bowel Disease (IBD)
Methods RCT
Participants Adults (18 - 75 years) with a diagnosis of Crohn's disease and ulcerative colitis in remission with se-
vere fatigue (subscale 'subjective fatigue' of the CIS (8 items) ≥ 35). Participants with no expecta-
tion of a surgery in the upcoming 3 months, able to attend 8 weekly group sessions of 2.5 hours in
the hospital, and able to read, write and speak Dutch are eligible to participate.
Interventions Experimental: The intervention consists of 8 weekly sessions of Mindfulness-Based Cognitive Ther-
apy. Each session will be administered in a group and will last 2.5 hours.
Comparator: The waiting-list control group will receive no intervention for three months and after-
wards will receive Mindfulness-Based Cognitive Therapy.
Outcomes Primary Outcome: Fatigue (Checklist Individual Strength (CIS-20) at baseline, 3, 6 and 12 months
Secondary Outcomes:
Fatigue interference (Fatigue Symptom Inventory), anxiety (Generalised Anxiety Disorder Assess-
ment (GAD 7)), depression (Beck Depression Inventory-II (BDI-II)), IBD-specific quality of life (IBDQ),
sleep quality (Pittsburgh Sleep Quality Index), labour participation (assessed with several ques-
tions) at baseline, 3, 6 and 12 months. Satisfaction with treatment (assessed with several ques-
tions) at 3 months
Starting date January 2017
Contact information Dr. Annika Tovote





Notes Estimated study completion date: February 2019
Estimated enrollment: 128 participants
NCT03162575 
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Trial name or title Effect of dietary therapy with a probiotic mixture on the gut microbiome and fatigue symptoms in
patients with quiescent inflammatory bowel disease - a clinical trial
Methods A randomised, double-blind, placebo-controlled trial
Participants 100 adults (aged 18 - 75 years) with a confirmed diagnosis of CD, UC or IBD-unspecified, quiescent
disease and persistent ongoing fatigue symptoms
Interventions Experiment: Probiotic mixture taken twice a day for 12 weeks.
Comparator: Placebo
Outcomes Primary outcomes:
Gut microbiome (16sRNA sequencing at week 12)
Serum inflammatory cytokines levels (Biosciences Cytometric Bead Array kits at week 12)
Metabolomic profiles (quantitative and semi-quantitative gas chromatography-mass spectrometry
and liquid chromatography-mass spectrometry methods at week 12)
Fatigue (FACIT-F at week 4 and week 12)
Starting date November 2017
Contact information Principal Investigator: Ashwin Ananthakrishnan Assistant Professor of Medicine, Massachusetts
General Hospital
Contact: Nynke Borren, MD 617-726-1997 nborrent@mgh.harvard.edu
Contact Christine Wong 617-724-7559 cywong4@mgh.harvard.edu
Notes Estimated study completion date: December 2019




Trial name or title A multicenter, randomized, double-blind, placebo-controlled maintenance and long-term exten-
sion study of the efficacy and safety of upadacitinib (ABT-494) in subjects with Crohn's disease who
completed the studies M14-431 or M14-433
Methods A multicentre, randomised, double-blind, placebo-controlled maintenance and long-term exten-
sion study
Participants 738 participants who receive double-blind treatment in Study M14-431 or Study M14-433 and
achieve clinical response, and complete study procedures in the parent study.
Interventions Experimental: Group A - Arm B: This is a maintenance group with 52 weeks which includes partici-
pants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and
will receive dose C.
Experimental: Group B - Arm C: This is a long-term extension group with 240 weeks which includes
participants who complete group A.
NCT03345823 
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Experimental: Group B - Arm A: This is a long-term extension group with 240 weeks which includes
participants who complete group A and will receive dose B.
Experimental: Group B - Arm B: This is a long-term extension group with 240 weeks which includes
participants who complete group A and will receive dose C.
Experimental: Group A - Arm A: This is a maintenance group with 52 weeks which includes partici-
pants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and
will receive dose B.
Outcomes Primary outcomes:
Clinical remission (average daily stool frequency and average daily abdominal pain score at week
52)
Endoscopic response (SES-CD at week 52)
Secondary outcomes:
Endoscopic remission (SES-CD at week 52)
Fatigue (FACIT-F at week 52)
Enhanced Clinical Response (decrease in average daily SF and/or decrease in average daily AP
score at week 52)
Quality of life (SF-36 at week 52)
Hospitalisations due to CD (at week 52)
Discontinuation of corticosteroid use for CD and achieve clinical remission (at week 52)
Clinical remission (average daily stool frequency and average daily abdominal pain (AP) score at
week 52)
Clinical remission (CDAI < 150 at week 52)
Endoscopic remission (SES-CD at week 52)
Draining fistulas (at week 52)
Reduction in draining fistulas (>= 50% at week 12)
Crohn's Symptoms Severity Questionnaire (CSS at week 52)
Discontinuation of corticosteroid use for CD (at week 52)
Starting date March 2018
Contact information AbbVie
Notes Estimated study completion date: March 2023




Trial name or title A study of the efficacy and safety of upadacitinib (ABT-494) in subjects with moderately to severely
active Crohn's disease who have inadequately responded to or are intolerant to biologic therapy
Methods A multicentre, randomised, double-blind, placebo-controlled induction study
Participants 855 adults (aged 18 - 75 years) with a confirmed diagnosis of Crohn's disease for at least 3 months
prior to baseline, moderate-to-severe disease activity with evidence of mucosal inflammation and
previous inadequate response or intolerance to any biologic therapy
NCT03345836 
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Interventions Experimental:upadacitinib dose A (oral; once daily) for 12 weeks or open-label upadacitinib dose A
(oral; once daily) for 12 weeks.
Comparator: matching placebo for upadacitinib
Outcomes Primary outcomes:
Clinical remission (average daily stool frequency and average daily abdominal pain score at week
12)
Endoscopic response (SES-CD at week 12)
Secondary outcomes:
Fatigue (FACIT-F at week 12)
Enhanced Clinical Response (decrease in average daily SF and/or decrease in average daily AP
score at week 2)
Quality of life (SF-36 at week 12)
Hospitalisations due to CD (at week 12)
Clinical remission (average daily stool frequency and average daily abdominal pain (AP) score at
week 12)
Clinical remission (CDAI < 150 at week 12).
Endoscopic remission (SES-CD at week 12)
Reduction in draining fistulas (>= 50% at week 12)
Crohn's Symptoms Severity Questionnaire (CSS at week 12)
Discontinuation of corticosteroid use for CD (at week 12)
Starting date November 2017
Contact information AbbVie Call centre
Telephone: 847.283.8955
Email: abbvieclinicaltrials@abbvie.com
Notes Estimated study completion date: March 2020




Trial name or title A multicenter, randomized, double-blind, placebo-controlled induction study of the efficacy and
safety of upadacitinib (ABT-494) in subjects with moderately to severely active Crohn's disease who
have inadequately responded to or are intolerant to conventional therapies but have not failed bio-
logic therapy
Methods A multicentre, randomised, double-blind, placebo-controlled induction study
Participants 300 adults (aged 18 - 75 years) with a confirmed diagnosis of Crohn's disease for at least 3 months
prior to baseline, moderate-to-severe disease activity with evidence of mucosal inflammation and
previous inadequate response or intolerance to conventional therapies
Interventions Experimental: upadacitinib dose A (oral; once daily) for 12 weeks
Comparator: matching placebo for upadacitinib
NCT03345849 
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Outcomes Primary outcomes:
Endoscopic response (SES-CD at week 12)
Clinical remission (average daily stool frequency and average daily abdominal pain score at week
12)
Secondary outcomes:
Crohn's Symptoms Severity Questionnaire (CSS at week 12)
Enhanced Clinical Response (decrease in average daily SF and/or decrease in average daily AP
score at week 2)
Discontinuation of corticosteroid use for CD (at week 12)
Clinical remission (average daily stool frequency and average daily abdominal pain (AP) score at
week 12)
Fatigue (FACIT-F at week 12)
Quality of life (SF-36 at week 12)
Endoscopic remission (SES-CD at week 12)
Reduction in draining fistulas (>= 50% at week 12)
Clinical remission (CDAI < 150 at week 12).
Hospitalisations due to CD (at week 12)
Starting date December 2017
Contact information AbbVie Call centre
Telephone: 847.283.8955
Email: abbvieclinicaltrials@abbvie.com
Notes Estimated study completion date: March 2020




Trial name or title A multicenter, randomized, double-blind, placebo controlled 52-week maintenance and an open-
label extension study of the efficacy and safety of risankizumab in subjects with ulcerative colitis
who responded to induction treatment in M16-067 or M16-065
Methods A multicentre, randomised, double-blind, placebo-controlled 52-week maintenance and an open-
label extension study
Participants 760 adults (aged 16 - 80 years) who have completed Study M16-065 or Study M16-067 and have
achieved clinical response
Interventions Experimental: Substudy 2: Open-label risankizumab dose 1: Participants randomised to receive
risankizumab dose 1 administered by subcutaneous (SC) injection
Experimental: Substudy 1: Double-blind risankizumab dose 2: Participants randomised to receive
risankizumab dose 2 administered by subcutaneous (SC) injection
Experimental: Substudy 2: Open-label risankizumab dose 2: Participants randomised to receive
risankizumab dose 2 administered by subcutaneous (SC) injection
NCT03398135 
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Experimental: Substudy 3: Open-label extension risankizumab: Participants who completed sub-
study 1 or 2 receive open-label risankizumab in substudy 3
Placebo Comparator: Substudy 1: Double-blind placebo: Participants randomised to receive place-
bo for risankizumab administered by subcutaneous (SC) injection
Experimental: Substudy 1: Double-blind risankizumab dose 1: Participants randomised to receive
risankizumab dose 1 administered by subcutaneous (SC) injection
Outcomes Primary outcome:
Clinical remission (adapted Mayo Score at week 52)
 
Secondary outcomes:
Clinical remission (adapted Mayo Score at week 52 in subjects with a clinical remission at week 0)
Discontinuation of corticosteroid use at week 52 in subjects who were taking steroids at baseline
(of induction) (at week 52)
Discontinued corticosteroid use, remained corticosteroid free for 90 days, and achieved clinical re-
mission per adapted Mayo Score at week 52 in subjects taking steroids at baseline (of induction) (at
week 52)
Endoscopic remission (endoscopy subscore at week 52)
Ulcerative colitis symptoms (UC-SQ at week 52)
Ulcerative Colitis (UC)-related surgeries (through week 52)
Hospitalisation (through week 52)
Health status (SF-36 at week 52)
Quality of life (IBDQ at week 52)
Fatigue (FACIT-Fatigue at week 52)
Endoscopic improvement (endoscopy subscore at week 52)
Clinical remission (full Mayo Score at week 52)
Endoscopic improvement (endoscopy subscore at week 52)
Clinical response (adapted Mayo score at week 52)
Histologic remission (Geboes Score at week 52).
Mucosal healing (endoscopic and histologic remission at week 52)
Starting date August 2018
Contact information AbbVie Call centre
Telephone: 847.283.8955
Email: abbvieclinicaltrials@abbvie.com
Notes Estimated study completion date: December 2023




Trial name or title A multicenter, randomized, double-blind, placebo controlled induction study to evaluate the ef-
ficacy and safety of risankizumab in subjects with moderately to severely active ulcerative colitis
who have failed prior biologic therapy
Methods A multicentre, randomised, double-blind, placebo-controlled induction study
NCT03398148 
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Participants 720 participants (aged 16 to <= 80 years) with a confirmed diagnosis of ulcerative colitis (UC) for at
least 3 months prior to baseline, active UC and intolerance or inadequate response to one or more
biologic therapies
Interventions Experimental: Substudy 1, induction 2: Double-blind risankizumab dose 2: Participants who re-
ceived risankizumab with inadequate response in induction 1 randomised to receive risankizumab
dose 2 administered by subcutaneous (SC) injection in induction 2
Experimental: Substudy 2, induction 1: Open-label risankizumab dose 2: Participants randomised
to receive risankizumab dose 2 administered by intravenous (IV) infusion
Experimental: Substudy 2, induction 2: Double-blind risankizumab dose 1(a): Participants who re-
ceived placebo with inadequate response in induction 1 randomised to receive risankizumab dose
1 administered by intravenous (IV) infusion in induction 2
Experimental: Substudy 2, induction 2: Double-blind risankizumab dose 3: Participants who re-
ceived risankizumab with inadequate response in induction 1 randomised to receive risankizumab
dose 3 administered by subcutaneous (SC) injection in induction 2
Experimental: Substudy 1, induction 1: Double-blind risankizumab dose 1: Participants ran-
domised to receive risankizumab dose 1 administered by intravenous (IV) infusion
Experimental: Substudy 1, induction 1: Double-blind risankizumab dose 2: Participants ran-
domised to receive risankizumab dose 2 administered by intravenous (IV) infusion
Experimental: Substudy 1, induction 2: Double-blind risankizumab dose 1(a): Participants who re-
ceived placebo with inadequate response in induction 1 receive risankizumab dose 1 administered
by intravenous (IV) infusion in induction 2
Experimental: Substudy 1, induction 2: Double-blind risankizumab dose 1(b): Participants who re-
ceived risankizumab with inadequate response in induction 1 randomised to receive risankizumab
dose 1 administered by intravenous (IV) infusion in induction 2
Experimental: Substudy 2, induction 1: Double-blind risankizumab dose 1: Participants ran-
domised to receive risankizumab dose 1 administered by intravenous (IV) infusion
Experimental: Substudy 1, induction 1: Double-blind risankizumab dose 3: Participants ran-
domised to receive risankizumab dose 3 administered by intravenous (IV) infusion
Placebo Comparator: Substudy 1, induction 1: Double-blind placebo: Participants randomised to
receive placebo for risankizumab administered by intravenous (IV) infusion
Experimental: Substudy 2, induction 2: Double-blind risankizumab dose 2: Participants who re-
ceived risankizumab with inadequate response in induction 1 randomised to receive risankizumab
dose 2 administered by subcutaneous (SC) injection in induction 2
Experimental: Substudy 1, induction 2: Double-blind risankizumab dose 3: Participants who re-
ceived risankizumab with inadequate response in induction 1 randomised to receive risankizumab
dose 3 administered by subcutaneous (SC) injection in induction 2
Placebo Comparator: Substudy 2, induction 1: Double-blind placebo: Participants randomised to
receive placebo for risankizumab administered by intravenous (IV) infusion
Experimental: Substudy 2, induction 2: Double-blind risankizumab dose 1(b): Participants who re-
ceived risankizumab with inadequate response in induction 1 randomised to receive risankizumab
dose 1 administered by intravenous (IV) infusion in induction 2
Experimental: Substudy 1, induction 1: Open-label risankizumab dose 3: Participants receive
risankizumab dose 3 administered by intravenous (IV) infusion
Outcomes Primary outcomes:
Clinical remission (Mayo score at week 12)
NCT03398148  (Continued)
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Secondary outcomes:
Clinical remission (full Mayo score at week 12)
Severity of Crohn's symptoms (Ulcerative Colitis Symptom Questionnaire (UC-SQ) at week 12)
Quality of life (IBDQ at week 12)
Fatigue (FACIT-Fatigue at week 12)
Clinical response (adapted Mayo score at week 12)
Endoscopic remission (endoscopy subscore at week 12)
Clinical response (partial adapted Mayo score at week 4)
Mucosal healing (endoscopic and histologic remission at week 12)
Health status (SF-36 at week 12)
Hospitalisation (through week 12)
Ulcerative Colitis (UC)-related surgeries (through week 12)
Endoscopic improvement (endoscopy subscore at week 12)
Starting date March 2018
Contact information AbbVie Call centre
Telephone: 847.283.8955
Email: abbvieclinicaltrials@abbvie.com
Notes Estimated study completion date: December 2021




Trial name or title The impact of perioperative dexamethasone on postoperative outcome in inflammatory bowel dis-
eases.
Methods A randomised, double-blind, placebo-controlled study
Participants 302 adults (aged 18 - 75 years) undergoing elective open and laparoscopic small and large bowel
operations for IBD, including CD and UC
Interventions Experiment: Dexamethasone 8 mg intravenously prior to anaesthesia induction
Comparator: Placebo of normal saline 8 mg intravenously prior to anaesthesia induction
Outcomes Primary outcome:
Prolonged ileus (defined as two or more of the following five criteria are met on day 4 postopera-
tively: nausea or vomiting; inability to tolerate an oral diet over last 24 h; absence of flatus over last
24 h; abdominal distension; and radiologic confirmation)
 
Secondary outcomes:
Postoperative nausea and vomiting, and additional antiemetics given within 24 hr after surgery
Postoperative pain on postoperative day (POD) 1, 3, and 5 (VAS for pain)
Postoperative fatigue on POD 1, 3, and 5 (FACIT-F)
GI-2 recovery (time to upper (first tolerance of solid food) and lower (first bowel movement) GI re-
covery)
Blood WBC levels (preoperative and on POD 1, 3 and 5)
Blood neutrophil percentage (preoperative and on POD 1, 3 and 5)
Serum C-reactive protein (CRP) level (preoperative and on POD 1, 3 and 5)
NCT03456752 
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Serum Interleukin-6 (IL-6) level (preoperative and on POD 1, 3 and 5)
Serum procalcitonin (PCT) (preoperative and on POD 1, 3 and 5)
Body composition (bioelectrical impedance analysis (BIA) preoperative and on POD 1)
Postoperative length of stay in days
Postoperative morbidity (comprehensive complication index (CCI))
Postoperative surgical site infections (SSIs) (superficial SSIs and deep SSIs)
Overall cost of treatment (in Chinese Yuan)
Starting date June 2018
Contact information Jianfeng Gong, MD, Department of General Surgery, Jinling Hospital, Medical School of Nanjing
University Nanjing, Jiangsu, China 210000
+86-25-80860036
gongjianfeng@hotmail.com
Notes Estimated study completion date: October 2019




Trial name or title A phase 2/3, randomized, double-blind, placebo- and active-controlled, parallel-group, multicenter
protocol to evaluate the efficacy and safety of guselkumab in participants with moderately to se-
verely active Crohn's disease
Methods A phase 2/3, randomised, double-blind, placebo- and active-controlled, multicentre trial
Participants 2000 adults (aged 18 years and older) with a diagnosis of CD or fistulising Crohn's disease of at least
3 months duration with colitis, ileitis, or ileocolitiis. Moderate-to-severe CD with intolerance or in-
adequate response to conventional or to biologic therapy for CD
Interventions Experiment: Phase 2 (GALAXI 1): Group 1 (Guselkumab) participants will receive guselkumab (dose
1) by intravenous (IV) infusion, followed by guselkumab (dose 2) by subcutaneous (SC) injection.
Participants who are eligible and willing to continue guselkumab may enter the Long-Term Exten-
sion (LTE) phase and continue to receive guselkumab.
Experiment: Phase 2 (GALAXI 1): Group 2 (Guselkumab) participants will receive guselkumab (dose
3) by intravenous (IV) infusion, followed by guselkumab (dose 2) by subcutaneous (SC) injection.
Participants who are eligible and willing to continue guselkumab may enter the LTE phase and con-
tinue to receive guselkumab.
Experiment: Phase 2 (GALAXI 1): Group 3 (Guselkumab) participants will receive guselkumab (dose
4) by intravenous (IV) infusion, followed by guselkumab (dose 5) by subcutaneous (SC) injection.
Participants who are eligible and willing to continue guselkumab may enter the LTE phase and con-
tinue to receive guselkumab.
Active Comparator: Phase 2 (GALAXI 1): Group 4 (Ustekinumab) participants will receive Ustek-
inumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who
are eligible and willing to continue Ustekinumab may enter the LTE and continue to receive Ustek-
inumab.
Experimental: Phase 2 (GALAXI 1): Group 5 (Placebo/Ustekinumab) participants will receive place-
bo administered by intravenous (IV) infusion. At week 12, non-responders will receive active treat-
ment (Ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) in-
jection. Participants who are eligible and willing to continue placebo/Ustekinumab may enter the
LTE and continue to receive placebo/Ustekinumab.
NCT03466411 
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Experimental: Phase 3 (GALAXI 2 and 3): Group 1 and Group 2 (Guselkumab) participants will re-
ceive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) in-
jection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase
and continue to receive guselkumab.
Active Comparator: Phase 3 (GALAXI 2 and 3): Group 3 (Ustekinumab) participants will receive
Ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants
who are eligible and willing to continue Ustekinumab may enter the LTE phase and continue to re-
ceive Ustekinumab.
Experimental: Phase 3 (GALAXI 2 and 3): Group 4 (Placebo/Ustekinumab) participants will receive
placebo administered by intravenous (IV) infusion. At week 12, non-responders will receive active
treatment (Ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC)
injection. Participants who are eligible and willing to continue placebo/Ustekinumab may enter the
LTE and continue to receive placebo/Ustekinumab.
Outcomes Primary outcomes:
Phase 2: Change from baseline in the Crohn's Disease Activity Index (CDAI) Score at week 12
Phase 3: Clinical remission (CDAI at week 12)
 
Secondary outcomes:
Phase 2: Clinical remission (CDAI at week 12)
Phase 2: Clinical response (CDAI at week 12)
Phase 2 and Phase 3: Patient-Reported Outcome (PRO)-2 remission (average daily stool frequency
and average daily abdominal pain score at week 12)
Phase 2: Clinical-biomarker response (CDAI and CRP/fecal calprotectin at week 12)
Phase 2 and Phase 3: Endoscopic response (SES-CD at week 12)
Phase 3: Clinical remission (CDAI at week 48)
Phase 3: Durable clinical remission (CDAI at week 48)
Phase 3: Corticosteroid-free clinical remission (CDAI at week 48)
Phase 3: PRO-2 remission (average daily stool frequency and average daily abdominal painscore.at
week 48)
Phase 3: Fatigue (Patient-Reported Outcomes Measurement Information System (PROMIS). Fa-
tigue Short Form Response at week 12)
Phase 3: Endoscopic response (SES-CD at week 48)
Starting date April 2018
Contact information Janssen Research & Development, LLC Clinical Trial
Notes Estimated study completion date: November 2024




Trial name or title Multicentric, double-blind, placebo controlled clinical trial with 5-hydroxytryptophan (5-HTP)
in patients with inflammatory bowel disease in clinical and biologic remission: effect on fatigue
scores
Methods A phase 2, multicentred, double-blind, randomised placebo-controlled trial, cross-over assignment
Participants Adults (aged 18 - 60 years) with a documented diagnosis of Crohn's disease or ulcerative colitis in
clinical remission over 3 months (physical global assessment; SCCAI ≤ 2 for ulcerative colitis or Har-
vey Bradshaw index ≤ 4 for Crohn's disease) reporting fatigue (score 5 or more on a 1 - 10 visual
analogue scale). Treated with biologicals and/or immunosuppressives since at least 6 months with
NCT03574948 
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stable dose over last 3 months and in biologic remission at day 0 (CRP < 10 mg/L and faecal calpro-
tectin value < 250 mg/kg)
Interventions Experimental: 5-HTP - 8 weeks active substance 5-HTP (2 x 100 mg per day)
Placebo comparator: 8 weeks placebo oral capsule (2 x 1 capsule per day)
Outcomes Primary outcome: Fatigue (visual analog scale)
Secondary outcome: Fatigue (FACIT-F); Depression (short Depression Anxiety and Stress Scale);
Physical activity (Adapted International Physical Activity Questionnaire); serum 5-HydroxyTrypto-
phane (5-HTP); serum 5-hydroxyindoleacetic acid; serum serotonin levels; serum melatonin levels;
faecal microbiome/metabolome
Starting date December 2018
Contact information Dr Martine De Vos
0032 9 332 23 71
martine.devos@uzgent.be
Dr Triana Lobaton Ortega
0032 9 332 23 89
Triana.LobatonOrtega@UZGENT.be
Notes Estimated study completion date:December 2020







BDI-II: Beck Depression Inventory
BIA: Bioelectrical impedance analysis
BMI: Body Mass Index
CCI: Comprehensive complication index
CD: Crohn's disease
CDAI: Crohn's Disease Activity Index
CD-PRO: Crohn's disease - Patient Reported Outcomes




DXA: Dual-energy X-ray absorptiometry
ED: Emergency department
ER: Emergency room
ESR: Erythrocyte sedimentation rate
EVOO: extra virgin olive oil
FACIT-F: Functional Assessment of Chronic Illness Therapy - Fatigue
FBC: Full blood count
FC: Faecal calprotectin
fl: femtolitre
FR-QoL-29: Food-related quality of life
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GAD: Generalised Anxiety Disorder
GI: Gastrointestinal
GOS: Galacto-oligosaccharides
HAD: Hospital Anxiety and Depression
Hbg: Hemoglobin
HBI: Harvey Bradshaw Index
Ht: hematocrit
IBD: Inflammatory bowel disease
IBD-F: Inflammatory Bowel Disease - Fatigue
IBDQ: Inflammatory Bowel Disease Questionnaire









mg/kg: milligram per kilogram
MFI: Multidimensional Fatigue Inventory
PCD: Paediatric Crohn's disease
PCDAI: Paediatric Crohn's Disease Activity Index
PCT: Procalcitonin
PedsQL: Pediatric Quality of Life Inventory
PGR-C: Patient Global rsting - Change
PGR-S: Patient Global Rating - Severity
PHQ15: Patient Health Questionnaire 15
POD: Postoperative day
PROMIS: Patient-Reported Outcomes Measurement Information System




QOLITI: Quality of Life Tool for IBD
RCT: Randomised controlled trial
retHb: reticulocyte hemoglobin
rRNA: Ribosomal ribonucleic acid
SC: Subcutaneous
SCCAI: Simple Clinical Colitis Activity Index
SES-CD: Simple Endoscopic Score for Crohn's Disease
SF: Stool Frequency
SF-36:36-Item Short Form
SIBDQ: Short Inflammatory Bowel Disease Questionnaire
SPCDAI:Short Pediatric Crohn's Disease Activity Index
SSIs:surgical site infections
STAI: State-Trait Anxiety Inventory
sTfR:soluble transferrin receptors
sTfR(-F): soluble transferrin receptors to log ferritin
STPI: State-Trait Personality Inventory
TB: Tuberculosis
TNFα: Tumor necrosis factor alpha
TNFr1: Tumor necrosis factor receptor 1
T2T:Treat-to-Target
UC: Ulcerative colitis
UC-SQ: Ulcerative Colitis Symptom Questionnaire
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UST: Ustekinumab
VAS: Visual Analogue Scale
VO2: maximal oxygen uptake





D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Adalimumab maintenance versus placebo





Statistical method Effect size
1 Fatigue: SF-36 Vitality 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Week 4 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Week 56 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Quality of life: SF-36 PCS 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Week 4 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Week 56 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Quality of life: SF-36 MCS 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Week 4 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Week 56 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Quality of life: IBDQ 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Week 4 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Week 56 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Adverse events 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Serious AEs 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Withdrawal due to AEs 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 1.1.   Comparison 1 Adalimumab maintenance versus placebo, Outcome 1 Fatigue: SF-36 Vitality.
Study or subgroup Adalimumab
maintenance
Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.1.1 Week 4 follow-up  
Favours [placebo] 105-10 -5 0 Favours [ADA mainte-
nance]
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Study or subgroup Adalimumab
maintenance
Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
Colombel 2007 499 42.3 (22.4) 250 44.2 (22.8) -1.9[-5.34,1.54]
Colombel 2007 319 48.1 (21.7) 166 49.2 (21.8) -1.1[-5.18,2.98]
   
1.1.2 Week 56 follow-up  
Colombel 2007 204 57.8 (23.1) 42 54.8 (21.6) 3[-4.25,10.25]
Colombel 2007 157 59.8 (21.5) 31 56.9 (21.5) 2.9[-5.39,11.19]




Analysis 1.2.   Comparison 1 Adalimumab maintenance versus placebo, Outcome 2 Quality of life: SF-36 PCS.
Study or subgroup Adalimumab
maintenance
Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.2.1 Week 4 follow-up  
Colombel 2007 310 44.3 (7.9) 163 44.6 (8.7) -0.3[-1.9,1.3]
Colombel 2007 468 42 (8.4) 245 42.7 (8.9) -0.7[-2.05,0.65]
   
1.2.2 Week 56 follow-up  
Colombel 2007 151 50 (8.1) 31 47.7 (7.9) 2.3[-0.77,5.37]
Colombel 2007 198 49 (8.4) 42 47.7 (8) 1.3[-1.39,3.99]




Analysis 1.3.   Comparison 1 Adalimumab maintenance versus placebo, Outcome 3 Quality of life: SF-36 MCS.
Study or subgroup Adalimumab
maintenance
Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.3.1 Week 4 follow-up  
Colombel 2007 310 46.8 (9.7) 163 46.7 (10.7) 0.1[-1.87,2.07]
Colombel 2007 486 44.3 (10.8) 245 44.9 (10.9) -0.6[-2.27,1.07]
   
1.3.2 Week 56 follow-up  
Colombel 2007 151 51.1 (9.6) 31 48.5 (10.6) 2.6[-1.43,6.63]
Colombel 2007 198 50.3 (10.1) 42 48.1 (10.5) 2.2[-1.28,5.68]




Analysis 1.4.   Comparison 1 Adalimumab maintenance versus placebo, Outcome 4 Quality of life: IBDQ.
Study or subgroup Adalimumab
maintenance
Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.4.1 Week 4 follow-up  
Colombel 2007 326 169.5 (25.9) 169 167.3 (30.2) 2.2[-3.15,7.55]
Colombel 2007 510 157.7 (31.1) 255 156.9 (32.4) 0.8[-4,5.6]
Favours [placebo] 2010-20 -10 0 Favours [ADA mainte-
nance]
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Study or subgroup Adalimumab
maintenance
Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
   
1.4.2 Week 56 follow-up  
Colombel 2007 158 187.1 (24.6) 32 173.3 (32.2) 13.8[1.99,25.61]
Colombel 2007 207 182.8 (27.8) 43 172.9 (32.1) 9.9[-0.4,20.2]




Analysis 1.5.   Comparison 1 Adalimumab maintenance versus placebo, Outcome 5 Adverse events.
Study or subgroup Adalimumab
maintenance
Placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Colombel 2007 451/517 221/261 1.24[0.81,1.89]
Favours [ADA maintenance] 200.05 50.2 1 Favours [placebo]
 
 
Analysis 1.6.   Comparison 1 Adalimumab maintenance versus placebo, Outcome 6 Serious AEs.
Study or subgroup Adalimumab
maintenance
Placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Colombel 2007 45/517 40/261 0.53[0.33,0.83]
Favours [ADA maintanence] 1000.01 100.1 1 Favours [placebo]
 
 
Analysis 1.7.   Comparison 1 Adalimumab maintenance versus placebo, Outcome 7 Withdrawal due to AEs.
Study or subgroup Adalimumab
maintenance
Placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Colombel 2007 30/517 35/261 0.4[0.24,0.66]
Favours [ADA maintanence] 200.05 50.2 1 Favours [placebo]
 
 
Comparison 2.   Adalimumab 40 mg eow versus placebo





Statistical method Effect size
1 Fatigue: FACIT- F 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Week 4 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Week 56 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Fatigue: SF-36 Vitality 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Statistical method Effect size
2.1 Week 4 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Week 56 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Quality of life: SF-36 PCS 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Week 4 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Week 56 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Quality of life: SF-36 MCS 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Week 4 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Week 56 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Quality of life: IBDQ 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Week 4 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Week 56 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Adverse events 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Serious AEs 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Withdrawal due to AEs 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 2.1.   Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 1 Fatigue: FACIT- F.
Study or subgroup Adalimumab 40mg eow Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
2.1.1 Week 4 follow-up  
Colombel 2007 169 35.6 (10.6) 168 34.6 (11.3) 1[-1.34,3.34]
   
2.1.2 Week 56 follow-up  
Colombel 2007 169 36.8 (11.2) 168 32.5 (12.6) 4.3[1.75,6.85]
Favours [placebo] 52.5-5 -2.5 0 Favours [ADA 40mg eow]
 
 
Analysis 2.2.   Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 2 Fatigue: SF-36 Vitality.
Study or subgroup Adalimumab 40mg eow Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
2.2.1 Week 4 follow-up  
Colombel 2007 166 49.8 (21.9) 166 49.2 (21.8) 0.6[-4.1,5.3]
Colombel 2007 252 44 (22.9) 250 44.2 (22.8) -0.2[-4.2,3.8]
Favours [placebo] 105-10 -5 0 Favours [ADA 40mg eow]
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Study or subgroup Adalimumab 40mg eow Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
   
2.2.2 Week 56 follow-up  
Colombel 2007 77 60 (20.4) 31 56.9 (21.5) 3.1[-5.73,11.93]
Colombel 2007 101 57.6 (22.9) 42 54.8 (21.6) 2.8[-5.1,10.7]
Favours [placebo] 105-10 -5 0 Favours [ADA 40mg eow]
 
 
Analysis 2.3.   Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 3 Quality of life: SF-36 PCS.
Study or subgroup Adalimumab 40mg eow Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
2.3.1 Week 4 follow-up  
Colombel 2007 245 42.6 (8.3) 245 42.7 (8.9) -0.1[-1.63,1.43]
Colombel 2007 160 44.8 (7.5) 163 44.6 (8.7) 0.2[-1.57,1.97]
   
2.3.2 Week 56 follow-up  
Colombel 2007 73 50.6 (6.8) 31 47.7 (7.9) 2.9[-0.29,6.09]
Colombel 2007 97 49.6 (7.5) 42 47.7 (8) 1.9[-0.94,4.74]
Favours [placebo] 105-10 -5 0 Favours [ADA 40mg eow]
 
 
Analysis 2.4.   Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 4 Quality of life: SF-36 MCS.
Study or subgroup Adalimumab 40mg eow Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
2.4.1 Week 4 follow-up  
Colombel 2007 245 45.2 (10.9) 245 44.9 (10.9) 0.3[-1.63,2.23]
Colombel 2007 160 47.4 (10.1) 163 46.7 (10.7) 0.7[-1.57,2.97]
   
2.4.2 Week 56 follow-up  
Colombel 2007 97 50.9 (9.4) 42 48.1 (10.5) 2.8[-0.89,6.49]
Colombel 2007 73 51.7 (8.8) 31 48.5 (10.6) 3.2[-1.04,7.44]
Favours [placebo] 105-10 -5 0 Favours [ADA 40mg eow]
 
 
Analysis 2.5.   Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 5 Quality of life: IBDQ.
Study or subgroup Adalimumab 40mg eow Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
2.5.1 Week 4 follow-up  
Colombel 2007 169 172.6 (24.6) 169 167.3 (30.2) 5.3[-0.57,11.17]
Colombel 2007 257 161.1 (29.9) 255 156.9 (32.4) 4.2[-1.2,9.6]
   
2.5.2 Week 56 follow-up  
Colombel 2007 77 187.9 (23.9) 32 173.3 (32.2) 14.6[2.22,26.98]
Colombel 2007 102 183.3 (27.2) 43 172.9 (32.1) 10.4[-0.53,21.33]
Favours [placebo] 2010-20 -10 0 Favours [ADA 40mg eow]
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Analysis 2.6.   Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 6 Adverse events.
Study or subgroup Adalimumab 40mg eow Placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Colombel 2007 231/260 110/130 1.45[0.78,2.67]
Favours [ADA 40mg eow] 1000.01 100.1 1 Favours [placebo]
 
 
Analysis 2.7.   Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 7 Serious AEs.
Study or subgroup Adalimumab 40mg eow Placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Colombel 2007 24/260 20/130 0.56[0.3,1.06]
Favours [ADA 40mg eow] 1000.01 100.1 1 Favours [placebo]
 
 
Analysis 2.8.   Comparison 2 Adalimumab 40 mg eow versus placebo, Outcome 8 Withdrawal due to AEs.
Study or subgroup Adalimumab 40mg eow Placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Colombel 2007 18/260 17/130 0.49[0.25,1]
Favours [ADA 40mg eow] 50.2 20.5 1 Favours [placebo]
 
 
Comparison 3.   Adalimumab 40 mg weekly versus placebo





Statistical method Effect size
1 Fatigue: FACIT-Fatigue 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Week 4 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Week 56 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Fatigue: SF-36 vitality 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Week 4 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Week 56 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Quality of life: SF-36 PCS 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Week 4 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Week 56 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Quality of life: SF-36 MCS 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Statistical method Effect size
4.1 Week 4 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Week 56 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Quality of life: IBDQ 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Week 4 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Week 56 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Adverse events 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Serious AEs 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Withdrawal due to AEs 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 3.1.   Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 1 Fatigue: FACIT-Fatigue.
Study or subgroup Adalimumab
40mg weekly
Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
3.1.1 Week 4 follow-up  
Colombel 2007 155 34.2 (11.2) 168 34.6 (11.3) -0.4[-2.86,2.06]
   
3.1.2 Week 56 follow-up  
Colombel 2007 155 35 (12.7) 168 32.5 (12.6) 2.5[-0.26,5.26]




Analysis 3.2.   Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 2 Fatigue: SF-36 vitality.
Study or subgroup Adalimumab
40mg weekly
Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
3.2.1 Week 4 follow-up  
Colombel 2007 247 40.5 (21.8) 250 44.2 (22.8) -3.7[-7.62,0.22]
Colombel 2007 153 46.2 (21.3) 166 49.2 (21.8) -3[-7.73,1.73]
   
3.2.2 Week 56 follow-up  
Colombel 2007 103 58 (23.4) 42 54.8 (21.6) 3.2[-4.73,11.13]
Colombel 2007 80 59.5 (22.7) 31 56.9 (21.5) 2.6[-6.46,11.66]
Favours [Placebo] 2010-20 -10 0 Favours [ADA 40mg]
 
 
Interventions for fatigue in inflammatory bowel disease (Review)









Cochrane Database of Systematic Reviews
Analysis 3.3.   Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 3 Quality of life: SF-36 PCS.
Study or subgroup Adalimumab
40mg weekly
Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
3.3.1 Week 4 follow-up  
Colombel 2007 150 43.7 (8.3) 163 44.6 (8.7) -0.9[-2.79,0.99]
Colombel 2007 241 41.3 (8.4) 245 42.7 (8.9) -1.4[-2.94,0.14]
   
3.3.2 Week 56 follow-up  
Colombel 2007 78 49.5 (9.2) 31 47.7 (7.9) 1.8[-1.66,5.26]
Colombel 2007 101 48.4 (9.3) 42 47.7 (8) 0.7[-2.32,3.72]




Analysis 3.4.   Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 4 Quality of life: SF-36 MCS.
Study or subgroup Adalimumab
40mg weekly
Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
3.4.1 Week 4 follow-up  
Colombel 2007 150 46.2 (9.3) 163 46.7 (10.7) -0.5[-2.72,1.72]
Colombel 2007 241 43.4 (10.7) 245 44.9 (10.9) -1.5[-3.42,0.42]
   
3.4.2 Week 56 follow-up  
Colombel 2007 101 49.8 (10.8) 42 48.1 (10.5) 1.7[-2.12,5.52]
Colombel 2007 78 50.5 (10.2) 31 48.5 (10.6) 2[-2.37,6.37]
Favours [placebo] 2010-20 -10 0 Favours [ADA 40mg wkly]
 
 
Analysis 3.5.   Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 5 Quality of life: IBDQ.
Study or subgroup Adalimumab
40mg weekly
Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
3.5.1 Week 4 follow-up  
Colombel 2007 157 166.2 (26.9) 169 167.3 (30.2) -1.1[-7.3,5.1]
Colombel 2007 253 154.2 (32) 255 156.9 (32.4) -2.7[-8.3,2.9]
   
3.5.2 Week 56 follow-up  
Colombel 2007 81 186.4 (25.4) 32 173.3 (32.2) 13.1[0.64,25.56]
Colombel 2007 105 182.3 (28.6) 43 172.9 (32.1) 9.4[-1.63,20.43]




Analysis 3.6.   Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 6 Adverse events.
Study or subgroup Adalimumab
40mg weekly
Placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Colombel 2007 220/257 110/130 1.08[0.6,1.95]
Favours [ADA 40mg weekly] 1000.01 100.1 1 Favours [placebo]
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Analysis 3.7.   Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 7 Serious AEs.
Study or subgroup Adalimumab
40mg weekly
Placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Colombel 2007 21/257 20/130 0.49[0.25,0.94]
Favours [ADA 40mg weekly] 100.1 50.2 20.5 1 Favours [placebo]
 
 
Analysis 3.8.   Comparison 3 Adalimumab 40 mg weekly versus placebo, Outcome 8 Withdrawal due to AEs.
Study or subgroup Adalimumab
40mg weekly
Placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Colombel 2007 12/257 17/130 0.33[0.15,0.7]
Favours [ADA 40mg weekly] 1000.01 100.1 1 Favours [placebo]
 
 
Comparison 4.   AndoSan versus placebo





Statistical method Effect size
1 Fatigue: Total Fatigue Score 2   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Day 14 follow-up 2 100 Mean Difference (IV, Fixed, 95% CI) -1.63 [-3.51, 0.26]
1.2 Day 21 follow-up 2 100 Mean Difference (IV, Fixed, 95% CI) -1.59 [-3.46, 0.28]
2 Fatigue: SF-36 Vitality subscale 2   Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Day 14 follow-up 2 100 Mean Difference (IV, Fixed, 95% CI) 3.84 [-3.78, 11.47]
2.2 Day 21 follow-up 2 100 Mean Difference (IV, Fixed, 95% CI) 3.53 [-3.91, 10.96]
 
 
Analysis 4.1.   Comparison 4 AndoSan versus placebo, Outcome 1 Fatigue: Total Fatigue Score.
Study or subgroup AndoSan Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
4.1.1 Day 14 follow-up  
Therkelsen 2016a 24 14.1 (4.5) 26 16.3 (4.9) 52.24% -2.2[-4.81,0.41]
Therkelsen 2016b 25 15.3 (4.9) 25 16.3 (5) 47.76% -1[-3.72,1.72]
Subtotal *** 49   51   100% -1.63[-3.51,0.26]
Heterogeneity: Tau2=0; Chi2=0.39, df=1(P=0.53); I2=0%  
Test for overall effect: Z=1.69(P=0.09)  
   
4.1.2 Day 21 follow-up  
Favours [AndoSan] 52.5-5 -2.5 0 Favours [Placebo]
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Study or subgroup AndoSan Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Therkelsen 2016a 24 15.1 (4.1) 26 16.9 (5.2) 52.26% -1.8[-4.39,0.79]
Therkelsen 2016b 25 14 (5.1) 25 15.4 (4.7) 47.74% -1.36[-4.07,1.35]
Subtotal *** 49   51   100% -1.59[-3.46,0.28]
Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.82); I2=0%  
Test for overall effect: Z=1.67(P=0.1)  
Test for subgroup differences: Chi2=0, df=1 (P=0.98), I2=0%  
Favours [AndoSan] 52.5-5 -2.5 0 Favours [Placebo]
 
 
Analysis 4.2.   Comparison 4 AndoSan versus placebo, Outcome 2 Fatigue: SF-36 Vitality subscale.
Study or subgroup Favours [AndoSan] Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
4.2.1 Day 14 follow-up  
Therkelsen 2016a 24 44.6 (18.9) 26 40.6 (19.4) 51.49% 4[-6.62,14.62]
Therkelsen 2016b 25 40 (21.5) 25 36.3 (17.8) 48.51% 3.68[-7.26,14.62]
Subtotal *** 49   51   100% 3.84[-3.78,11.47]
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%  
Test for overall effect: Z=0.99(P=0.32)  
   
4.2.2 Day 21 follow-up  
Therkelsen 2016a 24 46.9 (17.9) 26 38.3 (17) 58.83% 8.6[-1.09,18.29]
Therkelsen 2016b 25 39.2 (22.9) 25 42.9 (18.7) 41.17% -3.72[-15.31,7.87]
Subtotal *** 49   51   100% 3.53[-3.91,10.96]
Heterogeneity: Tau2=0; Chi2=2.55, df=1(P=0.11); I2=60.85%  
Test for overall effect: Z=0.93(P=0.35)  
Test for subgroup differences: Chi2=0, df=1 (P=0.95), I2=0%  
Favours [placebo] 4020-40 -20 0 Favours [AndoSan]
 
 
Comparison 5.   Ferric maltol versus placebo





Statistical method Effect size
1 Fatigue: SF-36 Vitality subscale 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Quality of life: IBDQ 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse events 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Serious AEs 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Withdrawal due to AEs 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
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Analysis 5.1.   Comparison 5 Ferric maltol versus placebo, Outcome 1 Fatigue: SF-36 Vitality subscale.
Study or subgroup Ferric maltol Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
5.1.1 Week 12 follow-up  
Gasche 2015 59 43.9 (20.8) 59 53.2 (22.6) -9.31[-17.15,-1.47]
Favours [Placebo] 2010-20 -10 0 Favours [Ferric Maltol]
 
 
Analysis 5.2.   Comparison 5 Ferric maltol versus placebo, Outcome 2 Quality of life: IBDQ.
Study or subgroup Ferric maltol Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
5.2.1 Week 12 follow-up  
Gasche 2015 60 179.7 (32.6) 60 176 (32.2) 3.7[-7.89,15.29]
Favours [Placebo] 5025-50 -25 0 Favours [Ferric maltol]
 
 
Analysis 5.3.   Comparison 5 Ferric maltol versus placebo, Outcome 3 Adverse events.
Study or subgroup Ferric maltol Placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Gasche 2015 35/60 43/60 0.55[0.26,1.18]
Favours [Ferric maltol] 500.02 100.1 1 Favours [Placebo]
 
 
Analysis 5.4.   Comparison 5 Ferric maltol versus placebo, Outcome 4 Serious AEs.
Study or subgroup Ferric maltol Placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Gasche 2015 2/60 2/60 1[0.14,7.34]
Favours [Ferric maltol] 1000.01 100.1 1 Favours [placebo]
 
 
Analysis 5.5.   Comparison 5 Ferric maltol versus placebo, Outcome 5 Withdrawal due to AEs.
Study or subgroup Ferric maltol Placebo Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Gasche 2015 8/60 5/60 1.69[0.52,5.51]
Favours [Ferric maltol] 1000.01 100.1 1 Favours [placebo]
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Comparison 6.   Electroacupuncture versus no treatment





Statistical method Effect size
1 Fatigue: FACIT-F 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Week 8 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Quality of life: IBDQ-9 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Week 8 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse events 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Serious AEs 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Withdrawal due to AEs 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 6.1.   Comparison 6 Electroacupuncture versus no treatment, Outcome 1 Fatigue: FACIT-F.
Study or subgroup EAc Control Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
6.1.1 Week 8 follow-up  
Horta 2017 15 33.2 (2.3) 12 25.2 (1.8) 8[6.45,9.55]
Favours [control] 105-10 -5 0 Favours [EAc]
 
 
Analysis 6.2.   Comparison 6 Electroacupuncture versus no treatment, Outcome 2 Quality of life: IBDQ-9.
Study or subgroup EAc Control Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
6.2.1 Week 8 follow-up  
Horta 2017 15 61.5 (1.6) 12 57 (1.4) 4.5[3.37,5.63]
Favours [control] 52.5-5 -2.5 0 Favours [EAc]
 
 
Analysis 6.3.   Comparison 6 Electroacupuncture versus no treatment, Outcome 3 Adverse events.
Study or subgroup EAc WL Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Horta 2017 0/18 0/16 Not estimable
Favours [EAc] 1000.01 100.1 1 Favours [WL]
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Analysis 6.4.   Comparison 6 Electroacupuncture versus no treatment, Outcome 4 Serious AEs.
Study or subgroup EAc WL Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Horta 2017 0/18 0/16 Not estimable
Favours [EAc] 1000.01 100.1 1 Favours [WL]
 
 
Analysis 6.5.   Comparison 6 Electroacupuncture versus no treatment, Outcome 5 Withdrawal due to AEs.
Study or subgroup EAc WL Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Horta 2017 0/18 0/16 Not estimable
Favours [EAc] 1000.01 100.1 1 Favours [WL]
 
 
Comparison 7.   Electroacupuncture versus sham electroacupuncture





Statistical method Effect size
1 Fatigue: FACIT-F 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Week 8 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Week 16 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Quality of life: IBDQ-9 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Week 8 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Week 16 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Adverse events 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Serious AEs 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Withdrawal due to AEs 1   Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 7.1.   Comparison 7 Electroacupuncture versus sham electroacupuncture, Outcome 1 Fatigue: FACIT-F.
Study or subgroup EAc Sham EAc Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
7.1.1 Week 8 follow-up  
Horta 2017 15 33.2 (2.3) 15 28.1 (2.2) 5.1[3.49,6.71]
   
7.1.2 Week 16 follow-up  
Horta 2017 15 31.4 (2.7) 15 28.8 (2.5) 2.6[0.74,4.46]
Favours [Sham EAc] 105-10 -5 0 Favours [EAc]
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Analysis 7.2.   Comparison 7 Electroacupuncture versus sham electroacupuncture, Outcome 2 Quality of life: IBDQ-9.
Study or subgroup EAc Sham EAc Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
7.2.1 Week 8 follow-up  
Horta 2017 15 61.5 (1.6) 15 57.8 (1.3) 3.7[2.66,4.74]
   
7.2.2 Week 16 follow-up  
Horta 2017 15 60.8 (1.8) 15 58.6 (1.6) 2.2[0.98,3.42]
Favours [Sham EAc] 105-10 -5 0 Favours [EAc]
 
 
Analysis 7.3.   Comparison 7 Electroacupuncture versus sham electroacupuncture, Outcome 3 Adverse events.
Study or subgroup EAc Sham EAc Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Horta 2017 0/18 1/18 0.32[0.01,8.27]
Favours [EAc] 1000.01 100.1 1 Favours [Sham EAc]
 
 
Analysis 7.4.   Comparison 7 Electroacupuncture versus sham electroacupuncture, Outcome 4 Serious AEs.
Study or subgroup EAc Sham EAc Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Horta 2017 0/18 0/18 Not estimable
Favours [EAc] 1000.01 100.1 1 Favours [Sham EAc]
 
 
Analysis 7.5.   Comparison 7 Electroacupuncture versus sham
electroacupuncture, Outcome 5 Withdrawal due to AEs.
Study or subgroup EAc Sham EAc Odds Ratio Odds Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Horta 2017 0/18 1/18 0.32[0.01,8.27]
Favours [EAc] 1000.01 100.1 1 Favours [Sham EAc]
 
 
Comparison 8.   Guided stress management versus conventional medical treatment





Statistical method Effect size
1 Fatigue: Average frequency symptom
(tiredness)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Post-intervention 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Statistical method Effect size
1.2 12 month follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Fatigue: Average severity of tiredness 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Post-intervention 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 12 month follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 8.1.   Comparison 8 Guided stress management versus conventional
medical treatment, Outcome 1 Fatigue: Average frequency symptom (tiredness).
Study or subgroup Stress management Standard care Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
8.1.1 Post-intervention  
García-Vega 2004 15 36.9 (43) 15 59 (50) -22.1[-55.47,11.27]
   
8.1.2 12 month follow-up  
García-Vega 2004 15 51.4 (36) 15 51.4 (49) 0[-30.77,30.77]
Favours [Stress Mx] 5025-50 -25 0 Favours [Standard care]
 
 
Analysis 8.2.   Comparison 8 Guided stress management versus conventional
medical treatment, Outcome 2 Fatigue: Average severity of tiredness.
Study or subgroup Stress management Standard care Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
8.2.1 Post-intervention  
García-Vega 2004 13 0.7 (0.7) 10 1.1 (1.1) -0.4[-1.18,0.38]
   
8.2.2 12 month follow-up  
García-Vega 2004 13 1.3 (0.8) 11 1 (0.9) 0.3[-0.39,0.99]
Favours [Stress Mx] 42-4 -2 0 Favours [Control]
 
 
Comparison 9.   Self-directed stress management versus conventional medical treatment





Statistical method Effect size
1 Fatigue: Average frequency of tired-
ness
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Post-intervention 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 12 month follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Statistical method Effect size
2 Fatigue: Average severity of tiredness 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Post-intervention 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 12 month follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 9.1.   Comparison 9 Self-directed stress management versus conventional
medical treatment, Outcome 1 Fatigue: Average frequency of tiredness.
Study or subgroup Self-directed Stress Mx Standard care Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
9.1.1 Post-intervention  
García-Vega 2004 15 41.8 (44) 15 59 (50) -17.2[-50.91,16.51]
   
9.1.2 12 month follow-up  
García-Vega 2004 15 21.8 (30) 15 51.4 (49) -29.6[-58.68,-0.52]
Favours [Self-direct SM] 200100-200 -100 0 Favours [Standard care]
 
 
Analysis 9.2.   Comparison 9 Self-directed stress management versus conventional
medical treatment, Outcome 2 Fatigue: Average severity of tiredness.
Study or subgroup Self-directed Stress Mx Standard care Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
9.2.1 Post-intervention  
García-Vega 2004 13 0.9 (0.8) 10 1.1 (1.1) -0.2[-1.01,0.61]
   
9.2.2 12 month follow-up  
García-Vega 2004 14 0.7 (0.8) 11 1 (0.9) -0.3[-0.98,0.38]
Favours [SD stress Mx] 42-4 -2 0 Favours [Standard care]
 
 
Comparison 10.   CBT with therapist support versus fatigue information leaflet only





Statistical method Effect size
1 Fatigue: IBD-F Section I 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Month 3 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Fatigue: IBD-F Section II 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Month 3 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Statistical method Effect size
3 Quality of life: UK-IBDQ 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Month 3 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 10.1.   Comparison 10 CBT with therapist support versus
fatigue information leaflet only, Outcome 1 Fatigue: IBD-F Section I.
Study or subgroup CBT Fatigue Info Leaflet Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
10.1.1 Month 3 follow-up  
Artom 2018 7 7.3 (4) 11 9.5 (4.6) -2.16[-6.13,1.81]
Favours [CBT] 4020-40 -20 0 Favours [Info Leaflet]
 
 
Analysis 10.2.   Comparison 10 CBT with therapist support versus
fatigue information leaflet only, Outcome 2 Fatigue: IBD-F Section II.
Study or subgroup CBT Fatigue Info Leaflet Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
10.2.1 Month 3 follow-up  
Artom 2018 7 25.7 (15.6) 9 47.3 (31.1) -21.62[-45.02,1.78]
Favours [CBT] 10050-100 -50 0 Favours [Info Leaflet]
 
 
Analysis 10.3.   Comparison 10 CBT with therapist support versus
fatigue information leaflet only, Outcome 3 Quality of life: UK-IBDQ.
Study or subgroup CBT Fatigue Info Leaflet Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
10.3.1 Month 3 follow-up  
Artom 2018 9 95.9 (10.6) 10 95.7 (10.5) 0.19[-9.32,9.7]
Favours [CBT] 10050-100 -50 0 Favours [Info Leaflet]
 
 
Comparison 11.   Physical activity advice plus omega 3 versus no physical activity advice plus omega 3





Statistical method Effect size
1 Fatigue: FACIT-F 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Statistical method Effect size
2 Fatigue: MFI 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Fatigue: IBD-F Section I 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Fatigue: IBD-F Section II 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Quality of life: IBDQ 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 11.1.   Comparison 11 Physical activity advice plus omega 3 versus
no physical activity advice plus omega 3, Outcome 1 Fatigue: FACIT-F.
Study or subgroup PA advice & omega 3 No PA advice & omega 3 Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
11.1.1 Week 12 follow-up  
McNelly 2016 11 38.5 (8.7) 14 32.1 (12.2) 6.4[-1.8,14.6]
Favours [No PAA & omega] 2010-20 -10 0 Favours [PAA & omega]
 
 
Analysis 11.2.   Comparison 11 Physical activity advice plus omega 3
versus no physical activity advice plus omega 3, Outcome 2 Fatigue: MFI.
Study or subgroup PA advice & omega 3 No PA advice & omega 3 Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
11.2.1 Week 12 follow-up  
McNelly 2016 11 13.6 (4) 14 14.1 (4.6) -0.5[-3.88,2.88]




Analysis 11.3.   Comparison 11 Physical activity advice plus omega 3 versus
no physical activity advice plus omega 3, Outcome 3 Fatigue: IBD-F Section I.
Study or subgroup PA advice & omega 3 No PA advice & omega 3 Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
11.3.1 Week 12 follow-up  
McNelly 2016 11 6.5 (4.1) 14 9.6 (5) -3.1[-6.67,0.47]
Favours [PAA & omega] 105-10 -5 0 Favours [No PAA &
omega]
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Analysis 11.4.   Comparison 11 Physical activity advice plus omega 3 versus
no physical activity advice plus omega 3, Outcome 4 Fatigue: IBD-F Section II.
Study or subgroup PA advice & omega 3 No PA advice & omega 3 Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
11.4.1 Week 12 follow-up  
McNelly 2016 11 21.7 (16.8) 14 34.8 (24.6) -13.1[-29.37,3.17]




Analysis 11.5.   Comparison 11 Physical activity advice plus omega 3 versus
no physical activity advice plus omega 3, Outcome 5 Quality of life: IBDQ.
Study or subgroup PA advice & omega 3 No PA advice & omega 3 Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
11.5.1 Week 12 follow-up  
McNelly 2016 11 171 (28) 14 167 (29) 4[-18.46,26.46]
Favours [No PAA & omega] 10050-100 -50 0 Favours [PAA & omega]
 
 
Comparison 12.   Physical activity advice plus placebo versus no physical activity advice plus placebo





Statistical method Effect size
1 Fatigue: FACIT-F 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Fatigue: MFI 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Fatigue: IBD-F Section I 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Fatigue: IBD-F Section II 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Quality of life: IBDQ 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 12.1.   Comparison 12 Physical activity advice plus placebo versus
no physical activity advice plus placebo, Outcome 1 Fatigue: FACIT-F.
Study or subgroup PA advice & placebo No PA advice & placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
12.1.1 Week 12 follow-up  
McNelly 2016 15 41.1 (7.2) 12 38.4 (6.5) 2.7[-2.48,7.88]
Experiment [No PA advice] 2010-20 -10 0 Favours [PA advice]
 
 
Analysis 12.2.   Comparison 12 Physical activity advice plus placebo
versus no physical activity advice plus placebo, Outcome 2 Fatigue: MFI.
Study or subgroup PA advice & placebo No PA advice & placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
12.2.1 Week 12 follow-up  
McNelly 2016 15 12.7 (3.5) 12 15.3 (2) -2.6[-4.7,-0.5]
Experiment [PA advice] 52.5-5 -2.5 0 Favours [No PA advice]
 
 
Analysis 12.3.   Comparison 12 Physical activity advice plus placebo versus
no physical activity advice plus placebo, Outcome 3 Fatigue: IBD-F Section I.
Study or subgroup PA advice & placebo No PA advice & placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
12.3.1 Week 12 follow-up  
McNelly 2016 15 6.8 (3.4) 12 8.5 (2.8) -1.7[-4.04,0.64]
Experiment [PA advice] 105-10 -5 0 Favours [No PA advice]
 
 
Analysis 12.4.   Comparison 12 Physical activity advice plus placebo versus
no physical activity advice plus placebo, Outcome 4 Fatigue: IBD-F Section II.
Study or subgroup PA advice & placebo No PA advice & placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
12.4.1 Week 12 follow-up  
McNelly 2016 15 19.4 (15.6) 12 27.9 (18.4) -8.5[-21.57,4.57]
Favours [PA advice] 5025-50 -25 0 Favours [No PA advice]
 
 
Analysis 12.5.   Comparison 12 Physical activity advice plus placebo versus
no physical activity advice plus placebo, Outcome 5 Quality of life: IBDQ.
Study or subgroup PA advice & placebo No PA advice & placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
12.5.1 Week 12 follow-up  
McNelly 2016 15 171 (32) 12 162 (33) 9[-15.72,33.72]
Experiment [No PA advice] 5025-50 -25 0 Favours [PA advice]
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Comparison 13.   Physical activity advice plus placebo versus no physical activity advice plus omega 3





Statistical method Effect size
1 Fatigue: FACIT-F 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Fatigue: MFI 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Fatigue: IBD-F Section I 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Fatigue: IBD-F Section II 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Quality of life: IBDQ 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Week 12 follow-up 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 13.1.   Comparison 13 Physical activity advice plus placebo versus
no physical activity advice plus omega 3, Outcome 1 Fatigue: FACIT-F.
Study or subgroup PAA & placebo No PAA & omega 3 Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
13.1.1 Week 12 follow-up  
McNelly 2016 15 41.1 (7.2) 14 32.1 (12.2) 9[1.64,16.36]
Favours [No PAA & omega3] 4020-40 -20 0 Favours [PAA & PL]
 
 
Analysis 13.2.   Comparison 13 Physical activity advice plus placebo
versus no physical activity advice plus omega 3, Outcome 2 Fatigue: MFI.
Study or subgroup PAA & placebo No PAA & omega 3 Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
13.2.1 Week 12 follow-up  
McNelly 2016 15 12.7 (3.5) 14 14.1 (4.6) -1.4[-4.39,1.59]
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Analysis 13.3.   Comparison 13 Physical activity advice plus placebo versus
no physical activity advice plus omega 3, Outcome 3 Fatigue: IBD-F Section I.
Study or subgroup PAA & placebo No PAA & omega 3 Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
13.3.1 Week 12 follow-up  
McNelly 2016 15 6.8 (3.4) 14 9.6 (5) -2.8[-5.93,0.33]




Analysis 13.4.   Comparison 13 Physical activity advice plus placebo versus
no physical activity advice plus omega 3, Outcome 4 Fatigue: IBD-F Section II.
Study or subgroup PAA & placebo No PAA & omega 3 Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
13.4.1 Week 12 follow-up  
McNelly 2016 15 19.4 (15.6) 14 34.8 (24.6) -15.4[-30.51,-0.29]




Analysis 13.5.   Comparison 13 Physical activity advice plus placebo versus
no physical activity advice plus omega 3, Outcome 5 Quality of life: IBDQ.
Study or subgroup PAA & placebo No PAA & omega 3 Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
13.5.1 Week 12 follow-up  
McNelly 2016 15 171 (32) 14 167 (29) 4[-18.2,26.2]
Favours [No PAA & omega3] 4020-40 -20 0 Favours [PAA & PL]
 
 
A D D I T I O N A L   T A B L E S
 
Adalimumab 40 mg every other week compared to placebo for fatigue in inflammatory bowel disease
Patient or population: participants with moderately-to-severely active disease
Setting: 92 centres in the United States, Europe, Canada, Australia and South Africa
Intervention: adalimumab 40 mg every other week
Comparison: placebo









































from 0 to 52, with high-
er scores indicating less
fatigue.
Table 1.   Adalimumab 40 mg every other week compared to placebo for fatigue in inflammatory bowel disease 
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*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of
the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from
the estimate of effect
Table 1.   Adalimumab 40 mg every other week compared to placebo for fatigue in inflammatory bowel
disease  (Continued)
1 Downgraded two levels due to very serious imprecision as the confidence interval was wide and the fatigue data represented the last-
observation-carried-forward when a participant had missing value, dropped out or switched to open-label therapy.
2 Downgraded two levels due to serious imprecision as the number of participants was small and confidence interval was wide.
3 Downgraded one level due to serious imprecision as the number of participants was small.
 
 
Adalimumab 40 mg weekly compared to placebo for fatigue in inflammatory bowel disease
Patient or population: fatigue in inflammatory bowel disease
Setting: 92 centres in the United States, Europe, Canada, Australia and South Africa
Intervention: adalimumab 40 mg weekly
Comparison: placebo
Table 2.   Adalimumab 40 mg weekly compared to placebo for fatigue in inflammatory bowel disease 
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from 0 to 52 with high-
er scores indicating less
fatigue.
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from 32 to 224, with
higher scores indicating
























































*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of
the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from
the estimate of effect
Table 2.   Adalimumab 40 mg weekly compared to placebo for fatigue in inflammatory bowel disease  (Continued)
1 Downgraded two levels due to very serious imprecision as the confidence interval was wide and the fatigue data represented the last-
observation-carried-forward when a participant had missing value, dropped out or switched to open-label therapy.
2 Downgraded two levels due to serious imprecision as the number of participants was small and confidence interval was wide.
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3 Downgraded one level due to serious imprecision as the number of participants was small.
 
 
Adalimumab maintenance compared to placebo for fatigue in inflammatory bowel disease
Patient or population: participants with moderately-to-severely active Crohn's disease












































SF-36 vitality subscale scores
ranged from 0 to 100, with
higher scores indicating better
vitality (less fatigue).
Quality of life

















summary scores ranged from 0
to 100, with higher scores indi-
cating better physical quality
of life.
Quality of life
















The SF-36 mental component
summary scores ranged from
0 to 100, with higher scores in-


















IBDQ scores ranged from 32 to
224, with higher scores indi-
























































Table 3.   Adalimumab maintenance compared to placebo for fatigue in inflammatory bowel disease 
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*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of
the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from
the estimate of effect
Table 3.   Adalimumab maintenance compared to placebo for fatigue in inflammatory bowel disease  (Continued)
1 Downgraded two levels due to serious imprecision as the number of participants was small and confidence interval was wide.
2 Downgraded one level due to serious imprecision as the number of events was small.
 
 
AndoSan compared to placebo for participants with mild-to-moderately active Crohn's disease
Patient or population: participants with mild-to-moderately active Crohn's disease


















































Total fatigue scores ranged from 0 to 33,
with higher scores indicating greater fa-
tigue.
Fatigue


















SF-36 vitality subscale scores ranged
from 0 to 100, with higher scores indicat-
ing greater vitality (less fatigue).
Quality of life - not measured - - - - This outcome was not measured.
Adverse events - not reported - - - - This outcome was not reported.
Serious adverse events - not re-
ported
- - - - This outcome was not reported.
Withdrawal due to adverse
events - not reported
- - - - This outcome was not reported.
Table 4.   AndoSan compared to placebo for participants with mild-to-moderately active Crohn's disease 
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*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of
the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from
the estimate of effect
Table 4.   AndoSan compared to placebo for participants with mild-to-moderately active Crohn's disease  (Continued)
1 Downgraded one level due to serious imprecision as the number of participants was small and confidence interval was wide.
2 Downgraded by one level due to high risk of bias for allocation bias (open allocation).
 
 
Ferric maltol compared to placebo for participants in remission or mild-to-moderately active Crohn's disease
Patient or population: participants in remission or mild-to-moderately active Crohn's disease
Setting: outpatients from 4 centres in Austria, Germany, Hungary and the UK
Intervention: ferric maltol
Comparison: placebo


























































from 32 to 224, with
higher scores indicat-

















follow-up: mean 12 weeks










Withdrawal due to adverse events
assessed with: MedDRA







Table 5.   Ferric maltol compared to placebo for participants in remission or mild-to-moderately active Crohn's
disease 
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follow-up: 12 weeks (0.52
to 5.51)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of
the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from
the estimate of effect
Table 5.   Ferric maltol compared to placebo for participants in remission or mild-to-moderately active Crohn's
disease  (Continued)
1 Downgraded two levels due to serious imprecision as the number of participants was small and confidence interval was wide.
 
 
Guided stress management compared to conventional medical treatment for participants with Crohn's disease in remission
Patient or population: participants with Crohn's disease in remission
Setting: outpatients from a single centre in Spain
Intervention: guided stress management




















































The average frequency of tiredness was
calculated as the number of symptomatic
days divided by total reported days x 100.
Higher mean scores indicated higher av-
erage frequency of tiredness.
Fatigue



















The severity of tiredness scores ranged
from 0 to 3, with higher scores indicating
greater severity of tiredness.
Quality of life - not measured - - - - This outcome was not measured.
Adverse events - not measured - - - - This outcome was not measured.
Table 6.   Guided stress management compared to conventional medical treatment for participants with Crohn's
disease in remission 
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Serious adverse events - not
measured
- - - - This outcome was not measured.
Withdrawal due to adverse
events - not measured
- - - - This outcome was not measured.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of
the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from
the estimate of effect
Table 6.   Guided stress management compared to conventional medical treatment for participants with Crohn's
disease in remission  (Continued)
1 Downgraded by two levels due to serious imprecision as the number of participants was small and the confidence interval was wide.
2 Downgraded by two levels due to high risk of bias for most criteria.
 
 
Self-directed stress management compared to conventional medical treatment for participants with Crohn's disease in remis-
sion
Patient or population: participants with Crohn's disease in remission
Setting: outpatients from a single centre in Spain
Intervention: self-directed stress management























































The average frequency symptom (tired-
ness) was calculated as the number of
symptomatic days divided by the total
reported days x 100. Higher scores indi-
cated greater average frequency of tired-
ness.
Fatigue

















Severity of tiredness scores ranged from 0
to 3, with higher scores indicating greater
severity of tiredness.
Table 7.   Self-directed stress management compared to conventional medical treatment for participants with
Crohn's disease in remission 
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score
was 1
Quality of life - not measured - - - - This outcome was not measured.
Adverse events - not measured - - - - This outcome was not measured.
Serious adverse events - not
measured
- - - - This outcome was not measured.
Withdrawal due to adverse
events - not measured
- - - - This outcome was not measured.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of
the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from
the estimate of effect
Table 7.   Self-directed stress management compared to conventional medical treatment for participants with
Crohn's disease in remission  (Continued)
1 Downgraded two levels due to serious imprecision as the number of participants was small and confidence interval was wide.
2 Downgraded by two levels due to high risk of bias for most criteria.
 
 
A P P E N D I C E S
Appendix 1. Embase search strategy
1. random$.mp.
2. factorial$.mp.





8. (singl$ adj blind$).mp.
9. (double$ adj blind$).mp.
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14. double blind procedure/
15. single blind procedure/
16. triple blind procedure/
17. randomized controlled trial/
18. or/1-17
19. exp Crohn disease/ or crohn*.mp.
20. (colitis and ulcerat*).mp. or exp ulcerative colitis/
21. (inflammatory bowel disease* or IBD).mp.
22. or/19-21
23. exp fatigue/
24. exp chronic fatigue syndrome/
25. (physical fatigue OR mental fatigue OR muscle fatigue).mp.
26. (energy OR tired* OR sleep* OR drows* OR letharg* OR lassitude OR weari*).mp.
27. (exhaust* OR listless* OR apath* OR malaise).mp.
28. ((asthenia OR asthenic) adj3 syndrome).tw.
29. (((lack or loss or lost) adj3 energy) or vigo* or vitality).tw.
30. or/23-29
31. 18 and 22 and 30
Limit to Human
Appendix 2. MEDLINE search strategy
1. random$.mp.
2. factorial$.mp.





8. (singl$ adj blind$).mp.
9. (double$ adj blind$).mp.
10. (tripl$ adj blind$).mp.
11. assign$.mp.
12. allocat$.mp.
13. randomized controlled trial/
14. or/1-13
15. exp Crohn disease/ or crohn*.mp.
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16. (colitis and ulcerat*).mp. or exp ulcerative colitis/
17. (inflammatory bowel disease* or IBD).mp
18. or/15-17
19. exp fatigue/
20. exp chronic fatigue syndrome/
21. (physical fatigue OR mental fatigue OR muscle fatigue).mp.
22. (energy OR tired* OR sleep* OR drows* OR letharg* OR lassitude OR weari*).mp.
23. (exhaust* OR listless* OR apath* OR malaise).mp.
24. ((asthenia OR asthenic) adj3 syndrome).tw.
25. (lack OR loss OR lost) adj3 (energy OR vigo* OR vitality).tw.
26. or/19-25
27. 14 and 18 and 26
Appendix 3. CINAHL search strategy
1. (TI fatigue or AB fatigue) OR (TI energy or AB energy) OR (TI sleep* or AB sleep*) OR (TI drows* or AB drows*) OR (TI lethargy* or AB
lethargy*) OR (TI lassitude or AB lassitude) OR (TI weari* or AB weari*) OR (TI exhaust* or AB exhaust*) OR (TI listless* or AB listless*) OR
(TI apath* or AB apath*) OR (TI malaise or AB malaise)
2. (TI inflammatory bowel or AB inflammatory bowel) OR (TI IBD or AB IBD) OR (TI Crohn* or AB Crohn*) OR (TI CD* or AB CD*) OR (TI colitis*
or AB colitis*) OR (TI UC or AB UC) OR (TI proctitis or AB proctitis) OR (TI ileitis or AB ileitis)
3. 1 AND 2
Appendix 4. PsycINFO search strategy
TI(fatigue OR energy OR sleep* OR drows* OR lethargy* OR lassitude OR weari* OR exhaust* OR listless* OR apath* OR malaise) AND
TI(inflammatory bowel OR IBS OR Crohn* OR CD OR colitis OR UC OR proctitis OR ileitis)
Appendix 5. CENTRAL search strategy






#7 #1 or #2 or #3 or #4 or #5 or #6
#8 MeSH descriptor: [Fatigue] explode all trees
#9 "chronic fatigue" or "physical fatigue" or "mental fatigue" or "muscle fatigue"
#10 energy or tired* or sleep* or drows* or letharg* or lassitude or weari* or exhaust* or listless* or apath* or malaise
#11 #8 or #9 or #10
#12 #7 and #11
Appendix 6. Data extraction
Study
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• Study aim
Participant characteristics
• Number of participants
• Setting of study
• Country of origin
• Demographic characteristics such as age and gender
• Disease characteristics such as disease type, disease status and disease duration
• Inclusion and exclusion criteria for participation in the study
Intervention characteristics
For each arm:·
• Assignment to groups·
• The aim, type, mode and content of the intervention·
• Time points of delivery ·
• Duration of the intervention, number and duration of sessions/dose
• Providers of the intervention
• Comparison intervention/s
• Setting of the intervention
• Participant adherence
Outcomes
• Time, frequency and duration at which outcomes are measured
• Instruments used for key primary and secondary outcomes




• Declaration of interest
• Sample size and evidence of power calculation
• Follow-up – withdrawal/dropout
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